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1 ABSTRACT
Lysosomal constituents are synthesised in the endoplasmic reticulum (ER), processed in the
Golgi cisternae and transported to the trans-Golgi network (TGN), from where they are sorted
for delivery to lysosomes. It is not known whether newly-synthesised lysosomal constituents
are targeted directly to lysosomes, or whether they are first delivered into preceding stages of
the endocytic pathway, in particular early endosomes. Horse-radish peroxidase (HRP) can be
endocytosed by cells and delivered to successive stages of the endocytic pathway. It thus
serves as a marker along the endocytic pathway. HRP catalyses the cross-linking of membrane-
permeable diaminobenzidine (DAB). This renders HRP-containi g organelles detergent
insoluble. The fraction of lysosomal constituents which colocalise with HRP in the endocytic
pathway can thus be determined experimentally. The present study examines the kinetics that
describe where and when newly-synthesised (metabolically labelled) lysosome-associated
membrane protein-1 (LAMP-1) colocalises with HRP in different organelles of the endocytic
pathway. The results show a transient presence of newly-synthesised LAMP-1 in early
endosomes and suggest that the bulk of newly-synthesised LAMP-1 enters the endocytic
pathway via early endosomes prior to its delivery to lysosomes. This study was extended to
include the cation-dependent mannose 6-phosphate receptor (CD-MPR) to serve as a control
protein that behaves differently to LAMP-1. Results for the CD-MPR are compatible with a
transient presence of the CD-MPR in lysosomes, to which the bulk of newly-synthesised CD-
MPR is transported before transport to late endosomes. Due to low expression levels of total
cellular CD-MPR, and especially endocytic CD-MPR, the CD-MPR pathway has not been
resolved clearly. Nevertheless, since different results have been obtained for the two membrane
proteins of this study, the present approach can be considered to provide specific information
on their different entry routes into the endocytic pathway.
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2 PREFACE
The intracellular millieu of the cell can communicate with its environment through the
exchange of materials via the endocytic system (reviewed in Mukherjee et al., 1997). The
processing of extracellular nutrients, regulation of cell-surface receptors, maintenance of
membrane homeostasis and defence against extracellular pathogens occur via the endocytic
and/or exocytic process. Extracellular and cell surface-derived materials are internalised
(internalisation being synonymous with endocytosis) through the invagination of the cell
membrane and the subsequent formation of vesicles, as shown in figure 2.1. These vesicles
fuse together and form what are known as early endosomes, from where molecules are sorted.
Re-usable molecules are recycled to the plasma membrane or the Golgi, while those destined
for degradation are retained in carrier vesicles. There are two models for the transfer of early
endosomal content to late endosomes. In the vesicular model, the carrier vesicles fuse with
already existing late endosomes. In the maturation model, the carrier vesicles mature into late
endosomes through the exchange of resident proteins.
Figure 2.1 Intracellular trafficking pathways. Main routes employed by
eukaryotic cells.
early
endosome
lysosome
late
endosome
plasma
membrane
endoplasmic
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trans-Golgi
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Late endosomes deliver their contents to lysosomes, the end station of the endocytic pathway,
by two mechanisms that occur concurrently. Using time-lapse confocal microscopy, these have
been identified as the ‘kiss-and-run’ and the ‘fusion-fission’ mechanisms. The ‘kiss-and-run’ 
mechanism involves transient fusion of late endosomes and lysosomes to exchange contents,
followed by rapid dissociation. In the ‘fusion-fission’ mechanism, late endosomes fuse fully
with lysosomes to form hybrid organelles from which lysosomes are reformed by fission
events (Bright et al., 2005; reviewed in Luzio et al., 2007).
Lysosomes are single-membrane-bound organelles that are the main site of degradation in the
endosomal pathway of multicellular organisms. The membrane is enriched in a group of highly
glycosylated trans-membrane proteins (LAMPs, LIMPs or LGPs) and sequesters a large
variety of acid hydrolases. The hydrolases digest the substances acquired via endocytosis (for
example, phagocytosis and pinocytosis) and autophagy. The digestive products are translocated
across the lysosomal membrane for use in the cytoplasm or transported to other cellular
compartments. The carbohydrates of the glycosylated membrane proteins form a dense
glycocalyx on the lumenal surface, as if to shield themselves and the membrane from the
hydrolytic enzymes (Neiss, 1984). Protease resistance has been observed for glycoproteins in
general (Yeo et al., 1985). Some lysosomal membrane proteins (LAMP-1, LAMP-2, LIMPs)
have been shown to be protected from the proteolytic environment of the lysosomal lumen by
the asparagine-linked oligosaccharides (Barriocanal et al., 1986; Kundra and Kornfeld, 1999),
in particular those containing poly-N-acetyllactosamines (Lee et al., 1990). These proteins may
serve to protect the membrane from the hydrolytic action of the diverse complement of
hydrolases and thus preserve the integrity of the lysosome. Although the role of lysosomal
membrane proteins have not been clearly determined (reviewed in Eskelinen et al., 2003), they
may be involved in more specific functions. For example, the transport of protons to maintain
the acidic pH in lysosomes (Ohkuma and Poole, 1978), the specific interaction and fusion of
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lysosomes with other organelles (Steinman et al., 1983), and the transport of amino acids and
carbohydrates resulting from the hydrolytic degradation (Cohn and Ehrenreich, 1969;
Ehrenreich and Cohn, 1969). The lamp family has been implicated in melanogenesis (Jimbow
et al., 1994). Levels of LAMP-2A in the lysosomal membrane have been correlated with
chaperone-mediated autophagic activity (Cuervo and Dice, 1996; Majeski and Dice, 2004) and
LAMP-2A has also been shown to promote MHC class II presentation of cytoplasmic antigens
(Zhou et al., 2005). In human peripheral blood mononuclear cells LAMP-1 and LAMP-2 are
activation-dependent cell-surface glycoproteins that mediate cell adhesion to the vascular
endothelium (Kannan et al., 1996). LAMP-2 and LAMP-3 might be indicators of platelet
activation (Kannan et al., 1995). LAMP-1 and LAMP-2 have been shown to play a role in
phagosome maturation (Huynh et al., 2007).
Cellular processes in which lysosomes function include protein turnover, cholesterol
homeostasis (Brown and Goldstein, 1976; Eskelinen et al., 2004), recycling of endocytic
nutrients, down-regulation of cell-surface receptors (Beguinot et al., 1984; Kasuga et al., 1981;
Mellman et al., 1983; Mellman and Plutner, 1984), defence against pathogens (Silverstein,
1977) and loading of processed antigens onto MHC class II molecules (Harding and Geuze,
1993). Lysosomes have also been implicated in regulated secretion (Peters et al., 1991), repair
of damaged plasma membrane (McNeil, 2002), and formation of an osteoclast’s rufled border 
(Stenbeck, 2002). Lysosomes are considered to be part of a family of lysosome-related
organelles with cell-specific functions, for example melanosomes (Raposo et al., 2001), lytic
granules, MHC class II compartments, platelet dense granules, basophil granules, azurophil
granules and Drosophila pigment granules (reviewed in Dell'Angelica et al., 2000). The crucial
role that lysosomes play in cellular metabolism is evident from the many diseases associated
with lysosomal malfunctioning.
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Lysosomal storage diseases include at least 40 enzymopathies where indigestible molecules
accumulate in lysosomes. The homeostasis of the cell is altered, thus leading to a diseased
state. Deficiency of LIMP-2 in mice results in ureteric pelvic junction obstruction, deafness
and peripheral neuropathy (Gamp et al., 2003). Lysosomes have been implicated in Danon’s 
disease (LAMP-2) (Nishino et al., 2000; Tanaka et al., 2000), Niemann-Pick type C1 (NPC1)
(Chang et al., 2005; Zhang et al., 2001), cystinosis (cystinosin) (Jonas et al., 1982), Salla
disease (sialin) (Renlund et al., 1983), Alzheimer’s disease (Tagawa et al., 1992), and more
generally, auto-immune diseases, resistance to drugs, cancer and infectious diseases. LAMP-1
plays a role in auto-immune disease (type 1 diabetes) progression (Bittencourt et al., 2005).
Lysosomal membrane proteins have been shown to be upregulated in tumour cells, mediating
adhesion of tumour cells to vascular endothelial cells and the extracellular matrix, and
promoting tumour progression (Furuta et al., 2001; Kanao et al., 2005; Kunzli et al., 2001;
Saitoh et al., 1992; Sarafian et al., 1998). In tuberculosis, phagosomes harbour virulent bacteria
and do not mature (Clemens and Horwitz, 1995; Thilo and de Chastellier, 1995), and thus do
not fuse with lysosomes. This has been considered as a main strategy for intracellular survival
of mycobacteria in that it avoids their exposure to the harsh hydrolytic environment in phago-
lysosomes. In spite of this non-fusion with lysosomes, these mycobacteria-containing
phagosomes, nevertheless, contain lysosomal enzymes and membrane constituents. This
apparent anomaly may find an explanation in the biogenesis of lysosomes (see Discussion).
Abnormal expression of lysosomes and lysosome-related organelles are characteristic of
human genetic diseases such as Chediak-Higashi and Hermansky-Pudlak syndromes
(Dell'Angelica et al., 1999; reviewed in Starcevic et al., 2002). The discovery of mutant genes
linked to these diseases is only beginning to reveal the molecular mechanisms implicated in the
biogenesis of lysosomes and lysosome-related organelles.
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The role of lysosomes in the above-mentioned diseases and the molecular processes underlying
lysosomal biogenesis (reviewed in Mullins and Bonifacino, 2001) remain poorly defined. A
thorough knowledge of how lysosomes are synthesised and maintained would contribute to a
better understanding of lysosome-related diseases. Unravelling lysosomal biogenesis requires a
complete elucidation of the dynamics of membrane and protein transport to and from the
lysosome, and the molecular machineries that govern these events. This would include
characterisation of the pathways along which newly-synthesised lysosomal membrane proteins
and lumenal enzymes are transported for delivery to lysosomes.
The sorting of enzymes and membrane proteins for delivery to lysosomes occurs in the TGN.
Lysosomal enzymes are sorted from other proteins by mannose 6-phosphate receptors (MPRs)
that bind the enzymes through a mannose 6-phosphate (man-6-P) recognition moiety on the
surface of the enzymes. A number of sorting signals in the MPR are then responsible for
ensuring delivery of lysosomal enzymes to lysosomes. The exact pathway for the delivery of
enzymes by MPRs has not been resolved. MPR-enzyme complexes are transported to an
endocytic organelle where the low pH causes the enzymes to dissociate. MPRs have
predominantly been localised to late endosomes at steady state. Late endosomes have thus been
presumed to be the endocytic organelle into which MPR-enzyme complexes are delivered and
where the dissociation of MPRs and enzymes occurs. MPRs are recycled to the TGN while the
enzymes are delivered to lysosomes. MPRs could deliver their cargo directly to late endosome
or indirectly via another endocytic organelle, for example early endosomes. Lysosomal enzyme
targeting is reviewed in (Dahms et al., 1989). The lysosomal membrane proteins do not have
the man-6-P recognition moiety (Barriocanal et al., 1986; Waheed et al., 1988). Their delivery
to lysosomes is therefore not mediated by MPRs (Croze et al., 1989). Instead, a tyrosine (tyr)
or a di-leucine (di-leu) motif in their cytoplasmic tails and the position of the motif relative to
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the membrane are critical for lysosomal sorting. This signal is similar to that for receptor-
mediated endocytosis (Chen et al., 1990; Jadot et al., 1992; Jing et al., 1990).
The similarity in the signals for lysosomal targeting and endocytosis prompted the much
debated and studied questions in the literature: Are lysosomal membrane proteins delivered to
lysosomes indirectly, that is, first to the cell surface via the secretory pathway and then to
lysosomes by endocytosis. Or, are they delivered to lysosomes directly? Since the plasma
membrane and early endosomes are in rapid dynamic equilibrium, these two compartments are
kinetically unresolved. The presence of a particular lysosomal membrane protein in the early
endosomal/plasma-membrane compartment could thus be due to delivery to the plasma
membrane via the secretory pathway or to early endosomes intracellularly from the TGN.
During initial studies, however, the presence on, or movement through, the plasma membrane
was generally interpreted to be as a result of delivery via the secretory pathway. Only gradually
did delivery via early endosomes through an intracellular pathway from the TGN find its way
into experimental design and interpretations.
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The goal of this project was to use a kinetic approach to characterise the pathway of newly-
synthesised LAMP-1, to serve as a marker for delivery of lysosomal membrane proteins from
the TGN. More specifically, the question asked was: Is LAMP-1 delivered to lysosomes
directly or via early endosomes, as shown in figure 2.2.
Figure 2.2 Pathways to be considered for the lysosomal delivery of LAMP-1.
LAMP-1 is predominantly localised to the late endosomes and lysosomes. Since
LAMP-1 has also been detected on the plasma membrane and in early endosomes,
albeit at low concentrations, this project specifically addressed the question whether
LAMP-1 is transported from the TGN directly to lysosomes or via early endosomes.
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?
?
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endoplasmic
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Golgi
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: LAMP-1 (Lysosome-associated membrane protein-1)
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As an example of a protein that behaves differently to LAMP-1, the study was extended to
include the CD-MPR, figure 2.3.
Figure 2.3 Pathways to be considered for the delivery of the CD-MPR into the
endocytic pathway. The CD-MPR is predominantly localised to the TGN and
endosomes, especially the late endosomes. There is also evidence for its presence
on the cell surface in low concentrations. Based on its steady-state distribution, it is
presumed to cycle between the TGN and late endosomes. However, the possibility
that it is first transported to early endosomes can not be excluded. This project
addressed the question whether the CD-MPR is transported from the TGN to early
endosomes.
: Mannose 6-Phosphate Receptor
: hydrolytic enzyme
?
?
lysosome
late
endosome
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3 INTRODUCTION
This section consists of two parts; the lysosomal membrane proteins and the MPRs. First,
background information about the different types and structures of lysosomal membrane
proteins or MPRs, their targeting signals and molecular machinery involved in targeting are
summarised. This is followed by a critical analysis of the studies performed to characterise the
targeting pathways of the respective proteins in the context of the main goal of this project.
3.1 LYSOSOMAL MEMBRANE PROTEINS
3.1.1 Types and structures
Lysosomal membrane proteins are known as lysosome-associated membrane proteins
(LAMPs), lysosomal membrane glycoproteins (LGPs) or lysosomal integral membrane
proteins (LIMPs) (reviewed in Eskelinen et al., 2003; Fukuda, 1990; Fukuda, 1991; Hunziker
and Geuze, 1996; Peters and von Figura, 1994). These proteins are richly glycosylated with
complex carbohydrates such as poly-N-acetyl-lactosamines, comprising 25–50% of their total
molecular weight. They are often terminally sialylated and thus have very acidic iso-electric
points (pIs between 2 and 4). They can be placed into three groups, based on their molecular
weights: 90 –120; 60 –85 and 30 –55 kDa, or six groups, based on their protein chemistry
and amino acid sequence: LAMP-1, LAMP-2, LAMP-3/LIMP-I, LIMP-II, lysosomal acid
phosphatase (LAP) and endolyn. Table 3.1.1 is a summary of the nomenclature and some
properties of the major lysosomal membrane proteins.
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Nomenclature LAMP-1 LAMP-2 LAMP-3 LIMP-II
Human hlamp-1/
lamp-A
CD107a
hlamp-2
lamp-B
CD107b
CD63 antigen
ME491
CD36L2
Rat LIMP-III
lgp-A
lgp120
lgp107
LIMP-IV
lgp-B
lgp110
lgp96
lgp95
LIMP-I
AD1-antigen
lgp85
Mouse mLAMP-1
P2B
mLAMP-2
mouse lgp110
Chicken LEP100
Others GpIIa
SGM110
AC17 antigen
Properties
Molecular mass (kDa) 90120 95120 3055 6085
Copies/cell ( X 10-4) 3060 2060 <20 <20
Polypeptide chain
(residues)
382396 380389 238 478
No. of N-glycans 1720 1617 3 up to 11
No. of O-glycans + + ? ?
Carbohydrate content (%) 5565 5565 2555 2045
Targeting signal gly-tyr gly-tyr gly-tyr di-leu
Table 3.1.1 Nomenclature and properties of the major lysosomal membrane
glycoproteins. This table was adapted from Eskelinen et al. (2003) and Fukuda (1991).
LAMPs have been spelled in various ways in the literature: for example, LAMP-
1/LAMP1/Lamp-1/Lamp1/lamp-1/lamp1 and LAMP-2/LAMP2/Lamp-2/Lamp2/lamp-
2/lamp2. LAMP-1 and LAMP-2 are the most widely used according to Eskelinen et al.
(2005), and have been applied in the writing of this thesis.
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3.1.1.1 LAMP-1 and LAMP-2
LAMP-1 (Chen et al., 1985; Howe et al., 1988; Lewis et al., 1985) and LAMP-2 (Granger et
al., 1990) are the most abundant glycoproteins in the lysosomal membrane (Marsh et al.,
1987). cDNAs from human, mouse, rat and chicken cells have been cloned. Their primary
sequences are strikingly conserved, with higher sequence similarity among LAMP-1 or
LAMP-2 genes across species than between LAMP-1 and LAMP-2 genes from the same
species (Fukuda et al., 1988; Sawada et al., 1993). LAMP-1 and LAMP-2 are encoded by
separate genes on chromosomes 13q34 and Xq24-25, respectively (Mattei et al., 1990). Taken
together, these observations imply that LAMP-1 and LAMP-2 diverged from a single gene
very early on in evolution, but the individual LAMP-1 and LAMP-2 genes have been
conserved during evolution. Although LAMP-1 and LAMP-2 are highly homologous, they are
immunogenically distinct.
They are both type-1 integral membrane proteins, figure 3.1.1. Both have three domains; a
large N-terminal ectodomain, a single transmembrane domain and a short C-terminal tail. The
lumenal domain consists of two domains. The two domains of LAMP-1 on either side of the
proline and serine-rich hinge region are homologous, whereas no such homology has been
detected for the two domains of LAMP-2 on either side of the proline and threonine-rich hinge
region (Fukuda et al., 1988). Each of the two ectodomains has two loops generated by
disulphide bonding between neighbouring cysteines. The 40 kDa protein core has 16 to 20 sites
for potential N-linked glycosylation, most of which are found to be glycosylated in the isolated
protein. Human LAMP-1 has been estimated to have 18, and human LAMP-2 16, N-linked
carbohydrate chains (Carlsson et al., 1988; Fukuda et al., 1988). The mature protein is thus
heterogeneous with molecular weights ranging between 90 to 120 kDa. O-linked
oligosaccharides are also attached to the hinge region (Carlsson et al., 1993). Some of the
glycans are modified by poly-N-acetyl-lactosamines (Carlsson and Fukuda, 1990) and are
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often terminally sialylated, thus accounting for the low pIs (2− 4). The cytoplasmic domain of
10–11 amino acid residues displays a higher degree of diversity for LAMP-2 than for LAMP-
1. Due to differential splicing, LAMP-2 has three isoforms. LAMP-2A, LAMP-2B and LAMP-
2C have distinct transmembrane domains and cytosolic tails (Hatem et al., 1995). At the C-
terminal end of the cytosolic tail of both LAMP-1 and LAMP-2 is a highly conserved gly-tyr
motif which interacts with the µ-subunit of four hetero-tetrameric adaptor protein (AP, defined
in section 3.1.3) complexes. The interaction of the gly-tyr motif with one or more of these AP
complexes leads to incorporation of LAMPs into coated vesicles that mediate selective protein
transport to lysosomes.
Figure 3.1.1 The structure of LAMP-1 and LAMP-2. Loops are formed by
disulphide bonds. The hinge region is flexible. This figure was adapted from
Fukuda (1991) and Hunziker and Geuze (1996).
ectodomain
S-S
S-S
COOH
H2N
cytoplasm
lysosomal membrane
lumen
S-S
hinge region
disulphide-bonded
loop
transmembrane domain
cytoplasmic domain
S-S
: N-linked poly-lactosaminoglycans and complex N-linked oligosaccharides
: O-linked carbohydrates are almost exclusively located at the flexible hinge region
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3.1.1.2 LAMP-3
The cDNA of LIMP-I, also known as LAMP-3 or CD63, has been isolated from human, mouse
and rat cells. It is a type III integral membrane protein that traverses the membrane four times,
as shown in figure 3.1.2. The core protein of 25 kDa has three N-glycosylation sites in the
lumenal domain close to the lipid bilayer. The poly-N-acetyl-lactosamine glycosyl moieties
added, yields a heterogeneous population of mature proteins with molecular weights from 30 to
54 kDa (Barriocanal et al., 1986). While there is no overall homology with either LAMP-1 or
LAMP-2, its 10-amino acid cytoplasmic tail contains the gly-tyr motif. Hence it has been
renamed LAMP-3.
Figure 3.1.2 The structure of LIMP-I (LAMP-3). This figure was adapted from
Hunziker and Geuze (1996).
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3.1.1.3 Limp-II
Limp-II cDNA has been cloned from rat cells. It is a type III integral membrane protein that
traverses the membrane twice, as depicted in figure 3.1.3. The ectodomain is the greater part of
the protein and the N-terminal and C-terminal cytoplasmic tails are 2 –4 and 20 amino acids,
respectively. The protein core of 50 kDa has 11 potential N-glycosylation sites on the
ectodomain, thus yielding a 74 to 85 kDa mature product (Barriocanal et al., 1986). The
ectodomain also has 5 cysteine (cys) residues which may form disulphide bonds. Limp-II is not
homologous to any of the LAMPs, a fact emphasised by limp-II utilising a completely different
lysosomal targeting signal, a di-leu-type signal.
Figure 3.1.3 The structure of limp-II. This figure was adapted from Hunziker and
Geuze (1996).
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3.1.1.4 Lysosomal acid phosphatase (LAP)
The LAP precursor is transiently associated with the membrane as an integral membrane
protein that is proteolytically processed into the mature soluble enzyme upon arrival in late
endosomes or lysosomes (Tanaka et al., 1990a; Waheed et al., 1988). It is a type I integral
membrane glycoprotein with a large N-terminal domain, a single transmembrane domain and a
cytoplasmic tail of 19 amino acids (figure 3.1.4.). The eight N-glycosylation sites on the
lumenal domain are used by complex-type oligosaccharides, in part substituted by sialic acid
residues, generating a membrane-associated LAP precursor of 63 kDa. The mature soluble
LAP is 52 kDa. A gly-tyr motif, similar to that found in LAMP-1,2 and3, is encoded by the
cytoplasmic tail.
Figure 3.1.4 The structure of LAP. This figure was adapted from Hunziker and
Geuze (1996).
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3.1.1.5 Endolyn
This protein is predominantly localised to lysosomes, but a substantial fraction also occurs in
endosomes, hence the name endolyn. cDNA of rat endolyn encodes a type I integral membrane
protein with a 13 amino acid cytoplasmic tail and many potential N and O-linked
glycosylation sites in the predicted lumenal domain, as shown in figure 3.1.5. Mature endolyn
has been observed as a heterogeneous population with molecular weights from 60 to 80 kDa. It
is mucin-like and shares 52% similarity with two mucins, Muc5C and Muc2. Endolyn may also
be distantly related to the lamp family. Two of the cysteines align with the conserved cys-3 and
cys-4 in domain 1 of LAMP-1 and LAMP-2. The transmembrane and cytoplasmic domain of
endolyn shares 35% similarity with those of the LAMPs. A tyr motif is encoded by its
cytoplasmic tail, but with no gly preceding it (Ihrke et al., 2000).
Figure 3.1.5 The structure of endolyn. The possible topology and structure of endolyn has
been predicted from the primary sequence. The position of the N-terminal O-glycosylated
domain relative to the membrane is not known. This figure was adapted from Ihrke et al.
(2000).
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3.1.2 Targeting signals
Two types of signals in the cytosolic tails of lysosomal membrane proteins are implicated in
lysosomal targeting: a tyr-containing signal in LAMP-1, LAMP-2, LAMP-3, LAP and
endolyn, and a di-leu type signal in LIMP-II. The tyr signal in LAMP-1, LAMP-2, LAMP-3
and LAP has a gly preceding the tyr. Mutations in these determinants result in lysosomal
mistargeting and cell-surface accumulation. These signals are thus important in targeting
lysosomal membrane proteins to lysosomes and in endocytosing cell-surfaceexpressed
lysosomal membrane proteins for delivery to lysosomes. However, their role in sorting newly-
synthesised proteins into specific pathways at the TGN is still largely undefined. The position
of both motifs relative to the membrane is important for their proper function (Fukuda, 1990;
Ogata and Fukuda, 1994; Rohrer et al., 1996; Williams and Fukuda, 1990). The gly-tyr motif
for LAMP-1, 2 and 3 occurs at the end of the cytoplasmic tail, while that for LAP occurs
seven amino acids away from the end. Overexpression of chimeras with different cytoplasmic
domains and/or targeting signals in HeLa cells (immortal cell-line derived from human cervical
cancer cells) by transient transfection shows that both the tyrand di-leu signal-dependent
targeting components are satu able. Overexpression of proteins containing these signals results
in cell-surface accumulation and interferes with targeting to the correct destinations (for
example, lysosomes). This is probably due to the saturation of specific components
(presumably specific receptors) of the targeting machinery operating in the sorting of proteins
at the TGN, early endosomes or plasma membrane. The evidence suggests that proteins with
tyr-based sorting signals share saturable components, irrespective of the targeted destination,
whereas tyrand di-leu-mediated targeting use distinct saturable components (Marks et al.,
1996).
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3.1.2.1 Tyrosine-containing signal
This signal consists of four amino acids, YXX, where Y is tyr, X is any amino acid, is a
bulky, hydrophobic amino acid that varies for the different lysosomal proteins (reviewed in
Bonifacino and Dell'Angelica, 1999).
3.1.2.1.1 LAMPs
LAMP-1,2, and3 have an 11 amino-acid cytoplasmic tail. The tyr motif occurs at the end of
the tail with seven residues separating it from the membrane. The tyr is preceded by a gly,
hence the signal is G7Y8XX11, where 7, 8, and 11 refer to the positions of the amino acids in
the 11 amino-acid cytoplasmic tail (Honing and Hunziker, 1995). For LAMP-1,is isoleucine
(ile); LAMP-2A, phenylalanine (phe); LAMP-2B, valine (val); LAMP-2C, leu and LAMP-3,
methionine (met) (Gough and Fambrough, 1997).
The cytoplasmic tail of human LAMP-1 fused to a cell-surfacereporter glycoprotein in
transformed African Green Monkey kidney fibroblasts (COS-1 cells) causes the chimera to be
delivered to lysosomes instead of the plasma membrane, whereas substitution of the tyr8 with
an alanine (ala) results in surface accumulation of the chimera (Williams and Fukuda, 1990).
These results implicate the requirement for a tyr-containing signal in the cytoplasmic tail for
lysosomal sorting. A similar tyr-containing signal mediates cell-surface internalisation, thus
potentially mediating sorting at both the TGN and the cell surface.
Mutagenesis and transfection of murine-LAMP-1 cDNA into human embryonic kidney
fibroblasts have revealed the three amino acids distal to the tyr residue to be X-X-. The tyr-
containing signal in the cytoplasmic tail was thus characterised to contain the amino-acid
sequence, Y-X-X-(Guarnieri et al., 1993).
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In cases where LAMP-1 is not normally detected on the cell surface (for example, Chinese
Hamster Ovary (CHO) and Madin-Darby Canine Kidney (MDCK) cells) substitution of gly7,
tyr8 or ile11 by ala results in LAMP-1 detection on the cell surface. The tyr8ala and ile11ala
mutants accumulate on the cell surface and abolish lysosomal delivery, whereas the gly7ala
mutant is internalised from the cell surface and delivered to lysosomes with the same kinetics
as the wild-type (Harter and Mellman, 1992; Honing and Hunziker, 1995). Using the yeast
two-hybrid approach, tyr-based sorting signals, in general, have been shown to bind the μ1 and
μ2 subunits of AP-1 and AP-2 (defined in section 3.1.3), respectively, in vitro. Mutation of the
tyr residue abolishes interaction with the μ2 subunit (Ohno et al., 1995). A possible role for the
gly7, tyr8 and ile11 in sorting at the TGN is suggested by the different affinities of the mutants
for the intact Golgi-restricted AP-1 adaptor protein in vitro. Binding of tyr8ala and ile11ala
mutants is virtually abolished when compared to the wild-type, while the gly7ala mutant binds,
but with reduced efficiency. Both wild-type LAMP-1 and the gly7ala mutant bind the plasma
membrane adaptor protein, AP-2, whereas the tyr8 and ile11 mutants’ binding is only slightly
better than for the AP-1. This is consistent with the endocytosis of LAMP-1 being unaffected
for the gly7ala mutant and practically non-existent for the tyr8 and ile11 mutants (Honing et al.,
1996). Taken together, these results therefore suggest that gly7 is important for efficient
lysosomal sorting at an intracellular sorting site such that LAMP-1 is not detected on the cell
surface, but is not critical for internalisation of cell-surface LAMP-1. In contrast, tyr8 and ile11
are critical for efficient intracellular lysosomal sorting, as well as sorting at the plasma
membrane and subsequent internalisation. In addition to ile, the second last amino acid,
threonine (thr), has also been shown to be important for binding of AP-1 and for lysosomal
delivery without detection on the cell surface (Obermuller et al., 2002). It can be concluded
that the LAMP-1 tyr motif is GYXTI.
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In mouse L cells transfected with chimeras composed of the lumenal domain of chicken
LAMP-1 (LEP100) and the transmembrane and cytosolic domains of the LAMP-2 isoforms, it
has been shown that the targeting signal in the cytosolic tail of each of the LAMP-2 isoforms
(a, b and c) is sufficient for lysosomal delivery of chimeric LAMP proteins (Hatem et al.,
1995). The three isoforms differ in the hydrophobic amino acid () at the end of the tail and are
differentially expressed on the cell surface at steady state. Site-directed mutagenesis identified
the terminal residue as critical in determining steady-state distributions of LAMP-2A, B and
C (Gough and Fambrough, 1997). The tyr motif for LAMP-2A is GYXXF, LAMP-2B,
GYXXV and LAMP-2C, GYXXL. At steady state LAMP-2C is predominantly localised to
lysosomes, whereas higher levels of LAMP-2A andB occur at the cell surface.
The C-terminal sequence in the cytoplasmic tail of human CD63 (LAMP-3) has the lysosomal
targeting motif, GYEVM. In normal rat kidney (NRK) cells transfected with a chimera
composed of the lumenal and transmembrane domains of human T-cell surface marker (CD8)
and the cytoplasmic tail of CD63, the CD8-CD63 chimera colocalise with endogenous LAMP-
2 and CD63. The GYEVM targeting motif in the cytoplasmic tail is thus sufficient to target
CD8 to lysosomes. Alanine-scanning mutagenesis of this motif in human CD63 has shown
increased cell-surface expression of the mutants in stably transfected NRK cells by immuno-
fluorescence microscopy. The order of cell-surface expression is: GAEVM > GYEVA >
GYAVM > AYEVM > GYEAM = GYEVM (wild-type) (Rous et al., 2002). The tyr is thus
more important than gly in preventing cell-surface expression. This is consistent with that
which has been observed for LAMP-1. The terminal amino acid, met, is also relatively
important in determining cell-surface expression, as has been observed for LAMP-1 and2.
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3.1.2.1.2 LAP
The tyr-containing signal in the 19 amino-acid cytoplamic tail of LAP is necessary and
sufficient for endocytosis and lysosomal targeting of LAP (Peters et al., 1990). Mutation of the
tyr in the cytoplasmic tail to phe and deletion of the cytoplasmic tail have resulted in cell-
surface accumulation. A chimera composed of the lumenal and transmembrane domains of
hemagglutinin (a cell-surface glycoprotein) and the cytoplasmic tail of LAP is rapidly
internalised. A chimera composed of the lumenal domain of the CD-MPR and the
transmembrane domain and cytoplasmic tail of LAP is delivered to lysosomes. Differential
internalisation of LAP cytoplasmic-tail truncation and substitution mutants has identified
PG8Y9RHV12 as the tyr motif, where P is proline (pro), G is gly, Y is tyr, R is arginine (arg), H
is histidine (his) and V is val. This motif is positioned six residues from the membrane and
seven residues from the end of the cytoplasmic tail (Lehmann et al., 1992; Obermuller et al.,
2002). Interestingly, substitution or truncation of amino acids in the C-terminal end of the tail
has the potential to inactivate this internalisation signal.
3.1.2.1.3 Endolyn
The last 10 amino acids of the cytoplasmic tail of endolyn are sufficient to re-direct CD8 to
endosomes and lysosomes. A chimera composed of the lumenal and transmembrane domain of
CD8 and the cytoplasmic tail of endolyn (CD8-endolyn) colocalises with endogenous endolyn
in stably transfected NRK cells, as was measured by double immuno-fluorescence confocal
microscopy (Ihrke et al., 2000). The cytoplasmic tail of endolyn contains the tyr motif,
NYHTL, at the C-terminus with no gly preceding the tyr, where N is asparagine (asp), Y is tyr,
H is his, T is thr and L is leu. The gly that precedes the tyr in other lysosomal membrane
proteins is absent. A chimera in which the tyr or the leu of the NYHTL motif is mutated to an
ala redistributes to the cell surface. The relatively higher expression of wild-type endolyn on
the cell surface and in endosomes when compared with lysosomal membrane proteins that have
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the GYXXmotif suggests that the gly confers greater efficiency in lysosomal sorting at an
intracellular sorting site such that appearance on the cell surface is reduced. This has been
confirmed when a mutant CD8-endolyn chimera that contained a GYHTL motif resulted in less
anti-CD8 antibody internalisation than a chimera with the wild-type NYHTL (Ihrke et al.,
2004). These observations correlate with what has been observed for LAMP-1 and LAMP-3
when the gly of the GYXXmotif was mutated to alanine.
When the above results are taken together, one can conclude that tyr in the GYXXmotif is
more important than gly and in maximising lysosomal sorting and minimising cell-surface
expression, but tyr, gly and together determine the efficiency of lysosomal sorting. The
second last amino acid has also been shown to play a role. Gly is implicated to function at an
intracellular sorting site while tyr probably functions at an intracellular sorting site, as well as
on the cell surface.
3.1.2.2 di-leucine type signal
This signal is designated L17I18, where L is leu, I is ile and 17 and 18 refer to the positions of
the amino acids in the 20 amino-acid cytoplasmic tail of LIMP-II. In COS-1 cells, the
cytoplasmic tail is sufficient to ensure efficient lysosomal targeting of transfected LIMP-II
without its detection on the cell surface (Vega et al., 1991). In two parallel studies, it has been
shown that the L17I18 motif in the carboxyl terminal four amino-acid sequence,
leu17Ile18ala19thr20, is critical to the targeting signal. Substitution or deletion of leu17 or ile18 of
LIMP-II leads to accumulation of the mutant protein on the cell surface with concomitant
reduced efficiency in or complete inhibition of lysosomal targeting. Ile18 has a greater tolerance
to substitution than leu17. Substitution of ile18 by leu causes no loss in targeting efficiency
(Ogata and Fukuda, 1994; Sandoval et al., 1994). The addition of three amino acids to the C-
terminus does not interfere with lysosomal sorting (Sandoval et al., 1994), while a deletion of
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nine amino acids next to the transmembrane domain abolishes the sorting function (Ogata and
Fukuda, 1994). The position of the sorting motif relative to the C-terminus is thus not
important, while its position relative to the transmembrane domain is essential in both
lysosomal targeting and internalisation from the cell surface.
3.1.3 Sorting machinery involved in targeting
Targeting signals specify the location to which lysosomal membrane glycoproteins are
destined. A mechanism has to exist whereby these glycoproteins are shuttled from the sites of
synthesis to lysosomes. This trafficking function involves the packaging of lysosomal
membrane glycoproteins into vesicles, a process facilitated by the sorting machinery of the
cell.
Generally, vesicle formation from the membrane is a multi-step process. Cargo proteins are
sorted into specific vesicles through the recognition of the sorting signals in their cytoplasmic
tails by coat proteins (sorting machinery). The coat is the structural anchor through which
vesicles can form. Coat proteins such as adaptor proteins (APs) bind cargo to structural protein,
mostly clathrin. Clathrin forms the shell that surrounds vesicles. It is not clear whether the
cargo proteins first concentrate in budding vesicles, with the binding of the coat proteins being
a subsequent event or whether the coat proteins bind to cargo proteins first, resulting in the
recruitment of cargo proteins into the budding vesicle. Once cargo proteins have been
concentrated in certain areas, membrane curvature follows. This results in the formation of pits
which are then pinched off from the membrane leading to fully-formed vesicles. The vesicles
are then sorted to their intracellular destination because of the presence of accessory proteins
that have been recruited during the vesicle formation step.
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The tyr- or di-leu-based signals in the cytoplasmic tails of cargo proteins interact with AP
complexes: AP-1, AP-2, AP-3 or AP-4. These are hetero-tetrameric complexes, consisting of 2
large subunits (~100 kDa), namelyβ and either γ, α, δ or ε, as is in AP-1, AP-2, AP-3 or AP-4,
respectively, a medium μ subunit (50 kDa) and a smal σ subunit (20 kDa). AP-1, AP-2 and
AP-3 form part of a clathrin-coat, whereas AP-4 forms part of a non-clathrin-coat. The
lysosomal targeting signals interact with the μ subunit (Gough et al., 1999; Ohno et al., 1995;
Ohno et al., 1996; Rous et al., 2002). However, exactly where and to what extent these
adaptors mediate the transport of lysosomal membrane protein is still unknown.
3.1.3.1 Adaptor protein-1
AP-1 forms part of the clathrin lattice that is known to mediate sorting at the TGN, although
AP-1 and clathrin have also been observed on early endosomes (Le Borgne et al., 1996;
Mauxion et al., 1996; Waguri et al., 2003). LAMP-1 cytosolic tails bind the μ subunit of AP-1
(Ohno et al., 1995) and intact AP-1 (Honing et al., 1996) in vitro. The residues, thr (T) and ile
(I), in the GYQTI motif of LAMP-1 are critical for AP-1 binding, as well as lysosomal
targeting without cell-surface detection (Obermuller et al., 2002). Using immuno-gold electron
microscopy in MDCK cells stably transfected with the wild-type and tyr8ala LAMP-1, the
wild-type has been observed to colocalise with AP-1coated vesicles and tubules in the trans-
region of the Golgi complex, but not the tyr8ala mutant (Honing et al., 1996). This is evidence
for AP-1mediated sorting of LAMP-1 at the TGN. However, overexpression of chimeric
proteins (the cytoplasmic tail of LAMP-1, LIMP-I and LAP fused to the lumenal and
transmembrane domains of the Varicellar-zoster virus (VZV) envelope glycoprotein) in HeLa
cells does not cause recruitment of AP-1 onto membranes (Le Borgne et al., 1998). TGN-
derived transport vesicles containing LAMPs or γ-adaptin (AP-1 subunit) together with MPRs,
generated in vitro, migrate to different positions on nycodenz gradients (Karlsson and Carlsson,
1998). Also, in 1A-deficient mouse fibroblasts there is no change in the steady-state
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distribution of LAMP-1 and no missorting of LAMP-1 via the cell surface, as was measured by
anti-LAMP-1 antibody uptake experiments. In contrast, the steady-state distribution of the
MPRs is shifted toward the endosomes (Meyer et al., 2000). These observations suggest that
LAMPs and MPRs are sorted at the TGN into different vesicles; the lamp-containing vesicles
being AP-1 negative and the MPR-containing vesicles, AP-1 positive. However, depletion of
AP-1 by ribonucleic-acid (RNA) interference did increase cell-surface expression (less than
two fold) of LAMPs, although the effects were much lower than for other adaptors (Janvier and
Bonifacino, 2005).
3.1.3.2 Adaptor protein-2
AP-2 is exclusively associated with plasma-membrane clathrin coats. A high-affinity
interaction has been observed between the cytoplasmic domain of LAP and adaptors from
plasma-membranecoated vesicles in vitro (Sosa et al., 1993). Depletion of clathrin and AP
complexes using RNA interference suggests that AP-2 and clathrin play the most important
role in targeting LAMPs to lysosomes. Clathrin depletion results in a three to four-fold increase
in cell-surface expression of LAMPs and AP-2 depletion, a five to ten-fold increase. Depletion
of AP-1, AP-3 or non-clathrin associated AP-4, singly or in combinations, had relatively lower
effects on cell-surface expression (less than two-fold increase) and on the steady-state
intracellular distribution (Janvier and Bonifacino, 2005).
3.1.3.3 Adaptor protein-3
AP-3 has been implicated in the sorting of lysosomal membrane glycoproteins to lysosomes
because depletion of AP-3 using anti-sense oligonucleotides in HeLa, NRK cells and mouse
fibroblasts causes selective misrouting of LAMP-1 and LIMP-II to the plasma membrane, as
was determined by antibody internalisation. However, the overall steady-state distributions of
LAMP-1 and LIMP-II remain unchanged (Le Borgne et al., 1998). This study implicates AP-3
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at an intracellular sorting site. The di-leu-based motif in the cytoplasmic tail of LIMP-II has
been shown to selectively bind AP-3 (Diment et al., 1998; Honing et al., 1998). Also,
Hermansky Pudlock syndrome patients who have a defect in the β3A subunit of AP-3 exhibit
increased cell-surface expression of LAMP-1, LAMP-2 and CD63 in fibroblasts (Dell'Angelica
et al., 1999; Starcevic et al., 2002). Using a yeast two-hybrid system, differential interaction
has been observed between the 3 subunit of AP-3 and the wild-type and alanine mutants of
the CD63 cytoplasmic tail. The strength of the interaction (GYEVM (wild-type) = GYEAM >
AYEVM > GYAVM >> GYEVA >> GAEVM) correlated with the extent of lysosomal
localisation of similarly mutated human CD63 expressed in stably transfected NRK cells (Rous
et al., 2002). Tyr is thus more important than gly in determining the strength of the interaction
with the 3 subunit of AP-3, but both tyr and gly are necessary for optimal binding. Similar
experiments have shown that the wild-type endolyn cytoplasmic tail with a NYHTL motif also
bound the 3 subunit of AP-3, but with lower affinity than a mutated cytoplasmic tail with a
GYHTL motif. A role for AP-3 in endolyn traffic has been confirmed by the mislocalisation of
wild-type rat endolyn to the cell surface in AP-3deficient pearl mouse cells. More efficient
lysosomal sorting of endolyn was restored upon transient transfection of these cells with wild-
type3A cDNA (Ihrke et al., 2004). Endolyn is a lysosomal membrane glycoprotein that has a
higher cell-surface and early endosomal expression than those with a GYXXmotif in their
cytoplasmic tails. Taken together, these results suggest that AP-3 functions at an intracellular
sorting site where lysosomal sorting efficiency (minimising cell-surface or early endosomal
expression) is determined by the presence of both tyr and gly in the tyr motif.
Immunofluorescence in mammalian cells has localised AP-3 to perinuclear buds or vesicles,
where it has partially colocalised with TGN markers, as well as buds or vesicles in the cell
periphery, where it has partially colocalised with endocytic tracers (Dell'Angelica et al., 1997;
Dell'Angelica et al., 1998; Simpson et al., 1996; Simpson et al., 1997). Using immuno-electron
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microscopy, AP-3 has been localised to a novel tubular sorting endosome. Resolution at this
level enhances the identification of micro-domains involved in protein sorting and other
colocalised proteins, such as AP-1, transferrin, transferrin receptor, asialoglycoprotein receptor,
low amounts of cation-independent mannose 6-phosphate receptor (CI-MPR) and LAMPs.
LAMPs concentrate in the AP-3 positive membranes of the tubular sorting endosomes, unlike
AP-3 mutant cells that exhibit enhanced recycling of lysosomal membrane proteins to the
plasma membrane. This tubular endosome is thus considered to be a site where lysosomal
membrane proteins are sorted from recycling membrane proteins destined for the plasma
membrane or TGN for lysosomal delivery (Peden et al., 2004). AP-3 may thus function at both
the TGN and early endosomes.
The exact molecular mechanisms employed by the various adaptor proteins to regulate
lysosomal membrane protein trafficking still need to be clearly defined. The results for AP-1
are contradictory and might imply that it plays a minor role in LAMP trafficking. The
involvement of AP-2 at the plasma membrane and AP-3 in peripheral sorting endosomes in
LAMP trafficking, as discussed above, have implications for transport of LAMPs via the
plasma membrane and/or early endosomes (see Discussion).
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3.1.4 Targeting pathways
Current studies suggest that some lysosomal membrane proteins are delivered directly to
lysosomes, others via the plasma membrane and/or early endosomes and still others via both
pathways. These apparent contradictory results could be due to lack of kinetic information,
with most studies having been done at steady state. Generally, the relative amounts of
lysosomal membrane proteins localised to a particular organelle at steady state has been
interpreted as a measure of the fraction of total protein delivered to lysosomes via this
compartment. However, steady-state observations contain no information on dynamic
membrane flow rates and the absence or very low levels of lysosomal membrane proteins in a
particular compartment could be a reflection of rapid movement through this compartment.
Furthermore, the presence of lysosomal membrane protein in a particular compartment could
be due to recycling and not because they are delivered there en route to lysosomes. Here
follows a critical analysis of these studies and their interpretations that support either direct
delivery to lysosomes or indirect delivery via the plasma membrane and/or early endosomes, or
both pathways.
3.1.4.1 Direct delivery to lysosomes
Suggestions for the direct pathway to lysosomes are based on observations that lysosomal
membrane proteins are preferentially localised to lysosomes (Barriocanal et al., 1986; D'Souza
and August, 1986; Lewis et al., 1985). Generally, the absence of lysosomal membrane proteins
on the plasma membrane or the lack of movement of lysosomal membrane proteins through the
plasma membrane has been interpreted to imply that lysosomal membrane proteins are
delivered directly to lysosomes.
In NRK cells and murine macrophages (J774 cells), the kinetics have been compared for the
appearance of newly-synthesised, pulse-labelled lysosomal proteins and plasma-membrane
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proteins in lysosomes and on the plasma membrane, respectively. Lysosomal proteins were
immunoprecipitated from Percoll density-gradient fractions and the accessibility of plasma-
membrane proteins to trypsinisation of intact cells was measured. Lysosomal membrane
glycoproteins and enzymes were delivered to lysosomes with the same lag and with similar
kinetics as plasma-membrane proteins were delivered to the plasma membrane (Green et al.,
1987). The authors have argued that if lysosomal membrane proteins are delivered via the
plasma membrane and endocytosis, they would have to be delivered to lysosomes with an
additional lag and with slower kinetics as has been observed for the delivery of membrane-
bound endocytic markers from the cell surface to lysosomes. The kinetics of this study have
been determined in terms of the half-times (t½[time]) of appearance of the various proteins at
their final destinations. However, the half-time of appearance of a specific protein in a
particular compartment is not a direct measure for the flux of a protein into a compartment.
Only when the half-time is related to the respective compartment’s pool size (m[molecules]) at 
steady state, can information on membrane flux (fm/t½ [molecules per time]) be obtained. A
comparison of the half-times of appearance of proteins at their final destinations is thus not a
meaningful assessment of the rate of their transport.
Further support for the direct pathway came in 1992 and 1995 with immuno-fluorescence and
antibody-internalisation studies. In NRK and transfected CHO cell lines that expressed low
levels of rat lgp120, this protein was not detected on the cell surface at steady state, by
immuno-fluorescence microscopy. This has been interpreted to imply that lgp120 is delivered
to lysosomes without appearance on the cell surface (Harter and Mellman, 1992). The same has
been observed in MDCK cells that stably expressed a chimeric protein, a fusion product of the
lumenal and transmembrane domain of a murine cell-surface protein (IgG FcRII-B2 receptor)
and the cytoplasmic domain of lgp120, FcR-lgp120. Neither wild-type lgp120 nor the chimera
was detected on the cell surface at steady state. Both were localised to lysosomes. The
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possibility that lgp120 is transported to the cell surface, but rapidly endocytosed for delivery to
lysosomes, was tested by incubating MDCK cells for 60 min at 37ºC in the presence of
antiserum against lgp120 or FcR-lgp120. No antibodies were internalised and this has implied
no movement of lgp120 or the chimera through the plasma membrane (Honing and Hunziker,
1995). This interpretation, however, has been based on the assumption that the antiserum to lgp
120 or FcR-lgp120 had a high affinity for the specific antigen, so that lgp120 or lgp120-FcR
would have been bound even at very low concentrations, before these proteins could have left
the plasma membrane. In fact, MDCK cells that overexpressed the corresponding proteins did
internalise antibodies. Similarly, in CHO cells that overexpressed lgp120, this protein was
detected on the cell surface by immuno-fluorescence microscopy. The same has been observed
for an endogenous lysosomal glycoprotein that was not detected on the cell surface of low-
expressing CHO cells. This suggests that surface expression results from the saturation of a
sorting site involved in the delivery of lysosomal membrane proteins from the TGN to
lysosomes (Harter and Mellman, 1992). A saturable sorting site could occur at the TGN or
plasma-membrane/early endosomal compartment (see Discussion). Evidence that this sorting
site is also very specific comes from cell-surface detection of lgp120 mutants in which the gly7,
tyr8 and ile11 residues of the tyr-sorting signal in the cytoplasmic tail were mutated (Harter and
Mellman, 1992; Honing and Hunziker, 1995; Williams and Fukuda, 1990). In the case of
overexpression of lgp120 or the expression of its mutants, the sorting site is possibly saturated
or less efficient, respectively, and thus misrouting of lgp120 or its mutants via the plasma
membrane occurs (as is popularly thought), or movement through the plasma-membrane/early
endosomal compartment is slower and thus more easily detectable.
Kinetics and cell-fractionation studies in NIH Swiss transformed mouse embryonic fibroblasts
(mouse HaNIH 3T3 cells) have suggested intracellular delivery of LAMP-1 to lysosomes
(D'Souza and August, 1986). The processing and delivery of newly-synthesised pulse-labelled
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LAMP-1 to lysosomes were followed by the immunoprecipitation of LAMP-1 from sucrose
density-gradient fractions. Newly-synthesised LAMP-1 was detected in fractions that were
coincident with the rough endoplasmic reticulum (after 15 min), Golgi (after 30 min) and
lysosomal markers (after 1h), but not in fractions positive for plasma-membrane markers.
These observations have been interpreted to imply that LAMP-1 is delivered intracellularly to
endosomes or lysosomes. Cell fractionation is generally not a quantitative technique. Newly-
synthesised LAMP-1 was chased for relatively long time intervals. If LAMP-1 moves rapidly
through the plasma membrane, it may not have been detected. Also, early endosomes were not
distinguished from lysosomes with early endosomal markers. Passage through early endosomes
could also have implied indirect delivery to lysosomes.
From similar studies in the human promyelocytic leukaemia cell line (HL60 cells) it has been
suggested that the majority of LAMP-1 is delivered directly to lysosomes and a minor fraction
is delivered to lysosomes via the plasma membrane (Carlsson and Fukuda, 1992). Pulse-chase
labelling, cell-surface biotinylation, fractionation of Percoll density-gradients and
immunoprecipitation were used to measure the kinetics of appearance of newly-synthesised
LAMP-1 on the plasma membrane and in lysosomes. Newly-synthesised LAMP-1
accumulated in lysosomes with biphasic kinetics and moved through the cell surface
transiently. The appearance of LAMP-1 on the cell surface was concurrent with its appearance
in dense lysosomes. At the time when the plateau (70% of total LAMP-1) of the first wave was
reached in dense lysosomes, LAMP-1 on the cell surface was at its maximum of only 2% of
total LAMP-1. The authors have argued that this excludes the possibility that the majority of
LAMP-1 first transits the cell surface before delivery to lysosomes. Newly-synthesised cell-
surfacederived LAMP-1 accumulated in lysosomes with slow kinetics, as for the second
phase of total LAMP-1 delivery to lysosomes. This has been interpreted to suggest that the
fraction of LAMP-1 transported to the cell surface is delivered to lysosomes during this second
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phase. After granulocytic differentiation of HL60 cells, the fraction of LAMP-1 that travelled
via the cell surface was reduced 10-fold even though the LAMP-1 expression levels increased
two-fold. A reduction of cell-surfaceexpressed LAMPs in HL60 cells, upon differentiation of
these cells to granulocytic precursors, has also been observed by (Mane et al., 1989). This is in
contrast to what has been observed by Harter (1992) and Honing (1995) for overexpressing
CHO cells, mentioned above. It suggests, however, that the sorting machinery in differentiated
cells is more efficient and that passage through the cell surface is due to inefficient sorting
(Carlsson and Fukuda, 1992).
Reservations about the reliability of the above results stem from the fact that cell fractionation
is generally not a quantitative technique. In Percoll density-gradients the lysosomal fraction
can be split between a low-density and a high-density fraction (Courtoy, 1993; Haylett and
Thilo, 1986). In the above study only the high-density fraction was used to measure the
appearance of LAMP-1 in lysosomes. The fact that LAMP-1 appearance on the cell surface
was co-incident with its appearance in lysosomes and that LAMP-1 was still at its maximum of
2% on the cell surface when the plateau of the first wave was reached in lysosomes are not
sufficient reasons to argue that the majority of LAMP-1 is not delivered to lysosomes via the
cell surface. An observed increase of molecules in a specific compartment is the net movement
of those molecules moving into and out of that compartment. So an observed increase does not
imply that no molecules are moving out of the compartment. This is an assumption that is
made by the authors. Molecules could thus be moving out of the plasma membrane
compartment and into lysosomes before the plateau is reached in the plasma-membrane
compartment. The kinetics produced in the above study are thus not sufficient to resolve this
question.
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Further support for the direct route has been taken from observed interactions between the
LAMP-1 cytosolic tail and AP-1. The cytosolic tail of LAMP-1 binds the μsubunit of AP-1 in
vitro (Ohno et al., 1995), as well as intact AP-1 (Honing et al., 1996). The tyr motif in the
cytoplasmic tail is necessary and sufficient to target LAMP-1 to lysosomes (Williams and
Fukuda, 1990). The residues, thr (T) and ile (I), in the GYQTI motif of LAMP-1 are critical for
AP-1 binding, as well as lysosomal targeting without cell-surface detection (Obermuller et al.,
2002). Immunogold-labelling of MDCK cells transfected with LAMP-1 has shown that AP-1
positive membranes (Golgi-derived) are positive for LAMP-1 (Honing et al., 1996). Since AP-
1 is the adaptor protein on clathrin-coated vesicles (CCVs) at the TGN, and CCVs do not
transport their cargo along the secretory route (Urbe et al., 1997), these observations have been
interpreted to support the direct route. However, CCVs could deliver their contents
intracellularly to early endosomes. The observation that in vitro-generated TGN-derived
transport vesicles that contain either LAMPs or γ-adaptin (AP-1 subunit) together with MPRs
migrate to different positions on nycodenz gradients (Karlsson and Carlsson, 1998) suggests
that LAMPs and MPRs are sorted at the TGN into different vesicles and that AP-1 might not
play such an important role in LAMP sorting. In fact, sorting of LAMP-1 is not affected in
1A-deficient fibroblasts, whereas the sorting of MPRs is affected (Meyer et al., 2000). Also,
GGAs (see 3.2.5.4 for definition) have been shown to play a role in MPR sorting at the TGN,
but not in LAMP-1 delivery to lysosomes (Puertollano et al., 2001). However, in this regard it
is worthwhile to note that lysosomal-associated multispanning membrane protein 5 (LAPTM5)
has been shown to be delivered to lysosomes by a pathway that involves ubiquitin-ligase
Nedd4 and ubiquitinated GGA3 (Pak et al., 2006).
The differential steady-state distributions of the three LAMP-2 isoforms that vary in their
cytoplasmic recognition signal have prompted the suggestion that the usage of the direct or
indirect (via the secretory pathway and plasma membrane) pathway is determined by the
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cytoplasmic targeting signal. The different LAMP-2 isoforms (A, B, & C) (Fambrough, 1995;
Hatem et al., 1995) have a similar tyr motif as LAMP-1 and would therefore probably be
gathered into similar CCVs at the TGN. However, transfection of mouse L cells with chimeras
consisting of the lumenal domain of avian LAMP-1 (LEP100) and the transmembrane and
cytosolic domains of avian LAMP-2 has shown that the various isoforms have different steady-
state distributions. Chimeras with the LAMP-2C cytosolic domain are predominantly localised
in lysosomes. Higher levels of the chimeras with the LAMP-2A or–B cytosolic domain occur
on the cell surface. This increase is not due to saturation of the sorting machinery, but due to
the differences in the recognition of the targeting signals. Site-directed mutagenesis identified
the hydrophobic amino acid () to be critical in determining the different steady-state
distributions. Based on the steady-state distribution of the various isoforms, Gough et al.
(1999) have argued that a particular LAMP-2 isoform may reach the endosomal system via the
direct or the indirect pathway (via the secretory pathway and plasma membrane), depending on
the signal in the cytoplasmic tail. However, it is also possible that all LAMP-2 isoforms are
delivered intracellularly via early endosomes. LAMP-2 isoforms with high affinity for sorting
sites in the early endosome/plasma-membrane compartment will result in efficient sorting to
lysosomes and therefore rapid movement through this compartment with limited cell-surface
expression at steady state. Alternately, LAMP-2 isoforms with low affinity for these sorting
sites will result in inefficient sorting, slower movement through this compartment and
increased cell-surface expression at steady state (see Discussion). Steady-state distributions do
not give any information about the possible movement of molecules through compartments.
Evidence for the direct delivery of LIMPs to lysosomes has been obtained from pulse-chase
experiments that were combined with immunoprecipitation of LIMPs in lysosomal fractions
obtained from Percoll density-gradients in NRK cells. The incorporation of newly-synthesised
LIMPs into the plasma membrane was determined by incubating the cells with anti-LIMP
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antibodies and then immunoprecipitating the LIMP-antibody complexes. None was detected on
the cell surface. Immunoprecipitation of LIMPs in fractions from Percoll density-gradients of
proteinase K treated cells confirmed that LIMPs in the fraction that colocalised with Golgi and
plasma-membrane markers did not originate from the cell surface. These data have been
interpreted to imply that LIMPs are delivered to lysosomes without appearance on the cell
surface (Barriocanal et al., 1986). In addition to Percoll density-gradient fractionation not
being quantitative, these observations also do not rule out the possibility that LIMPs are
delivered to lysosomes via early endosomes which migrate to the same position as the plasma
membrane and Golgi on Percoll density-gradients. The cytoplasmic tail of LIMP-II, which has
been shown to be sufficient for lysosomal sorting (Vega et al., 1991), contains a di-leu-based
motif (Sandoval et al., 1994) and selectively binds AP-3 (Diment et al., 1998; Honing et al.,
1998), an adaptor protein that has been colocalised with TGN markers in the perinuclear region
as well as with endocytic tracers in the cell periphery (Dell'Angelica et al., 1997; Dell'Angelica
et al., 1998; Simpson et al., 1996; Simpson et al., 1997). Since AP-3 forms part of a clathrin-
coat, it could mediate sorting of LIMP-II at the TGN along an intracellular route (either
directly to lysosomes or toward early endosomes), as well as at the early endosomes where it
could be prevented from recycling to the plasma membrane.
Further support for the direct pathway for LAMP-1 and LIMP-II has come from neuraminidase
treatment and biotinylation of cell-surface chimeras expressed in BHK-21 cells. Chimeras were
constructed of the lumenal and transmembrane domains of LAP (a lysosomal protein that
normally cycles between the plasma membrane and endosomes) and the cytoplasmic tails of
LAMP-1 or LIMP-II. The appearance of chimeras on the cell surface and their ability to cycle
between the plasma membrane and endosomes, as was determined from the extent of
desialylation of cell-surface chimera in response to neuraminidase treatment at 4ºC or 37ºC, or
protection of biotinylated cell-surface chimera from biotin stripping due to internalisation, were
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greatly reduced or abolished (Obermuller et al., 2002). These observations are, however, a
reflection of the steady-state distribution of these chimeras and do not give any information
with regard to the fluxes of movement of these proteins.
The above studies have been interpreted to imply that lysosomal proteins LAMP-1, LAMP-2C,
and LIMPs are not transported to lysosomes via the secretory pathway and the plasma
membrane. Instead, they are potentially sorted at the TGN into clathrin-coated vesicles and
directly delivered to lysosomes. Surface detection of these lysosomal membrane proteins as a
result of overexpression or mutations in the sorting motif (GYXX) of the cytoplasmic tail has
been interpreted to be due to saturation of or inefficient binding to an intracellular sorting site
(presumably the TGN) and thus misrouting to the plasma membrane via the secretory route.
However, it is also possible that these lysosomal membrane proteins are sorted at the TGN into
CCVs for transport to early endosomes. A second level of sorting could then occur in early
endosomes for transport of lysosomal membrane proteins to lysosomes via the endocytic
pathway. Early endosomes and the plasma membrane are in dynamic equilibrium. Saturation of
sorting sites or inefficient sorting could result in slower removal from the early
endosomal/plasma membrane compartment relative to the exchange of contents between these
compartments and thus surface detection.
Rous et al. (2002) have suggested, however, that a major fraction of CD63 (LAMP-3) is
delivered directly to lysosomes by a pathway that bypasses early endosomes. When NRK cells
stably transfected with wild-type human CD63 (LAMP-3) were treated with chloroquine,
CD63 was predominantly localised to lysosomes and only a small fraction occurred in early
endosomes, as was shown by indirect immunofluorescence. Chloroquine (a lysosomotropic
agent) is a weak base that increases the pH of endosomal compartments. Alkalinisation of
endosomes and lysosomes disrupts normal intracellular trafficking by inhibiting transport from
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early endosomes to lysosomes without affecting initial internalisation significantly (Clague et
al., 1994). A protein that cycles between early endosomes and the TGN (TGN38) was used as
an early endosomal marker. A chimera that consisted of the lumenal and transmembrane
domain of CD63 and the cytoplasmic tail of TGN38 (CD63-TGN38) colocalised with
endogenous TGN38 and served as a control of a protein that trafficks via early endosomes. The
rationale is that if CD63 is delivered to lysosomes via early endosomes, the CD63 would
accumulate in TGN38-positive early endosomes. CD63 was, however, mainly observed in
TGN38-negative structures while some colocalised with TGN38. These results have been
interpreted to imply that CD63 is mainly delivered to lysosomes by a pathway that bypasses
early endosomes while a small fraction is delivered via early endosomes.
Reservations about the implications of the above observations stem from the following
technical limitations: Immunofluorescence is generally not a quantitative technique. Results are
based on the assumption that upon treatment of cells with chloroquine, transport from early
endosomes to lysosomes is completely inhibited before newly-synthesised protein enters the
endocytic pathway. Hence, the appearance of the control CD63-TGN38 chimera in TGN38-
negative structures has been interpreted to be as a result of CD63-TGN38 delivered to late
endosomes and lysosomes before chloroquine was added. But according the methods, the
synthesis of protein was induced at the same time when chloroquine was added. So it is
possible that the full effect of chloroquine is not felt immediately upon administration and that
newly-synthesised proteins might enter the endocytic pathway before early endosome-
lysosome transport is completely inhibited, hence the appearance in lysosomes. No controls are
in place to label TGN38-negative structures as late endosomes or lysosomes. Also, chloroquine
treatment results in an abnormal cellular state. Intracellular trafficking might be affected at
other as yet unknown levels that are not controlled for here.
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3.1.4.2 Indirect delivery to lysosomes
The appearance of lysosomal membrane proteins (albeit at low concentrations) on the cell
surface, in early endosomes or both compartments at steady state or movement through these
compartments have generally been interpreted to imply that they are delivered to lysosomes via
the secretory pathway, plasma membrane and endocytosis. However, they could also be
delivered to early endosomes intracellularly and then reach the plasma membrane by recycling.
The plasma membrane and early endosomes are in dynamic equilibrium and cannot be
kinetically resolved.
3.1.4.2.1 Delivery via the secretory pathway, plasma membrane and endocytosis
Lysosomal membrane proteins have been observed on either the plasma membrane or on the
plasma membrane and in early endosomes of rat hepatoma and kidney cells (endolyn-78)
(Croze et al., 1989), chicken fibroblasts (LEP100) (Lippencott-Schwartz and Fambrough,
1986), rat hepatocytes (LAMP-2, LAP, LGP85, LGP107) (Akasaki et al., 1993; Akasaki et al.,
1994; Furuno et al., 1989a; Furuno et al., 1989b), BHK cells (LAP) (Braun et al., 1989;
Obermuller et al., 2002), mouse L-cells transfected with avian LAMP-1 (Mathews et al.,
1992), MDCK cells (endogenous AC17 antigen) (Nabi et al., 1991) and MDCK cells
transfected with endolyn (Ihrke et al., 2001), NRK cells (CD8-endolyn chimera) (Ihrke et al.,
2004), human leukaemia cells (LAMP-1 and LAMP-2) (Mane et al., 1989).
In rat hepatoma (Fu5C8) and NRK cells, immuno-cytochemical experiments have shown that a
78 kDa lysosomal membrane protein is present at low levels on the plasma membrane and
peripheral tubular endosomes. It is more concentrated on vacuoles, such as multivesicular
bodies (late endosomes), filled with endocytic tracers at 18.5ºC and positive for the MPR, as
well as on secondary lysosomes that contain hydrolases, but no MPRs or endocytic tracers at
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18.5 ºC. Since this protein is present in endosomes and lysosomes, it is termed endolyn-78
(Croze et al., 1989).
Using antibody internalisation at 37ºC, cell-surface (~2%) LAMP-1 (LEP100) in chicken
fibroblasts has been observed to be continually internalised and replenished, even in the
presence of cycloheximide, a molecule which inhibits protein synthesis. Cell-surface LAMP-1
is thus in continuous exchange with the intracellular pool (Lippencott-Schwartz and
Fambrough, 1986). Lysosomotropic agents result in LAMP-1 depletion from lysosomes and
augmentation in early endosomes. This has been interpreted to be due to a block in the flow of
LAMP-1 from endosomes to lysosomes and continuous recycling from lysosomes to the
plasma membrane. The exchange of cell-surface LAMP-1 with the intracellular pool is thus
probably a cycling between lysosomes and the plasma membrane via endosomes (Lippencott-
Schwartz and Fambrough, 1987).
Similar studies have been done in rat hepatocytes. Lysosomal glycoproteins of 107 kDa
(LAMP-1), 96 kDa (LAMP-2), 85 kDa and LAP have been shown to cycle between the cell
surface and the endocytic vacuolar system using antibody internalisation assays in the absence
or presence of cycloheximide. HRP linked to the Fab fragment of the antibody against either
one of the previously mentioned lysosomal proteins was internalised and accumulated in
lysosomes as has been observed by morphological studies or biochemical assays on Percoll
density-gradient fractions. The accumulation continued in the presence of cycloheximide. This
implied that dissociation of antibody from these lysosomal membrane proteins occurred in the
endocytic pathway (lysosomes) and that these lysosomal membrane proteins cycle between the
plasma membrane and the endocytic system (Akasaki et al., 1993; Akasaki et al., 1994; Furuno
et al., 1989a; Furuno et al., 1989b).
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LAP is synthesised as a membrane-bound precursor which is processed into the soluble mature
form in lysosomes. In transfected, LAP-overexpressing BHK cells, 17% of total LAP precursor
was accessible to neuraminidase treatment at 4ºC and therefore has been localised to the cell
surface. Newly-synthesised LAP (metabolically labelled for 30 min) appeared at the cell
surface with a half-time of 45 min, as was measured by antibody binding at 4ºC. The fraction
of LAP (labelled for 2 h) on the cell surface remained constant during a chase of up to 14 h, as
was measured by the response to neuraminidase treatment at 4ºC. During the 14th chase hour
LAP disappeared from the cell surface. LAP that was labelled for 2 h and chased for 2 h cycled
(a cycling time of 3 to 20 min has been estimated) between the plasma membrane and the
intracellular pool, based on its response to neuraminidase treatment. When cells were incubated
at 37ºC between neuraminidase treatments at 4ºC, intracellular LAP precursors became
susceptible to the removal of sialic acid residues. Braun et al. (1989) have interpreted these
results to imply that the LAP precursor is delivered to the cell surface where it cycles between
the plasma membrane and the endosomal pool for a considerable length of time before delivery
to lysosomes. In BHK-21 cells, the appearance on the cell surface and recycling between the
plasma membrane and the endosomes of chimera consisting of the lumenal and transmembrane
domain of LAMP-1 or LIMP-II (proteins which normally occur at very low levels on the cell
surface) and the cytoplasmic domain of LAP were greatly enhanced (Obermuller et al., 2002).
The above studies have shown that certain lysosomal membrane proteins continually cycle
between the plasma membrane and the intracellular pool (early endosomes and lysosomes) at
steady state. Kinetic studies have involved long labelling times of 30 min and 2 h and thus do
not provide sufficient kinetic data to make any definitive conclusions about the directional
movement of the lysosomal proteins.
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Using immunofluorescence in mouse-L cells, the plasma membrane has been implicated as a
site lying en route to lysosomes (Mathews et al., 1992). Mouse-L cells were transfected with
the chimera of the lumenal domain of the vesicular stomatitus virus G-protein and the
transmembrane domain and cytoplasmic tail of LEP100. Transient expression of the chimera
was visualised on the cell surface by immuno-fluorescence microscopy. The surface population
disappeared after protein synthesis inhibition by cycloheximide, and appeared and accumulated
in lysosomes when lysosome proteolysis was inhibited.
Indirect delivery via the plasma membrane or early endosomal compartment has been
suggested for the AC17 antigen in MDCK cells. Nabi et al. (1991) have observed a steady-
state expression of endogenous lysosomal membrane glycoprotein, AC17 antigen, and
transfected LEP100 on both apical (0.8%) and basolateral (2.1%) membranes of MDCK cells,
using periodate oxidation of cell-surface carbohydrates and reaction with biotin-X-hydrazide
followed by immunoprecipitation and 125I-streptavidin blotting. The passage of newly-
synthesised AC17 antigen through the basolateral membrane and early endosomes, but not the
apical membrane, has been observed from pulse-chase experiments in which antibodies to the
AC17 antigen were internalised during the last 15 min of the chase. According to the authors,
late endosomes in MDCK cells would be reached only after 15 min of fluid-phase endocytosis.
Non-immune antibodies were not noticeably internalised and therefore antibodies were
presumably not taken up by fluid-phase endocytosis. Newly-synthesised AC17 antigen
appeared at the basolateral membrane with a half-time of 35 min and disappeared with a half-
time of 35 min. The authors have argued that since the AC17 antigen moved through the
Golgi with a half-time of 25 min (based on Endo H resistance), the appearance on the
basolateral membrane (t1/2 = 35 min) was too rapid for prior delivery to lysosomes. The
fraction of newly-synthesised protein delivered via the basolateral membrane was determined
to be 74% by incubating the cells with anti-AC17 antigen antibody for 90 min, the time
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required for a 20 min pulse of AC17 antigen to move through the basolateral membrane/early
endosomal compartment. Movement of the AC17 antigen through the apical membrane was
measurable only after chloroquine treatment. The results have been interpreted to imply that
the AC17 antigen is targeted basolaterally before delivery to lysosomes and that apical
appearance is as a result of recycling from lysosomes (Nabi et al., 1991). While the above
study shows transient presence of newly-synthesised AC17 antigen through the basolateral
membrane and early endosomes, sufficient kinetic data is not available to conclude that 74% of
total newly-synthesised AC17 antigen is delivered via the basolateral membrane/early
endosomal compartment. Firstly, a 20 min 35S-methionine pulse is relatively long and would
thus contribute to a lack in kinetic resolution. Secondly, no kinetic information about the
appearance of newly-synthesised AC17 antigen in lysosomes is available to compare with its
appearance in the basolateral membrane/early endosomal compartment so as to draw
conclusions about the delivery path followed. As mentioned before, since the half-time of
appearance of a protein in a particular compartment is dependent on both its flux and pool size,
it cannot be used as a direct measure of the rate of transport into the compartment. Also,
nothing precludes the possibility that apical appearance of the AC17 antigen after chloroquine
treatment is due to newly-synthesised protein from the biosynthetic pathway that has become
detectable as a result of accumulation in the apical membrane/early endosomal compartment.
In a separate study in 2001, antibodies to endolyn have been shown to be preferentially
internalised from the apical domain and efficiently delivered to lysosomes in transfected
polarised MDCK cells. To distinguish between polarised sorting of newly-synthesised endolyn
at the TGN and redistribution to the cell surface after delivery to lysosomes, newly-synthesised
proteins were radiolabelled for 15 min and captured as they appeared on the apical or
basolateral membrane by chasing in the presence of antibodies to endolyn for 1 hour. However,
redistribution/recycling during this 1 hour chase cannot be ruled out. An analysis of CD8-
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endolyn chimeras in which the lumenal and transmembrane domain or just the lumenal domain
of endolyn is replaced by that of CD8 (a plasma-membrane protein) has revealed apical
targeting information in the lumenal domain of endolyn that predominated over basolateral
information in its cytoplasmic tail (Ihrke et al., 2001).
Endolyn has been shown to traffic via the cell surface by antibody-internalisation assays and
immunofluorescence in NRK cells expressing a chimera composed of the lumenal and
transmembrane domain of CD8 and the cytoplasmic tail of rat endolyn (CD8-endolyn) (Ihrke
et al., 2004). When AP-2mediated endocytosis was inhibited in 3T3 cells, lysosomal delivery
of endolyn was virtually abolished and cell-surface appearance increased. When transport from
early endosomes to lysosomes was inhibited by chloroquine treatment of NRK cells stably
transfected with the CD8-endolyn chimera, there was no colocalisation of the newly-
synthesised chimera with the lysosomal marker, lgp120. Although no early endosomal marker
was present, these results have been interpreted to imply that the CD8-endolyn chimera
accumulated in early endosomes. These results suggest that endolyn is delivered to lysosomes
almost exclusively along the indirect pathway, either via the secretory route, the plasma
membrane and endocytosis or intracellularly via early endosomes.
3.1.4.2.2 Intracellular delivery via early endosomes
Newly-synthesised 35S-labelled LAP has been observed in endosomes of rat liver cells. Its
presence in endosomes containing asialofetuin conjugated-HRP, a fluid-phase marker
endocytosed for 10 min, was measured as a loss of 35S-LAP due to the formation of insoluble
polymers, a reaction catalysed by HRP in the presence of DAB and hydrogen peroxide (Tanaka
et al., 1990b). The authors have interpreted this to be an indication of LAP present in early
endosomes. This introduces the possibility that newly-synthesised LAP is delivered to
lysosomes via early endosomes and is transported to the plasma membrane due to recycling.
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(Since the LAP cytoplasmic tail does not bind AP-1 in vitro (Obermuller et al., 2002), it is
possible that LAP might be sorted into Golgi-derived CCV’s that involve other adaptors.)
However, it is important to note that relatively long 35S-methionine pulses (30 and 60 min)
were used. This makes it difficult to clearly resolve where or when on the delivery path of LAP
the early endosomes are located.
Akasaki and co-workers (Akasaki et al., 1995; Akasaki et al., 1996) have examined the
transport of newly-synthesised lysosomal membrane proteins to early and late endosomes, in
addition to the cell surface and lysosomes. They performed kinetic studies on rat hepatocytes
using pulse-chase experiments, Percoll density-gradient fractionation, antibody binding and
internalisation and immunoprecipitation. The accumulation of labelled newly-synthesised
lysosomal membrane proteins on the plasma membrane, early endosomes, cell periphery, late
endosomes and lysosomes was measured. They have interpreted their kinetic curves to suggest
the following: LAMP-1 is delivered to lysosomes via the plasma membrane, early endosomes
and late endosomes, LAMP-1 being delivered to the plasma membrane with a slight delay.
LAMP-2 is delivered to lysosomes via early endosomes and late endosomes, with a small
amount reaching the plasma membrane via recycling. In addition to the LAMPs being
delivered to early endosomes directly from the TGN, a second wave is delivered from the late
endosomes due to recycling (and in the case of LAMP-1, also from the plasma membrane due
to endocytosis). A greater fraction of LAMP-2 is delivered via the cell peripheral
compartments than is the case for LAMP-1. They have suggested that this difference could be
due to the differences in the tyr motif in the cytoplasmic tail, resulting in differences in binding
affinities for the AP proteins and thus differences in the efficiencies with which they are
concentrated into CCVs.
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The conclusions of the above study remain limited because of technical and kinetic
uncertainties: Percoll density-gradient fractionation is not ideal for quantitative measurements
and may not clearly resolve endosomes from the TGN. Antibody binding to the cell surface at
4ºC was used to determine the amount of newly-synthesised protein that moved through the
plasma membrane. Proper quantification of LAMP on the cell-surface requires that the
antibody be added in excess, a detail the authors failed to address. Also, after the unbound
antibody was washed away and the cells were lysed so that the immunocomplexes could be
removed with Sepharose beads, it was assumed that the bound antibody would not dissociate to
establish a new equilibrium. The interpretation of the kinetic curves in the above experiments
is purely arbitrary. For example, it is an assumption that an increase of LAMP in a particular
compartment is as a result of newly-synthesised LAMP arriving from the TGN. It could be due
to recycling from another endocytic compartment. Also, the conclusion about the
compartments from which recycling of LAMP occurs is presumptive. There are no controls in
place to substantiate these interpretations. The delay (20 min) that has been observed in the
delivery of LAMP-1 to the plasma membrane is based on one experimental point. Relatively
long radio-active pulses of 20 min contribute to a lack in kinetic resolution. The rate-limiting
step in the trafficking of most proteins is export from the ER (Lodish et al., 1983). Subsequent
movement from the Golgi and TGN to the final destination occurs rapidly. Newly-synthesised
molecules would thus accumulate transiently in intermediate compartments. Unless very short
labelling periods are used, it is very difficult to determine when a labelled protein has exited
the TGN and kinetic resolution is compromised.
In an attempt to overcome this obstacle, Cook et al. (2004) have designed a LAMP-1 chimera
with a heterologous lumenal domain containing a motif that allows for tyr sulfation, a post-
translational modification restricted to the TGN, and the core sequence of avidin (Av) allowing
high-affinity interaction with biotinylated probes introduced into the endocytic pathway. The
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chimera could thus be radio-actively labelled with high specific-activity to serve as a marker
for exiting the TGN. The radio-actively labelled, newly-synthesised LAMP-1 chimera (YAL)
could then be captured as they entered endocytic vesicles by interaction with endocytosed
biotinylated IgG (BIG). YAL molecules were degraded in lysosomes after a lag of 15-20 min,
but entered the endocytic pathway within 5 min of chase. They have interpreted this to imply
that YAL does not enter lysosomes directly. This, however, assumes that YAL is degraded
immediately upon entering lysosomes. Pulse-chase experiments in which BIG was internalised
during the last 5 min of the chase have shown that YAL transits early endosomes. The authors
have suggested that YAL is delivered into the endocytic pathway only via early endosomes on
the basis of in vitro acceptor-donor fusion assays: 5 min acceptors-containing BIG produced
the same fusion activity as 60 min acceptors, or acceptor membranes prepared from cells
pulsed for 5 min with BIG and then chased for 30 min, when incubated with radio-actively
labelled TGN-derived YAL. Under conditions where the 5 min BIG pulse was chased for 45
min, they have shown with Percoll density-gradient fractionation that even though most BIG
was in late endosomes, the fusion activity was higher in early endosomes. Since rab5 (marker
for early endosomes) was also detected in late endosomal fractions, they have concluded that
the residual fusion activity in the late endosomal fractions was a result of contaminating early
endosomes (Cook et al., 2004).
Reservations about the above results stem from the following technical limitations: The authors
were unable to measure directly what fraction of the total newly-synthesised LAMP-1 chimera
was delivered via early endosomes. They did this indirectly with in vitro fusion assays. While
limiting donor membrane could be a reason for not having observed an increase in fusion
activity for the 60 min acceptors, the fusion product could also have been degraded in the
lysosomes. A contamination of late endosomal fractions with early endosomes does not
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necessarily imply that fusion seen in these fractions was a result of early endosomes only. The
behaviour of the chimera could be different to endogenous LAMP-1.
3.1.4.3 Summary
Arguments for direct delivery to lysosomes have been based on the absence of lysosomal
membrane proteins on the cell surface at steady state, no movement (or movement of only a
very small fraction) of newly-synthesised lysosomal membrane protein through the cell
surface, the fact that newly-synthesised proteins are delivered to the plasma membrane with the
same half-time as they are delivered to lysosomes, the colocalisation of lysosomal membrane
proteins and AP-1 in Golgi-derived membranes and the failure of newly-synthesised lysosomal
membrane proteins to accumulate in early endosomes upon chloroquine treatment of cells.
Arguments in favour of the indirect pathway via the secretory pathway and plasma membrane
have been based on the presence of lysosomal membrane proteins on the plasma membrane
and in early endosomes at steady state, albeit at low concentrations, an exchange of lysosomal
membrane proteins on the cell surface with an intracellular pool and the movement of newly-
synthesised lysosomal membrane proteins through the plasma membrane. Delivery of
lysosomal membrane proteins to lysosomes intracellularly via early endosomes has been
suggested by the observation of the movement of newly-synthesised lysosomal membrane
protein through early endosomes. The plasma membrane and early endosomes are in rapid
dynamic equilibrium and can not be kinetically resolved. Movement of newly-synthesised
lysosomal membrane protein through the plasma membrane or early endosomes could thus
either be due to delivery via the secretory pathway, the plasma membrane and endocytosis or
intracellularly via early endosomes, the plasma membrane being reached due to rapid exchange
with early endosomes.
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These apparent contradictory results and interpretations could be due to different cell types,
different lysosomal membrane proteins following different delivery paths, limitations of
experimental techniques and the lack of efficient kinetic resolution. Generally, experiments
have been performed at steady state. Even when pulse-chase experiments have been performed,
the relatively long labelling pulse limited detailed kinetic resolution.
To circumvent some of these problems, my approach allowed observation of the path of newly-
synthesised endogenous LAMP-1 in mouse P388D1 macrophages, labelled for a very short
period (5 min) at a very high specific-activity of 35S-methionine. The kinetics of 35S-labelled-
LAMP-1 entry into early endosomes or lysosomes were measured. As a reference, the kinetics
of LAMP-1 entry into the endocytic pathway (includes early endosomes and lysosomes) were
also measured. Results showed that the bulk of newly-synthesised LAMP-1 that entered the
endocytic pathway, entered via early endosomes and remained in early endosomes transiently.
I suggest that newly-synthesised LAMP-1 entered lysosomes only after it had left early
endosomes.
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3.2 MANNOSE 6-PHOSPHATE RECEPTORS
3.2.1 Types and structure
There are two types of MPRs, namely the cation-independent MPR (CI-MPR) and the cation-
dependent MPR (CD-MPR). The MPRs are type I integral membrane proteins. Their structures
are depicted in figure 3.2.1.
Figure 3.2.1 A schematic diagram of the CI-MPR and the CD-MPR
: potential glycosylation sites
: known, used glycosylation sites
This figure was adapted from (Dahms and Kornfeld, 1987; Dahms et al., 1989).
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3.2.1.1 Cation-independent mannose 6-phosphate receptor (CI-MPR)
The CI-MPR was first purified from bovine liver membranes using immunoprecipitation
succeeded by lysosomal -galactosidaseSepharose 4B affinity chromatography (Sahagian et
al., 1981). This receptor does not require cations for binding to its ligands, hence the name
cation-independent MPR. It consists of an N-terminal extracytoplasmic domain, a
transmembrane domain and a C-terminal cytoplasmic tail. The lumenal domain consists of 15
units with sequence identity to each other (16 38%) and to the extracytoplasmic domain of
the CD-MPR (14 28%) (Lobel et al., 1988). Two of the 19 potential glycosylation sites on
the lumenal domain are utilised. The oligosaccharides are asparagine-linked. It contains fucose
and terminal sialic acid residues. High-mannose residues are converted to complex-type
oligosaccharides, as determined by acquisition of resistance to Endo H in CHO cells (Pryor et
al., 1983; Sahagian and Neufeld, 1983). Phosphorylation of serine residues on the mature
protein occurs when this protein is in the TGN or just after it has exited from the TGN
(Meresse and Hoflack, 1993). Under reducing conditions the apparent molecular weight is 215
kDa. Under non-reducing conditions it migrates faster and can be resolved into two bands of
apparent molecular weights 180 and 168 kDa, suggesting the presence of intrachain disulphide
bonds (Sahagian and Neufeld, 1983). The calculated molecular weight of the CI-MPR’s 
protein component is 270 kDa. The actual molecular weight probably ranges between 275 − 
300 kDa as a result of glycosylation (Oshima et al., 1988). The CI-MPR is often referred to as
the MPR300. Two high-affinity man-6-P binding sites have been localised to domains 1 3
and 9 and one low-affinity site to domain 5 of the extracytoplasmic region. Domain 1 and 2 are
required for optimal binding by domain 3 (Hancock et al., 2002b; Reddy et al., 2004). Single
amino-acid substitutions in constructs that encoded either of the two man-6-P binding sites of
the CI-MPR and that were expressed in COS-1 cells, have identified four amino acids (gln392,
ser431, glu460, tyr465) in domain 3 and four (gln1292, his1329, glu1354, tyr1360) in domain 9 as critical
for man-6-P binding (Hancock et al., 2002a). A similar set four amino acids (gln644, arg687,
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glu709, tyr714) is also critical for carbohydrate recognition by domain 5 which has a higher
affinity for phosphodiesters than phophomonoesters (Chavez et al., 2007).
3.2.1.2 Cation-dependent mannose 6-phosphate receptor (CD-MPR)
This receptor has been first identified in P388D1 macrophages which fail to synthesise
detectable CI-MPR (Gabel et al., 1983; Pryor et al., 1983). My project is based on studies with
P388D1 macrophages and the CD-MPR. Therefore, I deal with this receptor here in more detail
than the CI-MPR. Cations are required for the binding of ligands, hence the name cation-
dependent MPR (Hoflack and Kornfeld, 1985a; Hoflack and Kornfeld, 1985b). The effect of
divalent cations on the binding efficiency of the CD-MPR is mediated by Asp103 (Sun et al.,
2005). The CD-MPR consists of an N-terminal extracytoplasmic domain, a hydrophobic
transmembrane domain and a C-terminal cytoplasmic tail. The lumenal domain is homologous
to the repeating units of the 215 kDa CI-MPR (Dahms and Kornfeld, 1987). This suggests that
both receptor types arose from a single ancestral gene. In BW5147 lymphoma and MOPC 315
plasmacytomal cells, the CD-MPR is synthesised as a 40 kDa glycoprotein that is processed to
a mature 43 kDa due to conversion of high-mannose residues to complex-type oligosaccharides
(Kornfeld, 1987b). It is also 43 kDa in human fibroblasts, but 46 kDa in human HepG2 cells,
U937 monocytes, blood-derived macrophages, rat Morris hepatoma 7777 cells (Stein et al.,
1987a) and mouse P388D1 macrophages (Hoflack and Kornfeld, 1985b). Hence the CD-MPR
is often referred to as the MPR46. It has been reported to have 7-8 asparagine-linked
oligosaccharides, of which 5 are converted to Endo H resistant types (Stein et al., 1987a), or 5
potential asparagine-linked glycosylation sites of which 4 are utilised (Dahms et al., 1989). N-
glycosylation assists the nascent CD-MPR to fold into a conformation that enhances ligand
binding and promotes efficient intracellular transport (Zhang and Dahms, 1993). The receptor
has potential serine phosphorylation sites and clusters of acidic residues. Ser56 is
phosphorylated, but is not essential for the stability, cell-surface expression or transport
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function of the receptor (Hemer et al., 1993). It has been shown to be palmitoylated at two
cysteines in its cytoplasmic tail (Reddy et al., 2003). Chemical cross-linking studies on
affinity-purified CD-MPR and solubilised membranes containing CD-MPR have indicated that
the mature protein exists as a homo-dimer. Similar studies on mutant CD-MPR have shown
that the transmembrane domain is important for dimer formation, but that a single lumenal
domain is necessary and sufficient for binding and release of ligand (Dahms and Kornfeld,
1989). Site-directed mutagenesis of the binding site of bovine CD-MPR, expressed transiently
in COS-1 cells, has revealed four amino acids (gln66, arg111, glu133, tyr143) which are essential
for ligand binding (Olson et al., 1999; Sun et al., 2005). This set of amino acids (gln, arg, glu,
tyr) is similar to that which is critical for binding in the binding sites of the CI-MPR. The three-
dimensional structure of the MPRs in complex with bound man-6-P confirms the mutagenesis
studies.
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3.2.2 Steady-state distribution
Immuno-cytochemical data on the intracellular distribution of the CI-MPR have on occasion
been contradictory. In general, using immuno-fluorescence and immuno-electron microscopy,
it has been observed in the endoplasmic reticulum, throughout the Golgi, in the TGN, coated
buds and coated vesicles arising from the TGN, in the plasma membrane, coated pits and
endosomes which include organelles that have been defined as CURL (compartment of
uncoupling of receptor and ligand) (Geuze et al., 1983; Geuze et al., 1984; Geuze et al., 1985),
figure 2.3. The bulk is localised to the TGN and endosomes (Geuze et al., 1984; Geuze et al.,
1985; Stein et al., 1987a; Willingham et al., 1983), predominantly late endosomes (Geuze et
al., 1988; Griffiths et al., 1988). MPRs are either present at very low levels, as in rat
parenchymal liver cells (Geuze et al., 1984) and in CHO cells (Willingham et al., 1983), or not
detected at all in lysosomes, as in human fibroblasts (Stein et al., 1987a; von Figura et al.,
1984), CHO cells (Sahagian and Neufeld, 1983) and rat hepatoma cells (Geuze et al., 1988).
Morphological studies on the CD-MPR are not as extensive, but evidence suggests that both
receptors exhibit a similar qualitative distribution (Bleekemolen et al., 1988). Using immuno-
labelling and semi-quantitative analyses, however, the CI-MPR has been observed to be
enriched in multi-vesicular endosomes while the CD-MPR is enriched in the associated tubules
and vesicles (ATV) which are different to those destined for the plasma membrane
(Klumperman et al., 1993). It has been suggested that this difference could be due to the CD-
MPR recycling much more rapidly to the TGN.
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3.2.3 MPR Function
The MPRs bind lysosomal enzymes in the TGN for delivery to lysosomes. The CI-MPR also
recognises and binds the insulin-growth factor (II) (IGF-II).
3.2.3.1 Biosynthesis of lysosomal enzymes
Lysosomal enzymes are co-translationally glycosylated in the rough endoplasmic reticulum
(RER). High-mannose residues are added at specific asparagine residues. The enzymes are
translocated into the ER with cleavage of the signal peptide and transported to the Golgi where
they are post-translationally modified. Specific determinants on lysosomal enzymes are
identified as signals for phosphorylation of mannose (Hasilik and Neufeld, 1980a) by enzymes,
N-acetylglucosaminyl-1-phosphotransferases and -N-acetylglucosaminyl phosphodiesterases,
localised in cis-Golgi cisternae (Pohlman et al., 1982).
3.2.3.2 Binding of lysosomal enzymes
Phopho-mannosyl residues on lysosomal enzymes are recognised by MPRs in the Golgi
(Hickman et al., 1974; Hieber et al., 1976). While the terminal man-6-P on lysosomal enzymes
is the critical determinant, inhibition binding studies have indicated that high-affinity binding is
attained through the recognition of an extended oligosaccharide structure, which probably
includes the manα1,2man linkage (Olson et al., 1999; Reddy et al., 2003). MPRs bind the
lysosomal enzymes in the Golgi at a pH close to neutral. Optimal binding of lysosomal
enzymes by CD-MPR occurs at pH 6.3, as determined by affinity-chromatography. At neutral
pH some lysosomal enzymes could be oriented such that the phosphorylated oligosaccharides
are not accessible to the CD-MPR binding site (Kornfeld, 1987a). Comparison of ligand-bound
versus ligand-free structures of the CD-MPR has revealed a significant change in the
quartenary structure. The binding pocket is re-organised by the relocation of a loop (glu134-
cys141). Olson et al. (2002) have proposed that the pKa of the sugar phosphate and his105 in the
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binding pocket could be responsible for its inability to bind ligand at the cell surface (pH 7.4),
and the pKa of glu133 could determine ligand release in the acidic environment of late
endosomes. The CI-MPR, on the other hand, is able to bind lysosomal enzymes on the cell
surface. Small changes in pH in the Golgi could result in differential binding by the two
receptors in the TGN (Kornfeld, 1987a).
3.2.3.3 Delivery of lysosomal enzymes to lysosomes
By binding to MPRs, lysosomal enzymes are sorted from the rest of the proteins in the TGN
(Duncan and Kornfeld, 1988; Griffiths and Simons, 1986; Willingham et al., 1983) and
packaged into CCVs. MPR-enzyme complexes are delivered into an acidic endocytic organelle
where the enzymes dissociate from the receptor due to the low pH (Dahms and Kornfeld, 1989;
Hoflack and Kornfeld, 1985a). The pKa of glu133 in the binding site could be responsible for
ligand release in the acidic environment (Olson et al., 2002). The requirement of an acidic
environment for the dissociation of enzymes from receptors is consistent with the depletion of
unoccupied receptors and the enhanced secretion of newly-synthesised acid hydrolases upon
chloroquine treatment of fibroblasts (Gonzalez-Noriega et al., 1980). (Chloroquine raises the
pH of acidic organelles above 6 and subsequently inhibits the dissociation of receptor-ligand
complexes. The depletion of unoccupied receptors results in missorting of lysosomal enzymes
and the blocking of endocytosis of exogenous lysosomal enzymes, hence the enhanced
secretion of enzymes.) Once the enzymes have dissociated from MPRs, phosphatases remove
the phosphates from the enzymes to prevent rebinding to receptors. If the acidic endocytic
organelle is a pre-lysosomal organelle, the enzymes are delivered to lysosomes along the
endocytic pathway. The receptors are sorted into tubular membrane elements and recycled to
the TGN for re-use (Duncan and Kornfeld, 1988). The recycling of the receptors to the Golgi is
triggered by the dissociation of the enzymes (Brown et al., 1986).
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3.2.4 Targeting signals
A series of sorting signals that ensure correct sorting of the MPRs at the plasma membrane,
TGN and endosomes has been identified (reviewed in Hille-Rehfeld, 1995).
3.2.4.1 Plasma membrane sorting
Internalisation of the CI-MPR at the cell surface is mediated by a tyr-based sorting signal,
Y24KYSKV29 (tyr24-lys-tyr-ser-lys-val29), in the 163-residue cytoplasmic tail (Canfield et al.,
1991; Jadot et al., 1992; Lobel et al., 1989). Three signals in the 67-residue cytoplasmic tail of
the CD-MPR mediate its internalisation: a signal that includes phe13 and phe18, F13PHLAF18
(phe13-pro-his-leu-ala-phe18), with phe18 being more important; a signal that involves tyr45,
Y45RGV48 (tyr45-arg-gly-val48) and a di-leu motif (L64-L65) at the C-terminal (Denzer et al.,
1997; Johnson et al., 1990).
3.2.4.2 Trans-Golgi Network sorting
Efficient sorting of the MPR at the TGN has been concluded from the characteristic steady-
state distribution of the MPR and efficient lysosomal enzyme sorting. The CI-MPR has two
signals in the cytoplasmic domain, a di-leu-based sorting signal, LLHV (leu-leu-his-val), and a
tyr-based endocytosis motif, Y24KY26SKV29, for efficient lysosomal enzyme sorting in the
Golgi. Deletion of LLHV partially impaired sorting. Mutation of YKYSKV does not affect
sorting, but in combination with the LLHV deletion disrupts enzyme sorting completely
(Johnson and Kornfeld, 1992a). There is evidence, however, that the cytoplasmic tail of the CI-
MPR is not sufficient to ensure the characteristic intracellular steady-state distribution of the
CI-MPR. In mouse 3T3 cells stably transfected with chimera composed of the lumenal and
transmembrane domains of the human epidermal growth factor (EGF) receptor and the
cytoplasmic tail of the CI-MPR (EEM) the EEM’s failed to localise to the TGN and the
endosomes. They predominantly localised to the cell surface and cycled efficiently between the
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cell surface and early endosomes (Dintzis and Pfeffer, 1990). However, chimeras composed of
the lumenal and transmembrane domains of the CI-MPR and the cytoplasmic tail of the human
EGF receptor (MME) or the lumenal domain of the CI-MPR and the transmembrane domain
and cytoplasmic tail of the EGF receptor (MEE) expressed transiently in CHO cells, localised
predominantly to a perinuclear structure, similar to the endogenous CI-MPR. These
observations have implicated determinants in the lumenal domain of the CI-MPR as being
involved in the targeting of the CI-MPR (Dintzis et al., 1994).
A di-leu-based sorting signal, HLL (his-leu-leu), in the cytoplasmic tail of the CD-MPR in
mouse L cells has been implicated in efficient intracellular sorting of cathepsin D (a lysosomal
enzyme). Mutation of the last five amino-acids (his-leu-leu-pro-met) to alanines resulted in
decreased efficiency of cathepsin D sorting. Mutation of the last two amino acids (pro-met) had
no effect, thus implicating only HLL. Ligand binding and receptor recycling from the cell
surface were unaffected. Hence, sorting at the level of the TGN was probably the step that was
affected (Johnson and Kornfeld, 1992b).
3.2.4.3 Endosomal sorting
Efficient sorting of the MPR in endosomes has been deduced from proper lysosomal enzyme
sorting and protection of the receptor from lysosomal delivery and subsequent degradation.
The effect of cytoplasmic tail truncation mutants and ala-scanning mutants (short stretches of
alanines were created using PCR mutagenesis) of bovine CD-MPR, expressed in mouse L
cells, on the recycling of the receptor to the TGN has been analysed using Percoll density-
gradient fractionation. Amino-acids 34-39 in the cytoplasmic tail are critical in preventing
lysosomal delivery and degradation of the receptor. The transmembrane domain contributes to
this function (Rohrer et al., 1995). Substitution of cys34 to ala caused lysosomal delivery of the
receptor and total loss of cathepsin D sorting. Cys34 is reversibly palmitoylated by membrane-
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bound palmitoyl-transferase that cycles between the plasma membrane and endosomes (Stockli
and Rohrer, 2004). This palmitoylation is impaired when amino-acids 34-39 are substituted by
alanines, thus causing abnormal receptor trafficking and missorting of cathepsin D (Schweizer
et al., 1996). A di-aromatic amino-acid motif, F18W19 (phe18-trp19), in the cytoplasmic tail of
the CD-MPR at a specific position relative to the transmembrane domain also determines
efficient sorting of the CD-MPR and avoids lysosomal delivery. Trp19 plays the main role,
while phe18, phe13 and neighbouring residues have a contributory role. According to Schweizer
et al. (1997), the substitution of phe18 and trp19 with other hydrophobic residues has no effect.
However, Nair et al. (2003) have reported that substitution with more bulky hydrophobic
amino acids decreased binding to Tip47 (a protein involved in this sorting step (Orsel et al.,
2000)) and resulted in delivery of receptor to lysosomes. Substitution with less hydrophobic
amino acids decreased binding to Tip47 further and increased receptor delivery to lysosomes
(Nair et al., 2003). In vitro transport from endosomal membranes to the TGN has also been
shown to be inhibited by a peptide that contains the acidic cluster di-leu motif of the CD-MPR
tail, thus implicating the di-leu motif (Medigeshi and Schu, 2003).
The CI-MPR, on the other hand, depends on a P49PAPRPG55 (pro49-pro-ala-pro-arg-pro-gly55)
loop and other hydrophobic amino acids in the cytoplasmic tail for efficient endosomal sorting.
The membrane-proximal residues, P49PAPRPG55 loop and V69A71 (val69-ala71), are important
for direct interaction with Tip47 and the membrane-distal residues are important for proper
folding and correct presentation (hydrophobic interphase) of the membrane-proximal
sequences (Orsel et al., 2000).
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3.2.5 Sorting machinery involved in targeting
The targeting signals specify the location to which MPRs must be transported. Presumably
MPRs carry lysosomal enzymes to endosomes from where MPRs are recycled to the TGN for
re-use, while the enzymes are delivered to lysosomes. A similar trafficking mechanism as
explained for LAMPs in section 3.1.3 shuttles MPRs between the TGN and endosomes.
Different sorting machineries are responsible for sorting MPRs into vesicles at the different
sites.
Adaptor proteins have been implicated in sorting at the TGN, plasma membrane and
endosomes. Clathrin-coat adaptor proteins such as AP-1, AP-2 and Golgi-localizing, γ-ear-
containing, ARF-binding protein (GGA’s) and AP-3 (can bind clathrin, but has been shown to
function without clathrin) are implicated in MPR trafficking. AP-1, GGA and AP-3 binding to
the membrane are regulated by ADP-ribosylation factor-1 (ARF-1), a small GTP-binding
protein. AP-1 and AP-2 mediate the binding between receptors and clathrin during the
formation of clathrin-coated vesicles at the TGN and the cell surface, respectively (Ahle et al.,
1988). Plasma-membrane-derived adaptor proteins (AP-2) and Golgi-derived adaptor proteins
(AP-1) bind to different signals in the cytoplasmic tail of the CI-MPR and CD-MPR (Glickman
et al., 1989; Honing et al., 1997; Pearse, 1988). Other proteins that have been implicated in
MPR recycling to the TGN and efficient lysosomal enzyme delivery are: dynamin (Nicoziani
et al., 2000), rab9 GTPase (Pryor et al., 2000), rab7 GTPase (Hoflack, 1998),
phosphatidylinositol 3-kinase (PI3-K) (Davidson, 1995; Reaves et al., 1996), Tip47 (Krise et
al., 2000; Orsel et al., 2000) and the mammalian retromer complex (Bonifacino, 2004).
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3.2.5.1 Adaptor protein-1
AP-1, also named the HAI-adaptor, colocalises with both the CI-MPR and the CD-MPR at the
trans-Golgi reticulum (TGR) (Klumperman et al., 1993). Both the MPR and the ARF-1 play a
role in CCV formation, which involves the recruitment of AP-1 to the TGN membranes and
subsequent clathrin-coat assembly. The exact sequence of how these molecular events unfold
has not been resolved. It has, however, been suggested that ARF-1 is responsible for creating
the initial high-affinity binding sites for AP-1 on the TGN membrane and that the MPRs
regulate ARF-GTP hydrolysis (Le Borgne et al., 1993; Le Borgne et al., 1996; Le Borgne and
Hoflack, 1997; Zhu et al., 1998; Zhu et al., 1999).
Two determinants in the cytoplamic tail of the MPRs are implicated in high-affinity binding of
AP-1 to TGN membranes: the casein kinase II phosphorylation site and a sequence that
includes the reversibly palmitoylated cys34, which is critical in preventing lysosomal delivery
of the receptor (discussed in 3.2.4.3). There is evidence that the phosphorylation of the casein
kinase II site is not a prerequisite for AP-1 binding, but this is still controversial. The
importance of the palmitoylation in AP-1-binding is not known (Honing et al., 1997; Le
Borgne et al., 1993; Mauxion et al., 1996). Glutathione-S-transferase (GST) pull-down assays
have shown that AP-1 does not bind the acidic-cluster-dileucine signal in the cytoplasmic tail
of the MPR (Puertollano et al., 2001).
Immunostaining for the γ-adaptin subunit of AP-1 in µ1A-adaptin-deficient mouse fibroblasts
has shown no labelling on TGN membranes (Meyer et al., 2000). The µ1A subunit thus
probably mediates binding of AP-1 to TGN membranes. Using quantitative immuno-electron
microscopy in secretory cells, it has been shown that MPRs and AP-1 colocalise on clathrin-
coated buds of immature secretory granules arising from the TGN. During maturation of the
secretory granules the MPRs and AP-1 are sorted out of the granules (Klumperman et al.,
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1998). This is evidence for AP-1 being involved in sorting the MPRs away from the secretory
pathway, and probably toward the endocytic pathway.
Evidence that AP-1 may also be involved in sorting at the endosomes has come to light. In
µ1A-deficient mouse fibroblasts, the steady state of both MPRs is shifted from the TGN to the
endosomes. Recycling of the MPR46 to the TGN is impaired (Meyer et al., 2000). In vitro
transport from µ1A-deficient endosomal membranes to the TGN is also severely hampered
(Medigeshi and Schu, 2003).
In HeLa cells, two-colour time-lapse video microscopy has shown colocalisation of chimera
consisting of a cyan fluorescent protein (CFP), the transmembrane domain and the cytoplasmic
tail of the CI-MPR (CFP-CI-MPR) and chimera consisting of a yellow fluorescent protein
(YFP)and the γ-subunit of AP-1 (YFP-AP-1) at the TGN, TGN-derived tubules and peripheral
structures (Waguri et al., 2003). This supports the notion that AP-1 may mediate sorting of the
MPR at the TGN and endosomes.
AP-1 binds both phosphofurin acidic cluster sorting protein 1 (PACS-1) (Wan et al., 1998,
Crump et al., 2001) and GGA (Doray et al., 2002a). Both proteins are involved in TGN-
endosome trafficking. AP-1 has been shown to colocalise with GGAs in clathrin-coated buds at
the TGN. It is possible that AP-1 mediates both retrograde and anterograde trafficking between
the TGN and endosomes. Interaction with either PACS-1 or GGA could determine the active
pathway.
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3.2.5.2 Adaptor protein-2
Tyrosine residues in positions 24 and 26 in the cytoplasmic tail of the CI-MPR are critical for
the binding of AP-2 at the plasma membrane. It has been suggested that this binding process
selects specific receptors for incorporation into CCVs and subsequent internalisation
(Glickman et al., 1989; Lobel et al., 1989; Pearse, 1988).
Studies on the binding of determinants in the cytoplasmic tail of the CD-MPR have been
inconsistent. Plasmon surface resonance has shown AP-2 binding to the phenylalanine
determinant, F13PHLAF18, and not the tyr motif (Honing et al., 1997). Yeast two-hybrid system
and mutational analyses, on the other hand, have shown binding of the medium subunit of AP-
2 (µ2) to the tyr-based signal and not the phenylalanine motif (Storch and Braulke, 2001). Both
studies, however, have shown AP-2 binding to a distal sequence rich in acidic amino acids
(casein kinase 2 site) and no binding to the di-leu motif (Puertollano et al., 2001).
3.2.5.3 Adaptor protein-3
AP-3 is localised to the TGN and endosomes and its association to the membrane is regulated
by ARF-1 (Ooi et al., 1998). Multiple, partially overlapping C-terminal signals, comprising a
di-leu motif, tyr motif and clusters of acidic residues in the cytoplasmic tail of the CD-MPR
have been shown to be involved in µ3A binding. The cytoplasmic tail of the CI-MPR,
however, fails to bind µ3A (Storch and Braulke, 2001). Cytosolic AP-3 inhibits in vitro
transport from endosomal membranes to the TGN (Medigeshi and Schu, 2003). This and the
fact that AP-3 binds PACS-1 (Crump et al., 2001) implicate AP-3 in endosome to TGN
transport.
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3.2.5.4 Golgi-localising, γ-ear-containing, ARF-binding proteins (GGA’s)
This is a monomeric, multidomain family of proteins that facilitates trafficking from the TGN
to the endosomes. Three of the four domains are homologous to other proteins according to
which the domains have been named. GGAs consist of an amino-terminal VHS (for Vps27,
Hrs and STAM homology) domain, a GAT (for GGA and TOM homology) domain, a non-
conserved linker region and a carboxy-terminal GAE (for -adaptin ear homology) domain
(Mullins, 2005). ARF-1 facilitates the association of GGAs to the TGN membrane (Black and
Pelham, H. R. B., 2000; Dell'Angelica et al., 2000; Zhdankina et al., 2001) and then regulates
the binding of GGAs with MPRs (Hirsch et al., 2003). Yeast two-hybrid systems, GST pull-
down assays and plasman resonance spectroscopy have shown that GGAs bind to the CI-MPR
and the CD-MPR (Puertollano et al., 2001; Zhu et al., 2001). The acidic cluster di-leu motif in
the cytoplasmic tail of MPRs interacts with the N-terminal (VHS) domain of the GGAs. The
spacing of the di-leu motif relative to the membrane is important for optimal GGA binding.
Specific amino acids in the cytoplasmic tail of the CI-MPR are responsible for the higher
affinity-binding of the CI-MPR compared to the CD-MPR (Doray et al., 2002b). GGAs have
been colocalised with MPRs at the TGN and peripheral vesicles. Tubulo-vesicular structures
were shown to bud from the TGN and move toward the cell periphery using
immunofluorescence and time-lapse, confocal microscopy in MDCK cells (Puertollano et al.,
2001). This is evidence that GGAs might mediate movement from the TGN to early
endosomes.
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3.2.6 Targeting pathways
Limited studies have been directed at determining the pathway along which MPRs transport
lysosomal hydrolases to lysosomes. Suggestions about its possible route have mostly been
based on steady-state observations. Here follows a critical account of the development of these
suggestions and interpretations.
3.2.6.1 Direct delivery of lysosomal enzymes by MPRs to lysosomes
In hepatocytes, exocrine pancreatic and epididymal epithelial cells, MPRs have been observed
in the cis-Golgi cisternae, coated vesicles, endosomes and lysosomes by electron microscopy
(Brown and Farquhar, 1984b). Since MPRs are limited to the cis side of the Golgi in these
cells, Brown et al. (1984) have suggested that MPR-enzyme complexes are packaged into
CCVs from the cis-Golgi cisternae. This does not, however, explain the presence of
phosphorylated, sialylated hybrid and complex type oligosaccharides in lysosomal enzymes in
lysosomes. These modifications can only occur in the trans-Golgi cisternae where the
necessary enzymes (for example, terminal glycosyltransferases) are localised. In normal
fibroblasts, MPRs have been observed in the Golgi, coated vesicles, lysosomes and endosomes
by immunocytochemistry. In mucolipidosis II (I-cell) disease fibroblasts, in which the
lysosomal enzymes lack man-6-P, the MPRs accumulate in one or two Golgi cisternae (has
been assumed to be the putative cis-Golgi sorting site) and coated vesicles concentrated on the
side of the presumed cis-Golgi sorting site. These vesicles were initially thought of as primary
lysosomes via which MPRs delivered lysosomal enzymes directly to secondary lysosomes
(Brown and Farquhar, 1984a). However, treatment of cultured clone 9 hepatocytes with NH4Cl
or chloroquine resulted in depletion of CI-MPRs from the Golgi and accumulation in dilated
vacuoles which were endosomes on the basis of the presence of endocytic tracers and absence
of lgp120 (Brown et al., 1984; Brown et al., 1986).
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3.2.6.2 Indirect delivery of lysosomal enzymes by MPRs to lysosomes
It is possible for MPR-enzyme complexes to be delivered into any one of the organelles along
the endocytic pathway. The enzymes would dissociate from the receptors because of the acidic
environment of endosomes and be delivered to lysosomes via the endocytic process, while the
receptors would recycle to the TGN.
Studies that involved the inhibition of intra-organellar acidification have suggested that MPR-
enzyme complexes are transported to a pre-lysosomal acidified organelle. A decrease in the
uptake of lysosomal enzymes by MPRs has been observed in CHO mutants defective in ATP-
dependent acidification of endosomes (Merion et al., 1983; Robbins et al., 1983; Robbins et
al., 1984). This is probably due to the inhibition of MPR-enzyme dissociation and a resultant
depletion of unoccupied receptors. Since the acidification of lysosomes is not defective in these
mutants, these observations have implied that MPR-enzyme complexes are delivered to an
acidic pre-lysosomal endosome. This view has been supported by observations from immuno-
cytochemical and biochemical experiments that have indicated that MPRs are generally either
present at very low levels or not detected at all in lysosomes (see section 3.2.2). Palmitoylation
of cys34 in the cytoplasmic tail of the CD-MPR has been shown to prevent lysosomal delivery
of the receptor (Schweizer et al., 1996). Localisation of the relevant palmitoyltransferase in the
plasma membrane and endosomes supports the view that CD-MPRs transport enzymes
indirectly to lysosomes (Stockli and Rohrer, 2004).
MPRs could transport lysosomal enzymes into the endocytic pathway via the secretory route,
to the plasma membrane from where the MPR-enzyme complexes would then be endocytosed.
Alternately, the enzymes are transported intracellularly via early endosomes or late endosomes
from where they would reach the cell surface by recycling.
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3.2.6.2.1 Delivery via the secretory route, plasma membrane and endocytosis
MPRs and lysosomal enzymes occur in coated pits of the plasma membrane and colocalise
with albumin in Golgi secretory vesicles, as observed by immuno-gold double-labelling.
Treatment of cells with lysosomotropic agents resulted in accumulation of MPRs in the TGR
and coated buds. Since these buds also contained albumin, a marker of the secretory pathway,
the data have been interpreted as suggesting that the MPR-lysosomal enzyme complexes are
transported in coated vesicles along the secretory route to the cell surface and endocytosed for
delivery of lysosomal enzymes to lysosomes (Geuze et al., 1984; Geuze et al., 1985).
Secreted lysosomal enzymes are often interpreted as a measure of the indirect pathway via the
secretory route to the plasma membrane. Secreted enzymes could reach the cell surface via
secretory vesicles in an unbound form or they could be bound to MPRs and then be released
into the extracellular medium by dissociation from the receptors. In non-transfected Baby
Hamster Kidney (BHK) and mouse L cells, antibodies to the binding site of the CD-MPR
reduce secretion of lysosomal enzymes. Endogenous CD-MPRs therefore contribute somewhat
to basal secretion (Chao et al., 1990). Since basal levels of secreted enzymes are low in cells
expressing both MPRs, it has been interpreted to imply that the indirect pathway via the
secretory route is only a minor pathway. This is supported by the fact that when cells were
incubated in media containing man-6-P or any other compounds that interfere with MPR-
dependent uptake of lysosomal enzymes, lysosomal enzymes were not depleted from the cells
and little, if any, extracellular accumulation occured (Hasilik and Neufeld, 1980b; Kasper et
al., 1996; Vladutiu and Rattazzi, 1978; von Figura and Weber, 1978). However, if binding
between enzyme and receptor is avid, very little, if any, enzyme would be released into the
extracellular medium. Low levels of secreted enzyme therefore do not necessarily exclude the
possibility for transport via the cell surface to be a major pathway.
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The CD-MPR has been shown to mediate both secretion and transport to lysosomes of
lysosomal enzymes. In BHK and mouse L cells that overexpressed CD-MPRs, secretion of
enzymes was induced. Incubation of these cells with antibodies against CD-MPRs reduced
their secretion (Chao et al., 1990). In mouse embryonic fibroblasts (MEFs) deficient in both
MPRs, overexpression of CD-MPRs has, however, been shown to reduce secretion and
mediate sorting of lysosomal enzymes to lysosomes (Kasper et al., 1996). The addition of
antibodies to the medium of Morris hepatoma 7777 cells, that only expressed CD-MPRs,
increased secretion of newly-synthesised lysosomal enzymes (Stein et al., 1987b). The ability
of the CD-MPR to mediate both secretion and transport of enzymes to lysosomes is best
explained by the fact that CD-MPR-enzyme complexes pass through a site from which ligands
can access the medium en route to lysosomes. The plasma membrane and early endosomes
have been proposed as candidates for this site (Chao et al., 1990). CD-MPRs can internalise
antibodies but do not endocytose exogenous lysosomal enzymes (Stein et al., 1987b). These
observations suggest that CD-MPRs do not bind lysosomal enzymes on the cell surface where
the pH is 7.4 (see section 3.2.3.2). It is therefore possible that as CD-MPR-enzyme complexes
move through the plasma membrane, the enzymes dissociate from the receptors. Since the
plasma membrane is in rapid equilibrium with early endosomes, it is possible for the CD-MPR-
enzyme complexes to evade this dissociation process on the cell surface and thus be
internalised. Alternately, CD-MPR-enzyme complexes could be delivered to early endosomes
where dissociation might not take place to the same extent as on the cell surface. Secretion or
delivery to lysosomes of enzymes will therefore depend on the affinity of the ligands for the
receptors.
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3.2.6.2.2 Intracellular delivery via endosomes
Several observations have indicated that MPR-enzyme complexes leave the TGN in CCVs
which deliver their cargo to the endocytic pathway without reaching the plasma membrane (Le
Borgne and Hoflack, 1998). MPRs and AP-1 are sorted out of maturing secretory granules
(Klumperman et al., 1998) probably toward the endocytic pathway. The identification of
CURL, where enzymes occur in the lumina of smooth vesicles while the MPRs are present on
the tubules (Geuze et al., 1984; Geuze et al., 1985), has suggested an endosomal site for the
delivery and dissociation of MPR-enzyme complexes. Also, immature lysosomal enzymes,
such as pro-cathepsin D, were detected in endosomes, labelled with early or late endocytic
tracers (Rijnboutt, 1992), and in CI-MPR positive membranes (von Figura and Hille-Rehfeld,
1994). Further evidence for delivery to endosomes came from treatment of cultured clone 9
hepatocytes with lysosomotropic agents (NH4Cl or chloroquine). The CI-MPR was depleted
from the Golgi and accumulated in dilated vacuoles which were endosomes, based on the
presence of endocytic tracers and absence of lgp120 (Brown et al., 1986).
Delivery via early endosomes
The secretion of lysosomal enzymes has often been interpreted in the literature to be as a result
of indirect delivery via the secretory route to the plasma membrane (Chao et al., 1990; Kasper
et al., 1996). However, this could also be an indication of MPR-enzyme complexes delivered
to early endosomes. The early endosomes are in dynamic equilibrium with the cell surface.
Any dissociation of enzymes from receptors in early endosomes could thus result in secretion.
Using quantitative immunocytochemistry, four categories of vacuoles have been identified in
rat hepatoma cells: MPR+/lgp120-, MPR+/lgp120+, MPR-/lgp120+ and MPR-/lgp120-, where ‘’ 
and ‘’ indicate the presence and absence of the specific protein, respectively. The kinetics of
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appearance of endocytic tracers (HRP) in these vacuoles have been determined indirectly
through the removal of MPR and lgp120 (detected via western blotting) from cell
homogenates, after these were subjected to HRPDAB cross-linking. Endocytic tracers
appeared in MPR+/lgp120- vacuoles almost immediately after endocytosis. Only after much
longer incubation periods did they appear in lgp120+ vacuoles (Geuze et al., 1988).
MPR+/lgp120- vacuoles could thus most likely be early endosomes into which MPR-enzyme
complexes are delivered. MPR+/lgp120+ vacuoles could most likely be late endosomes where
MPRs are sorted from lgp120 and recycled to the TGN.
Further evidence for the presence of the CI-MPR, as well as lysosomal enzymes, in early
endosomes came from determining their concentrations in early and late endosomes, using
immunoblotting and/or enzymatic assays in rat hepatocytes. The concentrations of the CI-MPR
as well as those of five lysosomal acid hydrolases were determined to be similar in early and
late endosomes separated on a discontinuous sucrose gradient (Runquist and Havel, 1991). The
CI-MPR was enriched in membranes corresponding to the receptor recycling compartment
whereas the acid hydrolases were reduced. In addition to mature cathepsin D, procathepsin D
was also detected in the endosome fractions, as if to suggest that processing of enzymes occurs
in endosomes.
The above observations reflect the steady-state distribution of the MPRs and lysosomal
enzymes and thus only provide circumstantial evidence for possible delivery via early
endosomes. Some kinetic information has become available with the work of Ludwig et al.
(1991). Using pulse-labelling, internalisation of antibody against cathepsin D (5 min) at the end
of every chase period and subsequent immunoprecipitation in the presence of excess unlabelled
cathepsin D, newly-synthesised cathepsin D has been shown to be a transient component of
early endosomes in NRK cells. The same amount of enzyme was observed in early endosomes
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in the presence of man-6-P in the medium. Man-6-P in the medium prevents possible uptake of
secreted enzymes. This suggests intracellular delivery to early endosomes, either directly from
the TGN or via recycling from late endosomes. The latter has been thought to be unlikely
because no evidence had existed for recycling from late endosomes. Due to the inability to
immunoprecipitate cathepsin D quantitatively, the authors have acknowledged that they were
unable to determine whether the early endosome is a major delivery site or whether what they
have observed is missorting of the enzymes destined to late endosomes (Ludwig et al., 1991).
Shifts in the steady-state distribution of the CI-MPR and an immature form of cathepsin D
toward early endosomes have also suggested delivery via early endosomes. Transport from
early to late endosomes was blocked in BHK cells that inducibly expressed dominant-negative
mutant forms of rab7 GTPase. Using pulse-labelling, gradient fractionation, HRPDAB cross-
linking and immunoprecipitation, the CI-MPR and an immature form of cathepsin D were
shown to accumulate in early endosomes. The increase in the early endosomal pool of
hydrolases was not due to secreted hydrolases because the experiments were performed in the
presence of man-6-P in the media. There was thus a delay in the processing of cathepsin D
(Hoflack, 1998). These observations are in favour of newly-synthesised cathepsin D and MPR
delivery via early endosomes.
Umeda et al. (2003) have shown that in normal and Niemann-Pick Type C (NPC) fibroblasts
the CI-MPR is preferentially localised to the TGN, positive for AP-1 and syntaxin 6, thus
indicating efficient recycling of the receptor from the endosomes to the TGN. This is in
contrast to what has previously been observed by Kobayashi et al. (1999), according to whom
the CI-MPR redistribute to late endosomes, positive for CD 63, in NPC fibroblasts. In NPC
fibroblasts cholesterol accumulates in late endosomes and late endocytic trafficking is
impaired. The fact that the CI-MPR does not accumulate in late endosomes and receptor
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recycling is not impaired in NPC fibroblasts (Umeda et al., 2003) imply that the late endosome
is not the site from where recycling occurs. When normal and NPC fibroblasts were treated
with chloroquine, an inhibitor of membrane flow from early endosomes, the CI-MPR
accumulated in early recycling endosomes, positive for early endosomal antigen 1 (EEA1) and
transferrin. Since the same was observed for TGN38 (a protein that normally recycles between
the TGN and the cell surface via early endosomes), the authors have interpreted these
observations to imply that the CI-MPR is delivered to early endosomes from the TGN and
recycled from early endosomes to the TGN (Umeda et al., 2003).
In HeLa cells, time-lapse video microscopy studies have shown movement and fusion of TGN-
derived tubules containing green fluorescent protein (GFP)CI-MPR (fluorescent chimera) to
and with the peripheral tubular network which is in dynamic equilibrium with early endosomes
(Waguri et al., 2003), thus supporting delivery to early endosomes.
Delivery via late endosomes
An ‘acidic reticular-vesicula structure’, where the bulk of the MPR is localised, has been 
identified in normal rat kidney cells (Griffiths et al., 1988). This structure is positive for
lysosomal enzymes and the lysosomal membrane protein, lgp120. It can be loaded with
endocytic markers at 37ºC, but not at 20ºC. It is thus a late endocytic structure, but not a
lysosome which is generally devoid of MPRs. Griffiths et al. (1988) have proposed that MPR-
enzyme complexes are delivered into this MPR/LGP-enriched late endosome where lysosomal
enzymes dissociate from MPRs and, together with LGPs, are packaged for delivery to
lysosomes, while MPRs are recycled to the TGN.
Work by (Kasper et al., 1996) has been interpreted to imply that CI-MPRs transport newly-
synthesised lysosomal enzymes along an intracellular route via late endosomes, and that
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lysosomal enzymes transported via the cell surface are missorted enzymes that have been
recaptured by CI-MPRs. In MEFs deficient in both MPRs, overexpression of CI-MPRs
completely restores lysosomal enzyme sorting. However, 25% of lysosomal enzymes are
transported via a man-6-Psensitive pathway. Since lysosomal enzyme transport is insensitive
to man-6-P in the medium in control MEFs that express both receptors or overexpress the CI-
MPR in addition to expressing the CD-MPR, the authors have suggested that this fraction of
enzymes binds CD-MPRs in the TGN, but not CI-MPRs. In the absence of CD-MPRs these
enzymes could be secreted. These missorted enzymes are recaptured probably because they can
bind CI-MPR on the cell surface. The authors have indirectly suggested that the remaining
75% lysosomal enzymes are transported via an intracellular man-6-Pinsensitive pathway.
Since early endosomes are in dynamic equilibrium with the cell surface, it has been considered
sensitive to man-6-P in the medium. The man-6-Pinsensitive pathway would thus probably be
via late endosomes. Another explanation for the above observations is that CI-MPRs transport
all enzymes via the man-6-Psensitive plasma membrane/early endosomal compartment; the
75% of enzymes just bind to CI-MPRs with a very high affinity such that they do not
dissociate, whereas the 25% of lysosomal enzymes binds with a lower affinity to CI-MPRs and
more tightly to CD-MPRs.
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3.2.6.3 Summary
From the above account it is clear that there is a substantial amount of circumstantial evidence
to suggest that delivery of MPR-enzyme complexes into the endocytic pathway could occur via
early endosomes. However, there is very limited kinetic information available to make any
conclusive arguments. Work presented here on the CD-MPR was aimed at providing a control
for the kinetic behaviour of a protein that has a different steady-state distribution to LAMP-1.
My approach was designed to allow direct observation of the pathway followed by newly-
synthesised endogenous CD-MPR in mouse P388D1 macrophages, labelled for a very short
period (5 min) at a very high specific activity of 35S-methionine. The kinetics of 35S-labelled-
CD-MPR entry into early endosomes or lysosomes were measured. As a control for total
endocytic CD-MPR along the time course, the kinetics of 35S-CD-MPR entry into the
endocytic pathway were also measured. Results suggested that the bulk of newly-synthesised
CD-MPR was delivered into the endocytic pathway via lysosomes from where they were
transported to late endosomes for recycling to the TGN. Due to relatively low CD-MPR
expression levels, however, results were not sufficiently reproducible to make any definite
conclusions.
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3.3 APPROACH OF THIS STUDY
To determine whether LAMP-1 or CD-MPR are delivered directly to lysosomes or via early
endosomes, the kinetics by which newly-synthesised 35S-LAMP-1/35S-CD-MPR entered into
either early endosomes or lysosomes were compared with the kinetics of entry into the
endocytic pathway.
3.3.1 Formation of newly-synthesised 35S-LAMP-1/35S-CD-MPR
Newly-synthesised LAMP1/CD-MPR was metabolically labelled by the incubation of P388D1
cells in medium containing 35S-methionine for 5 min at 37ºC. The pulse was then chased as a
function of time in medium with unlabelled methionine.
3.3.2 Capturing 35S-LAMP-1/35S-CD-MPR in the different organelles
The localisation of chased 35S-LAMP-1/S35-CD-MPR in the endocytic pathway, early
endosomes or lysosomes was determined by trapping it in the respective organelles. This
trapping was attained due to colocalisation with HRP that catalyses the cross-linking of DAB
in the presence of hydrogen peroxide (H2O2). HRP could be positioned in the respective
compartment by endocytic uptake for various times. All proteins in the specific organelle,
including the 35S-LAMP-1/35S-CD-MPR were then trapped in the resultant meshwork (Courtoy
et al., 1984; Stoorvogel, 1998).
Figure 3.3.1 HRPDAB cross-linking
cross-linked organelle
HRP-containing organelle
H2O2DAB
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3.3.3 The colocalisation of 35S-LAMP-1/35S-CD-MPR with HRP along the endocytic
pathway
HRP is a fluid-phase endocytic marker that can be administered to the cells such that it is
present along the entire endocytic pathway, early endosomes or lysosomes. To determine the
localisation of 35S-LAMP-1/35S-CD-MPR along the endocytic pathway, the endocytic
pathway was loaded with HRP by incubating the cells in medium that contained HRP before
labelling the cells with 35S-methionine. HRP was continually present during the labelling and
chase periods. To determine the localisation of 35S-LAMP-1/35S-CD-MPR in early
endosomes, the early endosomes were loaded with HRP by incubating the cells with HRP
during the last 5 min of every chase period. This was based on the finding that early endosomes
mature with a half-life of 3 min in P388D1 cells (Thilo et al., 1995). To determine the
localisation of 35S-LAMP-1/35S-CD-MPR in lysosomes, lysosomes were first loaded with HRP
before the pulse-labelling and chase procedures. The HRP internalisation periods that would
ensure optimal cross-linking of proteins in the endocytic pathway and lysosomes were
optimised as described in Results 4.1.3.2.
Figure 3.3.2 HRP Internalisation. HRP can be internalised by endocytosis and restricted to
specific organelles along the endocytic pathway depending on the period of incubation.
early
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3.3.4 Detection and quantitation of 35S-LAMP-1/35S-CD-MPR
Metabolically labelled cells in which HRP was localised to specific organelles were split into
two fractions. One fraction was subjected to HRPDAB cross-linking and the other served as a
control. The cells were lysed and the insoluble and cross-linked material was removed by
centrifugation. Antibodies against LAMP-1 or CD-MPR were used to immunoprecipitate
LAMP-1/CD-MPR from the detergent-soluble fraction of the lysate. The immunoprecipitant
was resolved using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).
The gel was dried and exposed using the InstantImager or Optiquant digital analysis program.
The position of the visible 35S-LAMP-1/35S-CD-MPR band was determined relative to
molecular-weight markers that were marked with 14C. Based on this pre-determined position,
the invisible LAMP-1/CD-MPR band was subsequently excised from wet gels relative to
silver-stained molecular-weight markers. The gel was solubilised in hydrogen peroxide and
subjected to scintillation counting for detection of 35S-LAMP-1/35S-CD-MPR. Since both total
and non-cross-linked 35S-LAMP-1/35S-CD-MPR were measured, the fraction of cross-linked
35S-LAMP-1/35S-CD-MPR was calculated using the equation discussed in Results 4.1.4.6.
CD-MPR
kDa
Experiment
cross-linked cells
Control
non-cross-linked cells
SDS-PAGE analysis
gel bands solubilised, 60°C, H2O2, overnight
35S-LAMP1/35S-CD-MPR counted
fraction of cross-linked 35S-LAMP1/35S-CD-MPR
immunoprecipitation
centrifugation
soluble &
non-cross-linked
material
detergent
solubilisation
detergent-insoluble
& cross-linked
material
detergent-insoluble
material
fraction of non-cross-linked 35S-LAMP1/35S-CD-MPR
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Figure 3.3.3 Sample processing and analyses
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3.4 PREDICTIONS
The outcome of such experiments can be predicted by compartmental modelling. New
lysosomal membrane protein is synthesised at rate dS/dt [mole/time] and enters the endocytic
pathway either via early endosomes or directly into lysosomes, followed by equilibration to
steady state as illustrated in the diagram below. Due to rapid equilibration between the plasma
membrane and early endosomes, these organelles are considered as a single, well-mixed
compartment. A second compartment consists of lysosomes and interacts with the first via late
endosomes.
In general, this biological process can be modelled as follows, where S enters the endocytic
pathway via one of the compartments, n1 or n2.
plasma
membrane
early
endosomes
late
endosomes lysosomes
Trans-Golgi
Network
S ?
endocytic pathway
S ?
k
[mole / time]
n1 [mole] n2 [mole]
Input↑S [mole]
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When (n’)1 designates the amount of newly-synthesised protein in pool n1, the differential
increase of (n’)1 is given by
 d(n’)1/dt + k*(1/n1 +1/n2)*(n’)1 = dS/dt + k*S/n2 ………………….................................... [1]
where entry of newly-synthesised protein [n’] is via compartment n1. Interchanging the indexes
describes entry via n2.
Because the bulk of LAMP-1 resides in lysosomes at steady state, the two options for input are
not symmetric. As an example, a steady state is assumed where 90% of LAMP-1 is in
lysosomes and 10% in early endosomes [n1 = 0.1 and n2 = 0.9]. For simplicity of modelling, it
is considered that LAMP-1 enters the endocytic pathway with first-order kinetics, as this
allows for an algebraic solution of equation 1. Zero-order input will result in a sigmoidal
increase of S and this would require numerical integration of equation 1.
Integration of equation 1 yields the kinetics that will be observed for the two scenarios of entry,
with LAMP-1 cross-linked in (1) the entire endocytic pathway, (2) lysosomes or (3) early
endosomes.
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Figure 3.4.1 Scenario 1 with LAMP-1 entering via
early endosomes. In this case n1 = early endosomes and
n2 = lysosomes.
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Figure 3.4.2 Scenario 2 with LAMP-1 entering via
lysosomes. In this case n1 = lysosomes and n2 = early
endosomes.
The different levels of steady-state abundance of LAMP-1 in early endosomes and lysosomes
result in clearly distinct outcomes for the two different routes of entry. This clear difference in
the pattern of the two sets of simulated curves makes it possible to unambiguously decide the
pathway followed by LAMP-1.
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4 RESULTS
In this section an account is first given of the optimisation of methods required to quantitate
soluble LAMP-1/CD-MPR and trap (cross-link) LAMP-1/CD-MPR in specific organelles
along the endocytic pathway. (Details of the optimised methods have been summarised in
Methods, section 6. Detailed methods as they apply to individual figures only, are indicated
under Methods in the figure legends.). I then show how these optimised methods were used to
measure the kinetics of 35S-LAMP-1/35S-CD-MPR delivery into the respective endocytic
organelles.
4.1 LAMP-1
The movement of newly-synthesised LAMP-1 through the cell was observed by using a short
pulse of metabolically labelled LAMP-1. Newly-synthesised, 35S-methionine-labelled LAMP-1
was chased for various periods and trapped by HRPDAB cross-linking in early endosomes,
lysosomes or the endocytic pathway. A rat antibody (ID4B) against mouse-LAMP-1 was used
to immunoprecipitate LAMP-1 from solution to quantitate the fraction of 35S-LAMP-1 that
became trapped. In order to quantitate the relative amounts of LAMP-1 that remained soluble
(in HRP-free compartments), the optimal conditions for quantitative detection of LAMP-1 had
to be established.
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4.1.1 Purification of anti-LAMP-1 antibodies and evidence for their functional
activity
ID4B antibodies were first tested for their functional activity. Rat hybridomas, which secrete
ID4B antibodies, were grown in tissue-culture and the antibody-containing tissue-culture
medium (ab-TCM) was collected, see Methods 6.3.1. To confirm that anti-LAMP-1 antibodies
were secreted into the TCM, the ID4B antibodies were purified from the TCM and tested for
functional activity. Antibodies were then initially used in the purified form, but later the TCM
was used as a direct source of antibodies. Two methods were tested for the purification of
ID4B; first, caprylic-acid precipitation followed by Amicon filtration (figure 4.1.1, panel A)
and second, protein-G affinity chromatography (figure 4.1.1, panel B, see Methods 6.4). The
first method did not yield an antibody band at the expected 160 kDa position (arrows). Protein-
G affinity chromatography yielded a protein that was observed as a 160 kDa band under non-
reducing SDS-PAGE conditions and as 50 and 25 kDa bands under reducing SDS-PAGE
conditions. This is characteristic of antibodies (Pain, 1963; Williamson and Askonas, 1968), as
was observed for the control antibodies against the low-density lipoprotein (LDL) receptor.
These observations implied that protein-G affinity chromatography was a much more efficient
method for purifying ID4B antibodies than caprylic-acid precipitation followed by Amicon
filtration. To determine whether the hybridomas were the only source of antibodies, protein-G
beads were incubated in TCM that had not been exposed to hybridomas. A protein in the same
position as the ID4B antibody was observed in figure 4.1.2, lane 1 (arrow). This was assumed
to represent antibody from foetal-calf serum in the TCM. The presence of secreted ID4B in
medium that had been exposed to hybridomas was confirmed by measuring its ability to bind
LAMP-1 via Western blotting and immunoprecipitation. To show that the ID4B identified a
protein that was localised to the lysosomal membranes, lysosomal membranes were used as an
antigen source, figures 4.1.3 and 4.1.4.
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Figure 4.1.1 Purification of ID4B from TCM using, (A) caprylic-acid
precipitation and Amicon filtration or, (B) protein-G affinity chromatography.
A: ID4B was partially cleared of non-specific proteins by caprylic-acid precipitation
as outlined in, “Antibodies - A Laboratory Manual” (Harlow and Lane, 1988). Non-
specific proteins were removed by centrifugation and filtration. The partially purified
ID4B antibodies were concentrated by Amicon filtration and analysed by SDS-
PAGE, as indicated in lanes 1 and 2 in panel A. No band was observed in the
expected position of 160 kDa (arrows). B: ID4B was purified by protein-G affinity
chromatography (Methods 6.4.2). The purified antibody was analysed by SDS-PAGE,
as in panel B. 160 kDa bands (arrows, lanes 1 and 2, duplicates) were observed under
non-reducing conditions. These bands were converted to 50 and 25 kDa bands under
reducing conditions (lanes 4 and 5, duplicates). This is characteristic for antibodies, as
can be seen for the control antibody against the low-density lipoprotein (LDL)
receptor (arrows, lanes 3 and 6). These observations indicated that protein-G affinity
chromatography is a much more efficient method for purifying ID4B than caprylic-
acid precipitation and Amicon filtration. Method: Caprylic-acid precipitation and
Amicon filtration: Two volumes of 60 mM Na-acetate (pH 4) were added to one
volume of ab-TCM while continuously stirring the mixture. If necessary, the pH was
adjusted to 4.8. Caprylic-acid (0.4 ml per 10 ml of original volume of ab-TCM) was
added drop-wise. The mixture was stirred for 30 min at room temperature. The
precipitated non-specific protein was pelleted by centrifugation, thrice at 9 000 g for
10 min, once at 18 000 g for 2 h and once at 18 000 g for 1 h, and discarded. Since
not all non-specific, precipitated protein could be removed by centrifugation, the
supernatant was filtered through a filter paper. The filtrate was then dialysed against
water and concentrated 5, 25or 50-fold by filtration through an X100 Amicon
membrane. The 25and 50-fold concentrated fractions were analysed by SDS-PAGE.
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Figure 4.1.2 Binding of antibody from foetal-calf serum to protein-G beads.
Protein-G beads were incubated with either neat TCM (lane 1) or TCM collected
from a culture of ID4B antibody-secreting hybridomas (lane 2). The bound proteins
were eluted as in Methods 6.14 and separated using non-reducing SDS-PAGE. A
band (arrow) in the position of non-reduced antibody was observed in both lanes.
The result indicated that protein-G beads also bound protein other than ID4B. This
protein was assumed to be antibody present in foetal-calf serum.
1 MW kDa
205
116
97
66
2
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
88
Figure 4.1.3 Western blot of LAMP-1 from lysosomal membrane fractions.
Lysosomal membranes, collected as a high-density fraction on a 27% Percoll
gradient, were prepared as in Methods 6.5.2, subjected to non-reducing SDS-PAGE
and Western blotting. The nitrocellulose membrane was either incubated with
commercially purchased partially purified ID4B-containing TCM, (lane 2-control)
or with ID4B-containing TCM collected in the laboratory, (lane 1). The ID4B
antibodies were detected using peroxidase-linked antibodies and the enhanced-
chemiluminescence (ECL) detection system (see Methods, 6.7.1). The broad band
(bracket) observed for both control (lane-2) and ID4B (lane-1) is mature LAMP-1.
MW
kDa
200
97
66
46
30
1 2
LAMP-1
200
97
66
46
30
MW
kDa
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
89
Figure 4.1.4 Immunoprecipitation of LAMP-1 from 35S-labelled lysosomal
membrane. LAMP-1 was immun precipitated from soluble 35S-labelled lysosomal
membranes by incubation with protein-GID4B complexed beads and subjected to
reducingSDS-PAGE, followed by autoradiography for 20 h. The lane profile, for
the 1st elution round, wa obtained through InstantImager scanning software and
aligned to the lane by eye. LAMP-1 is indicated by the profile peak. Method: To
purify 35S-labelled lysosomal membrane, cells (88·106) were incubated at 10·106
cells/ml, for 2 h at 37°C in medium, with a methionine concentration of 2·10-6 M at
a specific activity of 20 Ci/mmol. The lysosomal membrane was collected as a high-
density fraction on a 27% Percoll gradient and was lysed in 100l lysis buffer (see
Methods: 6.5). An arbitrarily chosen amount of protein-G beads (0.1 ml) was
incubated with 60g purified ID4B antibody (90l antibody at 0.7g/l made up
to 200l with lysis buffer) for 2 h at 4°C. The beads were washed 6 times with 1.0
ml lysis buffer. The soluble lysosomal membrane was diluted to a final volume of
200 l with lysis buffer and immunoprecipitated with the protein-GID4B
complexed beads, overnight at 4°C. The beads were washed as above. The bound
LAMP-1 was eluted from the beads through 3 rounds of 60 l elution buffer
(Gly/HCl, pH 2.65) for 5 min at room temperature.
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Lysosomal membranes were collected as the high-density fractions on a 27% Percoll gradient
as characterised by the lumenal lysosomal enzyme, N-acetyl glucosaminidase (NAGA), that is
predominantly localised to lysosomes (De Duve, 1983; Vaes, 1966; Haylett and Thilo, 1986).
A broad band which ranges from 90 kDa to 120 kDa is expected for LAMP-1 due to the
heterogeneity in its glycosylation. This can be observed in the Western blot, figure 4.1.3. The
smear below 90 kDa and above 120 kDa is probably due to non-specific binding and
overexposure. Since the control (lane 2) yielded the same result as the experiment (lane 1) and
the functional activity for ID4B observed here was confirmed with immunoprecipitation
(figure 4.1.4), it was not deemed necessary to further optimise the above result.
The heterogeneous band observed for the immunoprecipitation (figure 4.1.4) was also in the
expected molecular-weight (MW) range of 90 kDa –120 kDa that is indicative of mature
LAMP-1. Because lysosomal membrane was used as an antigen source, the detected
glycoprotein must have been of lysosomal origin. The antibodies secreted into the TCM thus
appeared specific for LAMP-1.
The experimental design of our kinetic experiments required the quantification of LAMP-1
from soluble cell extracts. The Western blot and immunoprecipitation were thus repeated using
soluble cell extract as an antigen source, figures 4.1.5 and 4.1.6.
A similar heterogeneous protein band in the molecular-weight range of 90 kDa to 120 kDa was
observed when soluble cell extract was used as an antigen source. These experiments further
confirmed the functional activity of the ID4B antibodies secreted into the TCM and also set the
stage for further optimisation of conditions for the quantitation of 35S-LAMP-1 in soluble cell
extracts.
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Figure 4.1.5 Western blot of LAMP-1 from detergent-soluble cell extract.
Proteins from soluble cell lysate were separated on an 8% polyacrylamide gel, lane
1 − 250·106 cells, lane 2 − 500·106 cells, lane 3 − 750·106 cells, and subjected to
Western blotting, see Methods 6.7.2. Blots were incubated with anti-LAMP-1
antibody (22-fold concentrated ID4B-TCM as prepared in Methods 6.4.3) diluted
5000-fold with Tris buffered saline-Tween 20 (TBS-T, see Reagents 7.5), 0.5% fat-
free milk powder. The primary antibody was detected with HRP-linked goat anti-rat
secondary antibody (cat. no. NA935, Amersham) diluted 2000-fold. The blot was
developed with KPL luminoglo. Method: Preparation of soluble cell lysate: Cells
were lysed at 50·106 cells/ml in LAMP-1 lysis buffer (see Reagents 7.5), 0.02%
NaN3. Lysate was incubated on a roller overnight at 4ºC. The following day the
insoluble material was removed by centrifugation, once at 8 000 g for 30 min and
once at 100 000 g for 30 min at 4ºC.
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Figure 4.1.6 Immunoprecipitation of LAMP-1 from 35S-labelled, detergent-
soluble cell extract. LAMP-1 was immunoprecipitated from soluble cell extract by
increasing amounts of protein-GID4B complexed beads and processed for the
quantitation of LAMP-1, as in figure 4.1.4. In lane 1, 20 l beads were incubated
with soluble cell extract in the absence of antibody as a control. Method: To
prepare 35S-labelled, soluble cell extract, cells (100·106) were incubated at 10·106
cells/ml, for 2 h at 37°C in medium, with a methionine concentration of 2·10-6 M at
a specific-activity of 40 Ci/mmol. Cells were washed extensively with Hepes-
salinebovine serum albumen (HeSBSA, see Reagents 7.5), once with 50 ml and 5
times with 10 ml and then lysed at 100·106 cells/ml LAMP-1 lysis buffer (Reagents
7.5). The lysate was incubated on ice for 30 min, freeze-thawed thrice and clarified
by centrifugation at 100 000 g for 1 h at 4°C in a fix angle rotor, 40 Ti. Protein-G
beads were saturated with ID4B antibody (ab) according to the maximal capacity of
the beads (11 mg/ml) as per manufacturer’s instructions: 200 l beads were
incubated with 2 mg ab in 2.07 ml phosphate-buffered saline (PBS, see Reagents
7.5), pH 7.4 (0.971 mg/ml), for 2 h at 4°C. The beads were washed 7 times with
LAMP-1 lysis buffer, resuspended in 600 l LAMP-1 lysis buffer and aliqouted as
indicated above the lanes. These increasing amounts of protein-GID4B complexed
beads were used to immunoprecipitate LAMP-1 from 100 l (10·106 cells) samples
of soluble cell extract, overnight at 4°C. The beads were washed 6 times with 1.0 ml
LAMP-1 lysis buffer and once with 1.0 ml dH2O. The bound LAMP-1 was eluted
from the beads through two rounds of 50l non-reducing sample buffer, at 95°C for
5 min. The two 50l eluted fractions were then pooled.
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4.1.2 Development of methods for quantification of 35S-LAMP-1
Immunoprecipitation served to remove total LAMP-1 (labelled and unlabelled) from cell
lysates. Proteins were separated using SDS-PAGE and the newly-synthesised 35S-LAMP-1 was
then detected and quantitated. In order to select conditions for optimal binding of the antibody
(ab) to antigen (ag) and solid phase, various aspects of the immunoprecipitation assay were
considered. This included the type of solid phase, binding buffer, incubation period, incubation
temperature and the immunoprecipitation approach (direct versus indirect, explained below).
For the efficient detection and quantitation of 35S-LAMP-1, digital analyses using
InstantImager software and scintillation counting were compared. In order to ensure the
quantitative immunoprecipitation of LAMP-1, conditions for a linear dose-response were
determined.
4.1.2.1 Selection of the solid phase
A protein can be removed from solution by an antibody in two ways. In the earlier methods the
primary antibody against the target protein was first added to the solution. The antibody-
antigen complexes were then precipitated by adding a secondary antibody at a critical
concentration, hence the term immunoprecipitation. A method developed later entails removing
the antigen-antibody complexes from solution with a solid phase. This method is also referred
to as an immunoprecipitation, although technically ag-ab complexes are not precipitated but
immobilised. Immobilisation of antigen-antibody (ag-ab) complexes was compared for three
solid phase systems: protein-G beads, Dynabeads and cyanogen-bromide(CN-Br)activated
beads. Protein-G beads bind directly to primary rat antibodies. Dynabeads and CN-
Bractivated beads can be coupled to secondary anti-rat antibodies via which the beads then
bind primary rat antibodies. Dynabeads, coupled to secondary anti-rat-Fc antibodies, were
commercially purchased. Secondary anti-rat-Fc antibodies (AAR-02) were covalently linked to
CN-Bractivated Sepharose beads in the laboratory (see Methods 6.8). These will henceforth
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be termed AAR-02 beads. Protein-G beads were compared with Dynabeads for the binding of
two primary antibodies that were secreted into TCM by hybridomas, namely anti-LAMP-1
antibody (ID4B) and anti-LAMP-2 antibody (ABL93), figure 4.1.7. Protein-G beads were
compared with AAR-02 beads for the binding of one primary antibody, ABL93, figure 4.1.8. It
was observed that protein-G beads bound much more ab than Dynabeads or AAR-02 beads.
Dynabeads or AAR-02 beads were, however, more specific. Hence, to compare the binding of
LAMP to these antibody-linked beads, both sets of beads were subsequently used to
immunoprecipitate 35S-labelled LAMP-2, figures 4.1.9 and 4.1.10. Protein-G beads yielded a
more intense LAMP signal than either Dynabeads or AAR-02 beads. Even though Dynabeads
were more specific for the binding of antibody, protein-G beads were chosen because these
yielded a greater LAMP signal.
4.1.2.2 Selection of buffer, temperature and period of immunoprecipitation
In an immunoprecipitation assay, antibody binding to the beads is pH, temperature and time
dependent. A sodium-acetate, pH 5 buffer was recommended for binding antibodies to protein-
G beads (Pierce). However, cells were lysed in a Tris/HCl, pH 7.5 buffer (D'Souza and August,
1986) to generate and maintain a physiological environment. The efficiency of ID4B binding to
protein-G beads in the two buffer systems was thus compared in table 4.1.1.
To establish the effect of time and temperature on the binding efficiency, ID4B was
incubated with protein-G beads under different time and temperature conditions (table
4.1.2.). Although the overnight incubation at 4ºC was observed to be optimal, incubation
conditions of 2 h at 4ºC were considered sufficient, and chosen for practical reasons and
to eliminate the possibility of extensive protein degradation over a longer time frame.
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Figure 4.1.7 Comparison of the binding efficiencies of protein-G beads versus
Dynabeads. Either ID4B or ABL93 ab-TCM was incubated with equal volumes of
protein-G beads or Dynabeads. Bound antibody was eluted from the beads as in
Methods 6.14 and separated on a non-reducing gel. The gel was silver-stained
(Methods 6.16.2). Arrows indicate antibodies. The protein-G beads bound much
more antibody. (In order to visualise the Dynabead bands, the gel had to be
overexposed and thus the protein-G bands appear to be overstained.)
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Figure 4.1.8 Comparison of the binding efficiencies of protein-G beads and
AAR-02 beads. Anti-rat-Fc antibody (AAR-02) was covalently linked to
cyanogen-bromide(CN-Br)activated Sepharose beads (see Methods 6.8). ABL93-
containing TCM was incubated with either AAR-02 beads (lane 1) or protein-G
beads (lane 2). The bound protein was eluted (as in figure 4.1.7) from the beads and
analysed on a non-reducing gel. The gel was coomassie-stained (Methods 6.16.1).
Arrow indicates antibody. Protein-G beads bound much more antibody. (In order to
visualise the AAR-02 bands, the gel had to be overexposed and thus the protein-G
bands appear to be overstained. Lanes, not necessary for the present illustration,
were eliminated by cropping. )
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Figure 4.1.9 Comparison of LAMP-2 immunoprecipitation by Dynabeads
versus protein-G beads. 35S-labelled LAMP-2 was immunoprecipitated with 50l
ABL93Dynabeads (lane 1) versus 20 l ABL93protein-G beads (lane 2).
Antigen-antibody (ag-ab) complexes were eluted with SDS-reducing sample buffer
and separated by SDS-PAGE. No LAMP-2 signal (box) was visible for the
Dynabead sample (lane 1). LAMP-2 was faintly visible when 250 l Dynabeads
(lane 4) was compared with 20 l ABL93protein-G beads (lane 3) under milder
elution conditions (Gly/HCl, pH 2.5). Protein-G beads were thus more effective.
(The two panels are excerpts from two different gels.)
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Figure 4.1.10 Comparison of LAMP-2 immunoprecipitation by protein-G
beads versus AAR-02 beads. 35S-labelled LAMP-2 was immunoprecipitated with
AAR-02 beads (A) or ABL93protein-G beads (B) through two rounds of
immunoprecipitations (lanes 1 & 5: 1st round, lanes 2 & 6: 2nd round). Lanes 3 & 7
served as a control where lysate was incubated with beads without antibody. This
precleared lysate was re-incubated with ab-linked beads in lanes 4 & 8. Ag-ab
complexes were eluted from the beads with SDS-reducing sample buffer and
analysed by SDS-PAGE. The LAMP-2 signal (brackets) obtained using protein-G
beads (B) was more intense than the signal obtained using AAR-02 beads (A).
Lanes 1 & 2 also indicate that immunoprecipitation with AAR-02 beads was not
reproducible, since a more intense signal was expected in lane 1 than in 2. Lane 3
shows more background for the AAR-02 beads when compared to lane 7 for the
protein-G beads. These results thus indicated that ABL93protein-G beads bound
LAMP-2 more efficiently.
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Table 4.1.1 The effect of buffer conditions on the efficiency of ID4B binding to
protein-G beads, in two different binding buffers. Varying amounts (ranging
from 23 to 48 µg) of protein-G–affinity-purified ID4B were incubated with protein-
G beads (0.1 ml), either in Na-acetate buffer, pH 5 or in Tris/HCl buffer, pH 7.5 for
2 h at room temperature. The beads were washed 6 times with 0.5 ml of the
respective immunoprecipitation buffer. The bound antibody was then eluted from
the beads through 2 rounds of 300l elution buffer (Gly/HCl, pH 2.5) for 5 min at
room temperature. The protein concentration was determined by the Lowry protein
assay (see Methods 6.9.1). The eluted antibody was expressed as a fraction of the
total amount added to the beads. The data indicated that protein-G beads bound
ID4B with similar efficiencies in both buffers, with Tris/HCl, pH 7.5 being slightly
favoured.
Incubation conditions Fraction of ID4B eluted
from protein-G beads (%)
1 h, room temperature 72 ± 4.5
1 h, 4ºC 79 ± 2.9
2 h, room temperature 80 ± 4.0
overnight, 4ºC 111 ± 6.8
Table 4.1.2 The effect of time and temperature on the efficiency of ID4B
binding to protein-G beads. ID4B was incubated with protein-G beads in
Tris/HCl, pH 7.5 buffer for 1 h or 2 h at room temperature and 1 h or overnight at
4ºC. The bound antibody was eluted from the beads and the concentration
determined by the Lowry protein assay (see Methods 6.9.1). The eluted antibody
was expressed as a fraction of the total amount added to the beads. Experiments
were done in triplicate. The overnight incubation at 4ºC was observed to be optimal.
91 ± 1082 ± 8Average
106775.
8971
3.
2.
1.
Sample Tris/HCl, pH 7.5Na-acetate, pH 5
4.
7985
8295
10080
Fraction of ID4B eluted
from protein-G beads (%)
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4.1.2.3 Selection of the elution buffer.
During the immunoprecipitation incubation the beads bind ab-ag complexes and potentially
non-specific proteins as well. The beads were washed extensively in an attempt to remove non-
specific proteins that may have been bound. However, tightly-bound non-specific proteins
would not be removed by the washing procedure. An elution buffer functions to release the ag-
ab complexes back into solution. It can potentially release some of these tightly-bound non-
specific proteins.
An elution buffer had to be chosen on the basis that it allowed for maximal LAMP-1 elution,
but minimal elution of non-specific protein. The efficiency of two elution buffers, reducing
sample buffer versus a low pH buffer, Gly/HCl, pH 2.65, was compared (figure 4.1.11).
Although the reducing sample buffer eluted a greater fraction of the total radioactivity that was
bound to the beads, the Gly/HCl, pH 2.65 was more specific, in that it eluted less of a non-
specific protein that was positioned just below the LAMP-2 band. Since this band could
potentially contaminate the LAMP band, the low pH buffer was chosen as the elution buffer.
To determine the number of elution rounds that would remove the maximum amount of
LAMP-1ID4B complexes from the beads, 35S-LAMP-1 was eluted from the beads through
three rounds of 60l elution buffer as described in figure 4.1.4 and analysed as shown in figure
4.1.12. The equation used in the figure is explained as follows: If f denotes the fraction of
LAMP-1 eluted with each elution round and L denotes the total bead load, then the first elution
round will elute f·L, leaving (1-f)·L. Every elution round (n) wil elute f·L·(1-f)(n-1). It was
observed that when 60 µl elution buffer was used to elute ag-ab complexes from 100 µl of
beads loaded at 0.6 µg antibody/µl beads, one third of the bead load was eluted with every
elution round. This implied that 33% of the total bead load was eluted during the first elution
round, 55% after the second round and 70% after the third elution round.
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Figure 4.1.11 Comparison of the efficiencies of two elution buffers.
Immunoprecipitation was performed in duplicate with ABL-93protein-G beads
and 35S-methionine-labelled LAMP-2containing lysate. Ag-ab complexes were
eluted with SDS-reducing sample buffer (lane 1) or Gly/HCl, pH 2.65 (lane 2).
Equal amounts (in dpm) of eluted products were loaded onto the gel. Only a
fraction (6%) of the SDS-sample buffereluted product was loaded, whereas all
Gly/HCl−eluted product was loaded. The Gly/HCl buffer eluted more of the
LAMP-2 signal (brackets) relative to a non-specific signal just below the LAMP
band (arrows). The sample buffer eluted 17-fold more total label (dpm), but only
twice as much of the LAMP-2 signal, determined on a gel not shown here.
Therefore, the Gly/HCl buffer was more efficient.
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Figure 4.1.12 Determination of the number of elution rounds required to
remove the maximum amount of LAMP-1−ID4B complexes from the beads.
35S-LAMP-1 immunoprecipitated and processed in figure 4.1.4, was quantified as
the area under the profile peak. The amount of LAMP-1 eluted from the beads
decreased with each successive elution round. The indicated curve is described by
the equation, En = f·L·(1-f)(n-1), where f is the fraction of LAMP-1 eluted with each
elution round, L is the total bead load and En is the amount of LAMP-1 eluted at
round n. The values L = 26 cpm, f = 0.33 were obtained from the best-fitted curve.
One third of the bead load was thus eluted with every elution round.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
103
The fraction (f) of ab-ag complexes eluted from the beads could be improved by increasing the
ratio of elution-buffer volume to antibody (µg) bound to the beads. However, 100% of the bead
load is unlikely to be removed in one elution round. The volume of elution buffer and number
of elution rounds were limited by the maximum volume of sample that could be loaded onto a
gel lane. The amount of antibody (µg) used, was determined by the linear dose-response
characteristics of the immunoprecipitation assay (established below).
4.1.2.4 Selection of the LAMP-1 detection method
The immunoprecipitation products eluted from the beads contained both unlabelled and newly-
synthesised 35S-labelled-LAMP-1. To quantitate the newly-synthesised LAMP-1, the 35S-
LAMP-1 had to be detected and quantified. The efficiency of detection of 35S-LAMP-1 relative
to background was critical in view of very short pulses of metabolic labelling required for
optimal kinetic resolution. Autoradiographic detection by the InstantImager system was
compared with scintillation counting of solubilised gel pieces, figure 4.1.13. The two detection
methods were reproducible as can be seen from the linear relationship between the data
obtained from the respective methods. The scintillation counter yielded 270-fold higher counts
per min than the InstantImager as determined from the slope of the graph. The excision of
LAMP-1 gel bands and scintillation counting was chosen as the method for 35S-LAMP-1
quantification because of its 270-fold higher detection sensitivity that would yield better
experimental resolution.
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Figure 4.1.13 (see legend on next page)
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Figure 4.1.13 Quantitation of immunoprecipitated 35S-LAMP-1 using Instant
Imager scanning software versus liquid scintillation counting. A: 35S-LAMP-1
was immunoprecipitated from soluble cell extract with ID4B antibodies and
protein-G beads, eluted from the beads and subjected to SDS-PAGE, followed by
autoradiography. The immunoprecipitated 35S-LAMP-1 was quantified by digital
analysis using InstantImager software. The lane profile for lane 5, also obtained
through InstantImager scanning software, was aligned to the lane by eye. B: The
LAMP-1 band was subsequently excised relative to molecular-weight markers, as
indicated, dissolved in 2 ml 30% H2O2 overnight at 60°C and then quantified by
scintillation counting in a scintillation counter. The counts obtained from the
scintillation counter were then plotted against the counts obtained from the
InstantImager. Results reflected a linear relationship with a slope of 268.1±7.8.
Method: P388D1 cells were metabolically labelled for 2 h, at 37°C with
35S-
methionine at 10-7 M (specific-activity = 1175 Ci/mmol). Soluble cell extract
(50·106 cells/ml) was prepared as in figure 4.1.6. Soluble 35S-LAMP-1 was
immunoprecipitated from 200 µl soluble cell extract (10·10-6 cells) by incubation
with 10 µl ID4B-containing, 50-fold concentrated TCM (Methods 6.4.3) overnight
at 4°C, followed by incubation with protein-G beads at the indicated volumes for 2
h at 4°C (lanes 1 − 3); Alternatively, the antibody was first bound to protein-G
beads and then the detergent-soluble lysate was added to the antibody-bound beads
(lanes 4 & 5). The bound LAMP-1 was eluted from the beads through 2 rounds (65
µl and then 55 µl) of 0.1 M Gly/HCl, pH 2.65 for 5 min at room temperature and
subjected to SDS-PAGE, followed by autoradiography for 64 h.
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4.1.2.5 The direct versus the indirect approach to immunoprecipitation
The immunoprecipitation could be performed in one of two ways. In the direct approach
antibody was added directly to the antigen. The ag-ab mixture was then added to the beads, see
lanes 1− 3, figure 4.1.13A. In the indirect approach antibody was first bound to the beads. The
ab-beads were then incubated with the antigen, see lanes 4 and 5, figure 4.1.13 A. Using the
scintillation counter results, the two methods did not yield significantly different results. Since
the direct approach required less hands-on manipulation and would thus probably result in less
experimental variation, it was henceforth selected as the method of choice.
4.1.2.6 Maximisation of specific signal relative to noise and non-specific proteins
The position of the LAMP-1 band relative to molecular-weight markers was determined using
lane profiles obtained from two gels through InstantImager software. The average of these
positions, dotted lines indicated in figure 4.1.13 A, was used to excise the LAMP-1 band
relative to molecular-weight markers from silver-stained wet gels. The LAMP-1 profile peak
was shouldered by a protein band just below the 97 kDa molecular-weight marker, see figure
4.1.13 A. This could have been the LAMP-1 precursor which is approximately 90 kDa.
However, it was also observed in the absence of antibody. This implied that a non-specific
protein that could potentially contaminate the LAMP-1 band was also located at this position.
The 7% SDS-polyacrylamide gel was already at the recommended concentration for optimal
resolution of proteins in the 100 kDa range. In an attempt to further improve the separation of
the proteins, gels were run for 40 min longer after the gel-front had run off. This was the
maximum amount of extra run-time that could be allowed for, without risking the loss of the
LAMP-1 band. During the electrophoretic separation of the proteins, labelled particles in the
protein mixture could have adhered to the gel non-specifically. This would have contributed to
lane background. To quantitate the counts due to specific signal, the counts due to lane
background had to be eliminated. The position of a region allocated as lane background,
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chosen on the basis that the radioactivity in this region was consistently lower than the rest of
the lane, was determined relative to molecular-weight markers, as indicated in figure 4.1.13 A.
A non-specific band was sometimes observed in the 205 kDa position as in figure 4.1.14. In the
presence of this non-specific signal, the area that could be allocated to lane background would
have been too small relative to the area of the specific LAMP-1 signal. The optimal reduction
of this non-specific signal to lane background levels was thus essential. Toward this end a
centrifugation step was introduced after the ag-ab incubation, figure 4.1.14. Using
InstantImager software analyses, it was determined that the centrifugation step removed 86%
of the non-specific signal while the LAMP-1 signal was not significantly affected. It was thus
decided to introduce this centrifugation step in all future immunoprecipitations.
4.1.2.7 Quantitative immunoprecipitation of LAMP-1
In an attempt to establish conditions for a linear dose-response of LAMP-1, I first set out to
determine the optimal ID4B/protein-G bead ratio (the minimum amount of protein-G beads
required to bind the maximum amount of antibody). The detergent-soluble fraction of a 35S-
LAMP-1containing cell lysate (10·10-6 cells at 50·10-6 cells/ml) was incubated with 10 l of
ID4B-containing, 50-fold concentrated TCM, followed by incubation with increasing volumes
of protein-G beads, see figure 4.1.13 A, lanes 1-3. As shown in figure 4.1.15 A, the amount of
35S-LAMP-1ID4B complexes bound, increased linearly with protein-G bead volume. This
implied that the amount of protein-G beads was the limiting factor and that the 35S-LAMP-
1ID4B complexes were not depleted from solution in the range of protein-G bead volumes
used. The ag-ab complexes were not depleted even when 5-fold less ag-ab complexes were
present in the incubation mixture, see figure 4.1.15 B. Either the protein-G bead volume had to
be increased or the ab concentration had to be decreased. The protein-G bead volume was
arbitrarily fixed at 50l, as this resulted in a sufficient yield being obtained.
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Figure 4.1.14 The elimination of a non-specific signal by centrifugation after
the antigen-antibody incubation step in the immunoprecipitation assay. P388D1
cells were metabolically labelled with 35S-methionine. 35S-LAMP-1 from the
detergent-soluble fraction of the cell lysate was incubated with ID4B antibody,
followed by centrifugation in a microfuge at 8 000 g for 10 min before incubation
with protein-G beads (lane 2). As a control, the centrifugation step was excluded
(lane 1). 35S-LAMP-1 was eluted from the beads, subjected to SDS-PAGE and
processed using InstantImager software. The centrifugation step reduced the non-
specific band (indicated by the arrow) to background levels.
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Figure 4.1.15 The binding capacity of protein-G beads. (A) The amount of 35S-
LAMP-1 (dpm for lanes 1-3 in figure 4.1.13) increased linearly with protein-G bead
volume. (B) This linearity was also observed when a 5-fold dilution of ag-ab
complex was used: 40 l of the detergent-soluble fraction of a cell lysate (2·106
cells at 50·106cells/ml) that contained 35S-LAMP-1 and 2 l ID4B antibody.
[variation between duplicates was smaller than symbol]
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Before the ab concentration could be reduced, it had to be ensured that the specific ab
concentration used, would generate a linear-dose response in an ag concentration range that
would yield experimentally reproducible results. The relationship between ab and ag
concentrations was thus first explored.
In order to determine the antigen concentration range for linearity of signal, fixed amounts of
protein-G beads (50 l) and ID4B antibodies (2 l of ab-containing, 50-fold concentrated
TCM) were used to precipitate LAMP-1 from increasingly higher concentrations of this
antigen, figure 4.1.16. A curve representing Michaelis-Menton kinetics was fitted to the data
and generated a Km of 10.63 units/ml. The response could be considered approximately linear
up to an antigen concentration of ~10 units/ml. This concentration of antigen is equivalent to
the concentration of LAMP-1 in the detergent-soluble fraction of a cell lysate prepared at a
concentration of 10·106 cells/ml. Pulse-chase experiments were designed such that the maximal
concentration at which cells could possibly be lysed in the final sample, was 10·106 cells/ml.
When cell loss due to washes in between experimental steps was factored in, the working cell
lysate concentration range was most likely less than 10·106 cells/ml, within the linear dose-
response range.
I can conclude that 2 µl of ID4B from 50-fold concentrated ID4B-TCM was sufficient to
generate a linear dose-response from LAMP-1 samples prepared from cell lysates below 10·106
cells/ml. This corresponds to the amount of ab that was used to optimise the amount of protein-
G beads in figure 4.1.15 B. In order to further optimise the ab to protein-G bead ratio, the
antibody concentration had to be reduced, as discussed above. To determine the minimal ab
concentration that would effect maximal precipitation of LAMP-1 at a concentration in the
linear dose-response range, increasing amounts of antibody were used to immunoprecipitate
LAMP-1 at 6.25·106 units/ml (figure 4.1.17).
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Figure 4.1.16 Optimisation of the cell-concentration range to be used for the
quantitative immunoprecipitation of 35S-LAMP-1. P388D1 cells were
metabolically labelled with 35S-methionine and lysed to prepare 35S-LAMP-1.
Increasing amounts of the detergent-soluble fraction of the cell lysate were added to
the immunoprecipitation assay in order to apply an increasing concentration of 35S-
LAMP-1 (indicated as the antigen concentration, where 1 unit of antigen is that
amount of 35S-LAMP-1 obtained from 106 cells). 35S-LAMP-1 was
immunoprecipitated with a constant amount of ID4B and protein-G beads. Error
bars (where larger than symbol) indicate variation between duplicates. Different
symbols refer to independent experiments. The curve shows Michaelis-Menton
kinetics with a Km = 10.63 units/ml. Values obtained for maximal binding (under
present assay conditions) were used to normalise the dpm values of the two
experiments. Method: P388D1 cells were metabolically labelled with 35S-
methionine at 1.16·10-7 M (specific-activity = 1175 Ci/mmol) for 2.5 h. Cells were
lysed at 50·106 cells/ml (Methods 6.12.1). The detergent-soluble fraction of the cell
lysate was aliqouted as explained above. 35S-LAMP-1 was immunoprecipitated
with 2l ID4B-containing, 50-fold concentrated TCM in a final volume of 162 l,
overnight at 4°C, followed by incubation with 50l protein-G beads for 2 h at 4°C.
35S-LAMP-1−ID4B complexes were eluted with Gly/HCl, pH 2.65, subjected to
SDS-PAGE, followed by solubilisation of LAMP-1−containing gel pieces and
quantitation by scintillation counting.
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Figure 4.1.17 Optimisation of the antibody volume required for the
quantitative immunoprecipitation of LAMP-1. P388D1 cells were metabolically
labelled with 35S-methionine and lysed to prepare 35S-LAMP-1. Increasing amounts
of ID4B were used to immunoprecipitate 35S-LAMP-1 at a concentration of 6.25
units/ml. Approximately 10l of either ID4B-1 or ID4B-2 (two separate batches of
ID4B-containing TCM, concentrated 10-fold) was sufficient to bind close to the
maximum amount of LAMP-1 at this ag concentration. Values obtained for
maximal binding (under present assay conditions) were used to normalise the dpm
values of the two experiments. Method: P388D1 cells were starved in methionine-
free medium (30 min) and metabolically labelled (1 h) with 35S-methionine at 10-7
M. Labelled proteins were chased for 1 h. Cells were lysed as in figure 4.1.16. A
constant amount of the detergent-soluble fraction of the cell lysate (20 l) was
added to the immunoprecipitation assay at a final volume of 160 l to prepare an
antigen concentration of 6.25 units/ml. 35S-LAMP-1 was immunoprecipitated with
the indicated volumes of either ID4B-1 or ID4B-2 (concentrated 10-fold). Samples
were processed as explained in figure 4.1.16.
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An amount of ~10 µl ID4B and above from a 10-fold concentrated ID4B-TCM was required to
ensure maximal precipitation of LAMP-1 at a concentration in the mid-point of the linear dose-
response range. I could thus conclude that 10 µl ID4B from 10-fold concentrated ID4B-TCM
(2 µl of ID4B from 50-fold concentrated ID4B-TCM) was the minimal amount of antibody
required to generate a linear dose-response from LAMP-1 samples prepared from cell lysates at
the mid-point of the linear dose-response range. The latter corresponds to the amount of
antibody that was used to optimise the amount of protein-G bead volume in figure 4.1.15 B. If
the ab concentration was to be reduced, to further optimise the ab to protein-G bead volume
ratio, the corresponding optimal cell concentration range to achieve a linear dose-response
would have been lower. This would have implied working at very low cell concentrations that
could potentially have resulted in increased fractional cell loss and thus increased experimental
variation. It was thus decided to maintain the ID4B concentration at 10 l of a 10-fold
concentrated (2l of a 50-fold concentrated) ID4B-TCM.
A linear response was important in order to detect quantitative differences in LAMP-1
abundance in two samples prepared from the same cell concentration when LAMP-1
abundance in one of the samples was reduced by the removal of LAMP-1 by HRPDAB cross-
linking, see Methods 6.11.4. At very high LAMP-1 concentrations the antibodies become
saturated and the LAMP-1 binding responses are non-linear. Measurements would then no
longer reflect the difference in LAMP-1 abundance. This was illustrated in figure 4.1.18 where
an expected constant difference in LAMP-1 abundance decreased in samples prepared from
cell lysates at concentrations above 10·106 cells /ml.
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Figure 4.1.18 The effect of high LAMP-1 concentrations in the
immunoprecipitation assay on detecting differences of LAMP-1 abundance.
Using immunoprecipitation, the ratio of LAMP-1 abundance in two samples with
different LAMP-1 concentrations (LAMP-1 was removed from one of the samples
by HRPDAB cross-linking, see Methods 6.11.4), prepared from the same cell
concentration, was determined for samples of increasing overall LAMP-1
concentrations (indicated as increasing cell concentrations). Due to non-linear
LAMP-1−binding responses at high LAMP-1 concentrations (see figure 4.1.16), the
deviation from an expected constant ratio (~50%) was observed to become higher at
cell concentrations above 10·106 cells/ml (arrow). (100% corresponds to no
difference in LAMP-1 abundance.)
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4.1.2.8 Reproducibility of the immunoprecipitation assay
In view of the many steps involved in the processing of experimental samples, it was important
to assess, where possible, the reproducibility of measurements along the way. To determine the
extent to which the immunoprecipitation assay was reproducible, it was performed in
quadruplicate on the same day, using the same reagents and equipment (figure 4.1.19). It can
be concluded that within a single experiment the excision of protein bands from gel lanes was
reproducible with a variation that ranged from 1.9% to 3.8% and that the
immunoprecipitation assay was reproducible with a variation of3.6%.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
116
1 2 3 4 1-4
0
1000
2000
3000
4000
5000
6000
Duplicates
Im
m
un
op
re
ci
pi
ta
te
d
35
S-
LA
M
P-
1
(d
pm
)
Figure 4.1.19 Reproducibility of immunoprecipitation of 35S-LAMP-1. P388D1
cells were metabolically labelled with 35S-methionine. 35S-LAMP-1 was
immunoprecipitated, eluted from the beads and processed for quantitation by
scintillation counting. The immunoprecipitation assay was performed in
quadruplicate, as indicated by bar graphs labelled 1, 2, 3 and 4. The product of each
assay was run on duplicate gel lanes. The error bars in bar graphs 1, 2, 3 and 4 refer
to variation between duplicate gel lanes and range from 1.9% to 3.8%. The bar
graph labelled 1-4 refers to the average from the four assays and the error bar shows
a variation of 3.6% among assays. Method: P388D1 cells were metabolically
labelled with 35S-methionine at 2.8·10-7 M (specific activity = 588 Ci/mmol) for 3 h.
Cells were lysed as in figure 4.1.16 and immunoprecipitation was performed as in
figure 4.1.17 with 4 µl ID4B from 25-fold concentrated ID4B-TCM.
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4.1.3 Optimisation of conditions for kinetic experiments
Kinetic experiments entailed following the movement of newly-synthesised LAMP-1 into
specific organelles of the endocytic pathway, as mentioned in Introduction 3.3. To distinguish
newly-synthesised LAMP-1 from already existing LAMP-1 molecules, the former was labelled
with 35S-methionine as this label is incorporated into newly-synthesised proteins. To
differentiate between 35S-labelled-LAMP-1 that had entered specific endocytic organelles and
that which was present in the rest of the cell, the former was trapped in the respective
organelles by HRPDAB cross-linking. Conditions for optimal metabolic labelling of LAMP-1
with 35S-methionine and trapping of LAMP-1 in the specific endocytic organelles were
established, as follows.
4.1.3.1 Metabolic labelling
The period of metabolic labelling had to be as short as possible to maximise kinetic
resolution. The period over which the total pulse of newly-synthesised 35S-LAMP-1 entered the
endocytic pathway had to be short in comparison to its trafficking towards its final destination.
In order to generate a short pulse with a 35S-LAMP-1 signal that had sufficient intensity, it was
important to ensure that the amount of 35S-LAMP-1 produced over such a short pulse was
optimal. The amount of 35S-LAMP-1 produced is determined by the rate of protein synthesis,
which in turn is proportional to the amino acid concentration available in the medium. The
intensity of the signal of one molecule of 35S-LAMP-1 is determined by the number of 35S-
methionine residues incorporated into that molecule. This in turn is dependent on the specific
activity of 35S-methionine in the medium. The minimum methionine concentration range
that would ensure optimal rates of protein synthesis and efficient incorporation of 35S-
methionine was determined, see figure 4.1.20.
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Figure 4.1.20 Determination of the methionine concentration in the medium
required for optimal rates of protein synthesis and efficient incorporation of
35S-methionine. P388D1 macrophages were starved for 2 h at 37°C in methionine-
free medium. Cells were incubated in TCM (5·106 cells/ml) with increasing
methionine concentrations, corresponding to decreasing 35S-methionine specific-
activities. After 2 h incubation at 37°C, cellular protein was precipitated with
trichloro-acetic acid (TCA), see Methods 6.9.3. In A, the total amount of
methionine (mmole) incorporated into protein was calculated on the basis of the
effective specific-activity of methionine in the medium (Equations 7.4). This
served as a measure of the total amount of protein synthesised by the cell over a 2 h
period. As indicated by the arrow, the availability of methionine was no longer a
rate limiting factor above ~5·10-6 M. In B, the fraction of TCA-precipitable 35S-
methionine (35S-methionine incorporated into protein) was calculated and plotted
against methionine concentration. Efficient incorporation of 35S-methionine
occurred below ~2·10-6 M, above which decreasing specific-activity was no longer
compensated by increasing rates of protein synthesis (compare (cf.) with A).
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A minimum methionine concentration of ~2·10-6 to 5·10-6 M was established as required for
optimal rates of protein synthesis and efficient incorporation of 35S-methionine over a 2 h
period. A 35S-methionine concentration at 10-7 M was chosen for short labelling periods, such
as 5 min and further explored for its feasibility.
The general procedure was as follows: Cells were incubated in methionine-free medium for 30
min at 37°C to ensure the depletion of unlabelled methionine. At time zero, 35S-methionine was
added to the warm medium (37°C) to ensure maximum uptake of 35S-methionine and
incorporation into protein. The cells were incubated for 5 min in the medium containing 35S-
methionine, after which the labelling was stopped by rapid cooling in a mixture of ice and
water. The labelling medium was removed after the cells were pelleted. To ensure the maximal
removal of residual 35S-methionine, cells were washed with medium containing unlabelled
methionine. The 35S-protein was then chased through the endoplasmic reticulum, Golgi, TGN
and into the endocytic pathway by incubating the cells in medium with unlabelled methionine
at 37°C. Samples were processed b using the optimised conditions for immunoprecipitation
and detection of 35S-LAMP-1, as discussed in 4.1.2. A labelling pulse of 5 min was found to
give enough signal intensity for satisfactory quantification of 35S-LAMP-1. Lane background
varied from 20% of the specific signal at early time-points to 5% at later time-points.
4.1.3.2 HRP internalisation
HRP catalyses the cross-linking of DAB. When this occurs in an organelle, the resultant
meshwork traps the proteins in the organelle, see Introduction 3.3.2 and 3.3.3. Three cross-
linking situations were envisaged: the early endosomes, lysosomes and the entire endocytic
pathway.
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To cross-link newly-synthesised 35S-LAMP-1 in early endosomes, 35S-LAMP-1 was first
chased and then HRP was endocytosed for 5 min at the end of every chase period. A 5 min
HRP internalisation period to fill early endosomes was chosen, based on the fact that early
endosomes in P388D1 cells mature with a half-life of 3 min (Thilo et al., 1995). These 5 min
endosomes were indeed characteristic of early endosomes, since they were positive for the
early endosomal markers, EEA1 (Mu et al., 1995) and Rab 5b (Chavrier et al., 1990), see
figure 4.1.21. Some limited staining for EEA1 and Rab 5b was also observed for lysosomes.
This was probably due to contamination of the lysosomal fraction on the 27% Percoll gradient
with early endosomes. (No surface label has previously been detected in the lysosomal fraction
(Haylett and Thilo, 1986).) Accordingly, limited Rab 5b was also observed in non-cross-linked
lysosomes.
To cross-link newly-synthesised 35S-LAMP-1 in the endocytic pathway, the entire endocytic
pathway was loaded with HRP before and during the entry of 35S-LAMP-1. To cross-link
newly-synthesised 35S-LAMP-1 in lysosomes, a pulse of HRP was chased to lysosomes before
the entry of 35S-LAMP-1. The period of HRP internalisation required to fill the endocytic
pathway and the length of the HRP pulse to be chased to lysosomes were determined, as shown
below in figures 4.1.22 to 4.1.26.
For my quantitative assays, it was important to ensure maximal cross-linking of the proteins in
the organelle. The concentration of HRP in an organelle would determine the efficiency of
cross-linking. This in turn is dependent on the concentration of HRP in the medium in which
the cells are incubated and the period over which HRP is internalised. The lumenal lysosomal
protein, NAGA, can easily be measured and was used for optimising the conditions for HRP-
catalysed DAB cross-linking. The assay for measuring NAGA was developed from Hall et al.
(1978) by Thomas Haylett, see Methods 6.9.4.
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Figure 4.1.21 Characterisation of early endosomes by EEA1 and Rab 5b. Early
endosomes (5 min HRP pulse) or lysosomes (30 min HRP pulse, 70 min chase)
were filled with HRP, cross-linked and separated on a 27% Percoll gradient (see
Methods 6.5.3). Peripheral proteins on early endosomes or lysosomes were
solubilised, subjected to SDS-PAGE and Western blotting (see Methods 6.7.2). The
transfer was performed for 3 h. To detect the EEA1, proteins were separated on a
7% gel and rabbit polyclonal primary antibody against mouse EEA1 (1 mg/ml,
diluted 500-fold) was used. To detect Rab 5b, proteins were separated on a 13% gel
and a rabbit polyclonal anti-human Rab 5b (200 µg/ml, diluted 100-fold) primary
antibody was used. A peroxidise-labelled anti-rabbit antibody (Amersham, cat.no.
NIF824, diluted 1000-fold) was used as a secondary antibody. The blots were
developed with the KPL luminoglo. The EEA1 blot was exposed for 10 min and the
Rab 5b blot for 5 min. Early endosomes were positive for EEA1 and Rab 5b
(arrows). (Non-lysosomes include plasma membrane and early endosomal
components.)
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The cross-linking of NAGA was dependent on HRP concentration in the medium when only a
5 min pulse of HRP was chased to lysosomes (figure 4.1.22). When HRP was endocytosed for
30 min, cross-linking was independent of HRP concentrations at 1 mg/ml and above in the
medium (figure 4.1.23). A pulse of 30 min was thus chosen to ensure that cross-linking of
NAGA in lysosomes was independent of HRP concentration in the medium. The period of
HRP internalisation to fill the entire endocytic pathway for maximal cross-linking of NAGA
(77%) was observed to be 100 min (figure 4.1.24). To ensure maximal cross-linking of NAGA
in lysosomes in the case of a 30 min pulse of HRP (1 mg/ml), a chase period of about 70 min
was necessary to make up for a total delivery time of 100 min. Since NAGA is a lumenal
lysosomal protein, as opposed to LAMP-1 which is an integral lysosomal membrane protein,
the above conditions were tested to confirm whether these would be directly applicable to the
cross-linking of LAMP-1.
To measure the cross-linking of LAMP-1, LAMP-1 was first labelled with 35S-methionine.
The labelled proteins were then equilibrated to steady state. The effect of HRP concentration in
a 30 min pulse chased to lysosomes on cross-linking was measured, as shown in figure 4.1.25.
The fraction of cross-linked LAMP-1 remained constant (40%) and independent of HRP
concentration below 3 mg/ml, but decreased and showed greater experimental variation at
concentrations higher than 3 mg/ml.
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Figure 4.1.22 The effect of concentration in a 5 min pulse of HRP uptake on the
cross-linking of NAGA. FITC-D (Fluorescein isothiocyanate-dextran) was
internalised by P388D1 cells and chased to lysosomes to serve as a marker for intra-
lysosomal cross-linking. P388D1 cells were incubated in medium containing HRP at
one of the indicated concentrations. HRP was endocytosed for 5 min and chased to
lysosomes. Half of each sample was treated for HRPDAB cross-linking and the
other half served as a measure of the total NAGA/FITC-D. Cross-linked
NAGA/FITC-D was expressed as a percentage of the total NAGA/FITC-D in each
sample. The cross-linking of both FITC-D and NAGA was dependent on the
concentration of HRP in the medium when only a 5 min pulse of HRP was chased
to lysosomes. Error bars indicate variation (standard error of the mean, SEM)
between duplicate determinations of the fraction of cross-linked FITC-D or NAGA
from the same sample. Method: P388D1 cells were subjected to a 5 min pulse of
FITC-D (6 mg/ml), which was then chased for 30 min to lysosomes at 37°C. Cells
were split into 5 batches, each of which was suspended in medium containing HRP
at one of the indicated concentrations. HRP was endocytosed for 5 min and chased
to lysosomes for 40 min at 37°C. Half of each sample was treated for HRPDAB
cross-linking, see Methods 6.11.4. The other half served as a measure of total
NAGA/FITC-D in the sample. In both cases, soluble NAGA was quantified by
measuring the product of an enzymatic reaction spectrophotometrically, see
Methods 6.9.4. FITC-D was measured spectrophotometrically.
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Figure 4.1.23 The effect of concentration in a 30 min pulse of HRP uptake on
the cross-linking of lysosomal FITC-D and NAGA. P388D1 cells were subjected
to a 5 min pulse of FITC (6 mg/ml), which was then chased for 30 min to lysosomes
at 37°C. Cells were split into 6 batches, each of which was suspended in medium
containing HRP at one of the indicated concentrations. HRP was endocytosed for 30
min at 37°C. Samples were analysed as described in figure 4.1.22. Concentration of
HRP in the medium did not affect the cross-linking efficiency of both FITC-D and
NAGA after a 30 min pulse of HRP. Error bars indicate variation (SEM) between
duplicate determinations of the fraction of cross-linked FITC-D or NAGA from the
same sample.
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Figure 4.1.24 Time required for HRP to fill the endocytic pathway, and thus
also for HRP delivery to lysosomes, to effect maximal cross-linking of NAGA.
P388D1 cells were incubated at 37ºC in the presence of HRP (1 mg/ml) for the
indicated times. Samples were analysed as described in figure 4.1.22. A curve was
fitted manually and indicated a maximal cross-linking of 77% after about 100 min
of HRP uptake. Different symbols refer to independent experiments.
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Figure 4.1.25 The effect of HRP concentration in a 30 min pulse on the cross-
linking of LAMP-1 in lysosomes. P388D1 cells were metabolically labelled with
35S-methionine to produce 35S-LAMP-1. HRP was internalised at the indicated
concentrations during the last 30 min of the labelling period. The internalised HRP
was chased to lysosomes for a further 2.5 h (total duration of the chase period of an
HRP pulse in a cross-linking experiment was ~3 h). Samples at the indicated HRP
concentrations were split into two fractions, one of which was treated for
HRPDAB cross-linking. The other fraction served as a measure for total 35S-
LAMP-1. In both fractions, the soluble (non-cross-linked) 35S-LAMP-1 was
quantified by scintillation counting of the appropriate band after SDS-PAGE of the
immunoprecipitated soluble LAMP-1. The amount of cross-linked 35S-LAMP-1 was
expressed as a fraction of the total 35S-LAMP-1 in each sample. Different symbols
refer to duplicate immunoprecipitations of individual samples. Labelling method:
P388D1 cells were starved for 15 min in methionine-free medium. 35S-methionine
was added, the cell suspension split into 5 aliquots and cells were metabolically
labelled at 37°C for 1.5 h.
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To determine the period of HRP internalisation that would ensure maximum LAMP-1 cross-
linking in the entire endocytic pathway, HRP was endocytosed continuously for the indicated
times and the fraction of cross-linked 35S-LAMP-1 was determined (figure 4.1.26). Although a
maximum of 76% cross-linking was achieved after about 150 min HRP internalisation, 100
min (as determined for NAGA) was considered acceptable because cross-linking increased by
only 6% in the extra 50 min period.
From the above experiments it could be concluded that the conditions established for the
efficient cross-linking of NAGA as a lysosomal marker were also applicable to cross-linking of
LAMP-1. These conditions were then used to design the appropriate assay conditions for
optimal cross-linking of LAMP-1 during the kinetic experiments, diagrammatically represented
in figure 4.1.27. To ensure maximal cross-linking of LAMP-1 in the endocytic pathway, HRP
(1 mg/ml) was internalised for at least 100 min to fill the entire endocytic pathway before a 5
min 35S-methionine pulse was chased into the endocytic pathway in the continued presence of
HRP (figure 4.1.27, A). To cross-link LAMP-1 in early endosomes, the 5 min 35S-methionine
pulse was first chased into the cells and HRP (1 mg/ml) was internalised during the last 5 min
of every chase period (figure 4.1.27, B). To ensure maximal cross-linking of LAMP-1 in
lysosomes, an HRP (1 mg/ml) pulse of 30 min was chased for 70 min (a total delivery time of
100 min) to lysosomes before the 5 min 35S-methionine pulse was chased into the endocytic
pathway (figure 4.1.27, C). These conditions were applied in the actual pulse-chase
experiments to observe the kinetics of entry of newly-synthesised 35S-LAMP-1 into the
endocytic pathway, early endosomes or lysosomes.
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Figure 4.1.26 Maximal cross-linking of LAMP-1 in the endocytic pathway.
P388D1 cells were metabolically labelled with 35S-methionine to produce 35S-
LAMP-1. Horse-radish peroxidase (HRP) (3 mg/ml) was endocytosed for the
indicated times, when samples were taken and cooled on ice. Samples were
analysed for the degree of cross-linking, as described in figure 4.1.25. A curve was
fitted manually and indicated a maximum cross-linking of 76% after about 150 min.
Labelling method: P388D1 cells were starved in methionine-free medium for 30
min and metabolically labelled with 35S-methionine for 60 min. The 35S-methionine
labelled proteins were equilibrated to steady-state levels by incubation of the cells in
medium with unlabelled methionine at 37ºC for 1 h.
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Figure 4.1.27 A diagrammatic representation of the pulse-chase experiments.
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4.1.4 Biosynthetic pathway for LAMP-1
Having established the conditions for the quantitative localisation of newly-synthesised
LAMP-1 along the endocytic pathway, the following experiments were aimed to observe its
pathway en route to lysosomes. As described in the Introduction (3.4), two different pathways
can be considered. LAMP-1 can enter the endocytic pathway either via early endosomes, or be
delivered directly into lysosomes. Because these two scenarios lead to markedly different
kinetics for the entry of LAMP-1 into the respective organelles (see figures 3.4.1 and 3.4.2), an
unambiguous conclusion seemed feasible, despite the known potential for a high degree of
experimental variation of the present approach.
4.1.4.1 The biosynthetic processing of newly-synthesised 35S-LAMP-1
As a basis for studying its delivery into the endocytic pathway, the rate of protein synthesis in
general, and LAMP-1 in particular, had to be established. As shown in figure 4.1.28, the rate of
35S-protein synthesis remained constant throughout the 5 min 35S-methionine pulse, as was
reflected by the linear increase in TCA-precipitation of total protein. When the 35S-methionine
was replaced with excess unlabelled methionine after 5 min, the 35S-methionine concentration
in the cells was diluted. 35S-methionine incorporation into protein became negligible and no
further increase was observed. In contrast to the TCA-precipitation of total 35S-labelled protein,
35S-LAMP-1 was observed via immunoprecipitation. Accordingly, it would only be observed
once it had become antigenic. The kinetics of processing of newly-synthesised 35S-LAMP-1
were determined by combining the data of total newly-synthesised soluble immunoprecipitable
35S-LAMP-1 (dpm) formed with time in the non-cross-linked fractions of all the kinetic
experiments to follow into one graph, as in figure 4.1.29. The 5 min pulse of 35S-LAMP-1 was
processed within 50-60 min into mature immunoprecipitable 35S-LAMP-1 with a half-time of
approximately 14 min. Because the methionine concentration in the cells under the above
experimental conditions remained in excess, the rate of protein synthesis, including LAMP-1,
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in the cells was constant. The gradual decrease in the rate at which mature 35S-LAMP-1
became immunoprecipitable with time was thus not due to a decrease in the rate of total
LAMP-1 synthesis. It was also not due to gradual dilution of the 35S-methionine concentration
when the 35S-methionine was replaced by excess unlabelled methionine, as judged by the rapid
termination in the incorporation of 35S-methionine into total protein after 5 min (figure 4.1.28).
Because 35S-LAMP-1 was observed with immunoprecipitation and SDS-PAGE, it would only
be detected once it had become immunoprecipitable. The gradual decrease in the rate at which
35S-LAMP-1 became immunoprecipitable suggests that unprocessed 35S-LAMP-1 in the Golgi
was mixed and gradually diluted with incoming unlabelled LAMP-1 and was then processed
into immunoprecipitable protein on a random basis rather than on a first-come-first-serve basis.
4.1.4.2 Entry of 35S-LAMP-1 into the endocytic pathway
The next step was to determine the kinetics with which newly-synthesised LAMP-1 entered the
endocytic pathway in general. This served as a reference for the more detailed pathways of
entry into either early endosomes or directly into lysosomes. The total endocytic pathway was
defined by its accessibility to endocytosed HRP (figures 4.1.24 and 4.1.26) and entry of 35S-
LAMP-1 was determined by HRP-mediated cross-linking as in figure 4.1.30. The rate of
LAMP-1 entry into the endocytic pathway at steady state can be expected to remain constant
under the experimental conditions used. The initial 15 to 20 min lag can be ascribed to
movement of 35S-LAMP-1 through the endoplasmic reticulum and Golgi. The initial slowly
increasing rate at which 35S-LAMP-1 entered the endocytic pathway could be expected as
previously formed unlabelled LAMP-1 is gradually replaced by 35S-LAMP-1. The slow
decrease in the rate at the end of the 35S-LAMP-1 pulse (around 50 to 60 min) reflects the
dilutions with subsequently synthesised unlabelled LAMP-1.
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Figure 4.1.28 Determination of the kinetics with which total protein is
processed. Cells were metabolically labelled with 35S-methionine for 5 min after
which the labelled protein was chased. Samples were taken for the indicated times.
The amount of radio-actively labelled total protein synthesised per cell was
determined using TCA-precipitation. Method: Cells (107 cells/ml) were starved for
30 min in methionine-free medium. At time = 0 min 35S-methionine at 10-7 M
(specific-activity, 1175 Ci/mmole) was added to the medium and the cells were
metabolically labelled at 37ºC, 5% CO2 for 5 min. The cells were then cooled
immediately to stop the internalisation of 35S-methionine. Cells were washed and re-
incubated with unlabelled medium. Samples were taken during the 5 min labelling
period and the chase period at the indicated times. Cells were washed thrice with
HeSBSA (10 ml) and transferred to an eppendorf in 1 ml HeSBSA. Cells were
centrifuged at 200 g for 3 min, resuspended in 100 µl HeSBSA and subjected to
TCA-precipitation (see Methods 6.9.3).
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Figure 4.1.29 Biosynthetic processing of immunoprecipitable 35S-LAMP-1.
P388D1 cells were starved in methionine-free medium for 30 min at 37C. At time
zero, 35S-methionine was added at 10-7 M (specific-activity = 1175 Ci/mmole) and
cells were labelled for 5 min. 35S-LAMP-1 was then chased by replacing the 35S-
methionine-containing medium with unlabelled methionine-containing medium.
Cells were washed and lysed. 35S-LAMP-1 was immunoprecipitated from the
detergent-soluble fraction of the lysate, processed via SDS-PAGE and quantitated
by scintillation counting (see Methods). Differently coloured symbols refer to
independent experim nts. Since all experiments did not extend across the entire
time-course, individual experiments were normalised to a best-fit steady state that
started at approximately 60 min and averaged around 1000 dpm. An exponential
curve, allowing for background as a degree of freedom, was chosen as a best-fit to
the data for 35S-LAMP-1. The data were compatible with a half-time of 14 min for
the processing of LAMP-1 into immunoprecipitable LAMP-1.
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Figure 4.1.30 Delivery of newly-synthesised 35S-LAMP-1 into the endocytic
pathway. The endocytic pathway of P388D1 cells was filled with HRP (70 min). In
the continued presence of HRP, cells were starved in methionine-free medium (30
min), metabolically labelled with 35S-methionine for 5 min and further incubated in
the presence of unlabelled methionine for the indicated times, when samples were
taken and cooled on ice. One half of each sample was treated for HRPDAB cross-
linking. The other half served as a measure for total 35S-LAMP-1. In both cases, the
soluble (non-cross-linked) 35S-LAMP-1 was quantified by scintillation counting of
the appropriate band after SDS-PAGE of the immunoprecipitated soluble LAMP-1
(see Methods). Delivery of 35S-LAMP-1 into the endocytic pathway was expressed
as the amount of cross-linked 35S-LAMP-1, as a fraction of the total 35S-LAMP-1,
in each sample. The curve was fitted manually. The fraction of 35S-LAMP-1 cross-
linked at steady state was 67%. In A, different symbols refer to independent
experiments. In B, the average from the different experiments is shown. Vertical
error bars indicate variation (SEM) among the data obtained in the time intervals
indicated by the horizontal error bars.
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The entry of 35S-LAMP-1 into the endocytic pathway thus appears sigmoidal. A curve
predicted in Introduction 3.4 could not be fitted to the data and was thus fitted manually. A
steady-state level of about 67% 35S-LAMP-1 was reached after 60 to 70 min. The fact that the
5 min pulse of 35S-LAMP-1 was processed within 50 to 60 min into mature
immunoprecipitable 35S-LAMP-1 (figure 4.1.29) and entered the endocytic pathway in about
the same time (figure 4.1.30) suggested that entry into the endocytic pathway is a rapid
process. This is in accordance with previous results that for most proteins the rate-limiting step
in their trafficking from the site of their synthesis to their final destination is exit from the ER,
with subsequent steps being rapid (Lodish et al., 1983).
4.1.4.3 Entry of 35S-LAMP-1 into lysosomes
The kinetics of entry of 35S-LAMP-1 into lysosomes were observed by cross-linking 35S-
LAMP-1 as it entered lysosomes (figure 4.1.31). A curve was manually fitted to the data. A
steady-state level of about 38% 35S-LAMP-1 was reached after 60 to 70 min. When the entry
of 35S-LAMP-1 into lysosomes was compared to its entry into the endocytic pathway, it was
observed that 35S-LAMP-1 entered lysosomes with a more pronounced biological lag (figure
4.1.33). This suggests that the bulk of 35S-LAMP-1 entered the endocytic pathway via an
endocytic organelle other than the lysosomes.
4.1.4.4 Entry of 35S-LAMP-1 into early endosomes
The kinetics of entry of 35S-LAMP-1 into early endosomes were observed by cross-linking 35S-
LAMP-1 as it entered early endosomes, see figure 4.1.32. A transient presence of 35S-LAMP-1
was observed in early endosomes. Because of the overall low amounts of 35S-LAMP-1 in this
compartment, the quantitation was less accurate and resulted in substantial scattering of the
data.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
136
0 20 40 60 80 100 120
0
20
40
60
80
100
5' pulse
Time (min)
Fr
ac
tio
n
of
LA
M
P-
1
cr
os
s-
lin
ke
d
(%
)
0 20 40 60 80 100 120
0
20
40
60
80
100
5' pulse
Time (min)
Fr
ac
tio
n
of
LA
M
P-
1
cr
os
s-
lin
ke
d
(%
)
Figure 4.1.31 Delivery of newly-synthesised 35S-LAMP-1 to lysosomes. An
HRP-uptake pulse (30 min) was chased into lysosomes for 40 min in P388D1 cells.
The cells were then starved in methionine-free medium for 30 min (HRP was
chased for a total period of 70 min, equivalent to a delivery time of 100 min.),
labelled with 35S-methionine for 5 min, followed by further incubation in the
presence of unlabelled methionine for the indicated times when samples were taken
and cooled on ice. Samples were processed as in figure 4.1.30. Delivery of 35S-
LAMP-1 into lysosomes was expressed as the amount of cross-linked 35S-LAMP-1,
as a fraction of the total 35S-LAMP-1, in each sample. The curve was fitted
manually. The fraction of 35S-LAMP-1 cross-linked at steady state was ~38%. In A,
different symbols refer to independent experiments. In B, the average from the
different experiments is shown. Vertical error bars indicate variation (SEM) among
data obtained from the independent experiments in the time intervals indicated by
horizontal error bars.
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Figure 4.1.32 Delivery of newly-synthesised 35S-LAMP-1 to early endosomes.
P388D1 cells were starved in methionine-free medium (30 min), labelled with 35S-
methionine (5 min) and further incubated at the indicated times when samples were
taken and cooled on ice. HRP was internalised during the last 5 min of each time
point. Samples were processed as in figure 4.1.30. Delivery of LAMP-1 into early
endosomes was expressed as the amount of cross-linked LAMP-1, as a fraction of
the total LAMP-1, in each sample. The curve was fitted manually. The fraction of
35S-LAMP-1 cross-linked at steady state was ~5.5%. The data are compatible with a
transient presence of LAMP-1 in early endosomes. In A, different symbols refer to
independent experiments. In B, the average from the different experiments is
shown. Vertical error bars indicate variation (SEM) among data from the
independent experiments in the time intervals indicated by the horizontal error bars.
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In this regard it should be realised that due to technical constraints no more than 9 data points
could be obtained for a single experiment. When averaged between independent experiments
(figure 4.1.32 B), the data nevertheless allowed an unambiguous distinction between the two
different scenarios as presented in figures 3.4.1 and 3.4.2. When the entry of 35S-LAMP-1 into
early endosomes was compared with its entry into the endocytic pathway, it was observed that
during the initial period of the time course the two curves were co-incident, see figure 4.1.33.
This implies that the bulk of the 35S-LAMP-1 entered the endocytic pathway via early
endosomes. The transient presence of 35S-LAMP-1 in early endosomes suggests that the early
endosome is a station en route to lysosomes.
4.1.4.5 Entry of 35S-LAMP-1 into late endosomes and conclusion
Taken together, these results imply that the bulk of 35S-LAMP-1 entered the endocytic pathway
via early endosomes before its delivery to lysosomes. It can be expected that this delivery
occurs via the late endosomes as an intermediate stage. Because HRP could not be loaded
exclusively into the late endosomes, it was not possible to measure specific cross-linking of
35S-LAMP-1 in this compartment. Entry of 35S-LAMP-1 into late endosomes could be
calculated as the difference between the amount of LAMP-1 in the total endocytic pathway and
the combined amounts in early endosomes and lysosomes. When the curves in figures 4.1.30,
4.1.31 and 4.1.32 were combined in this way, the kinetics of delivery to late endosomes could
be constructed as in figure 4.1.33. From the curves, it was observed that at steady state about
67% 35S-LAMP-1 occurred in the endocytic pathway, 38% in lysosomes, 23% in late
endosomes and 6% in early endosomes. At steady state, LAMP-1 is present in early endosomes
at an insignificant level. However, a comparison of the curves in figure 4.1.33 with those for
the two scenarios as in Introduction 3.4 (see figures 3.4.1 and 3.4.2) allowed the unambiguous
conclusion that LAMP-1 enters the endocytic pathway via early endosomes.
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Figure 4.1.33 Comparison of the entry of 35S-LAMP-1 into individual
compartments. The curves obtained for the experiments where 35S-LAMP-1 was
cross-linked in the endocytic pathway (EP), lysosomes (LYS) and early endosomes
(early EN) were used to calculate the curve for 35S-LAMP-1 entry into the late
endosomes (late EN) by subtracting the sum of the early endosomal and lysosomal
curves from that of the endocytic pathway. At steady state, the LAMP-1 level was at
about 23% in late endosomes.
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4.1.4.6 Technical limitations of the experimental system
Kinetic experiments were repeated several times because of technical limitations. The number
of time-points that could be accommodated per experiment was limited to 9. The inter-
experimental variation in LAMP-1 cross-linking at a single time-point was12% on average. It
was as low as 5% when the LAMP-1 signal and the cross-linked fraction were high and as
high as20% when the LAMP-1 signal and the cross-linked fraction were low. This variability
in the variation of cross-linking may find an explanation in the equation used to calculate the
fraction of cross-linking: Y = [1 - (S-X)/(T-X)] * 100, where Y = the fraction of cross-linked
LAMP-1 (%), X = lane background (dpm), S = soluble LAMP-1 (dpm) from the cross-linked
sample, T = soluble LAMP-1 (dpm) from the non-cross-linked sample (total LAMP-1). From
the equation, the amount of soluble LAMP-1 (dpm) in the cross-linked (S) and non-cross-
linked (T) samples determines the fraction of LAMP-1 cross-linked (Y). Any variation in lane
background (X) will affect the accuracy with which the effective soluble LAMP-1 (S and T) is
determined. To examine the effect of lane background (X) on Y, theoretical curves were
simulated for a specified range of lane background (X) values at low and high levels of LAMP-
1 signal and cross-linking. Curves were generated for two scenarios with comparable levels of
cross-linking (10%), but different levels of LAMP-1 signal:
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From these simulations it can be concluded that there is a critical point (arrows) above which
the fraction of cross-linking (%) becomes sensitive to variation in lane background. The cross-
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linked fraction is more sensitive to lane background when the LAMP-1 signal is low. The
following curves were generated for two scenarios with comparable levels of total LAMP-1
signal, but different levels of cross-linking:
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High levels of cross-linking are more sensitive to lane background than low levels of cross-
linking. Lane background therefore probably contribut d to the high degree of variation in Y
(15 to20%) observed during the initial time points when cross-linking was low, mainly due
to low LAMP-1 signal. However, considerable variation in Y was also observed when cross-
linking was low and LAMP-1 signal was high, for example, during the later time points of the
experiment when LAMP-1 was cross-linked in early endosomes. When the cross-linked
LAMP-1 fraction is low, the difference in T and S is small even though the LAMP-1 signal in
general is high and so resolution would be compromised. Lane background was sometimes
affected by cross-linking. In such cases, lane background for cross-linked samples (X1) was
observed to be lower than lane background for non-cross-linked samples (X2). This could be
explained by the cross-linking of non-specific proteins. This difference in lane background
sometimes resulted in negative cross-linking. Negative cross-linking comes about when (S-X1)
> (T-X2). This will be the case when S~T and X1>X2. By repeating the cross-linking of LAMP-
1 in a particular compartment in several experiments, a sufficient number of reproducible
points from independent samples were obtained to generate a curve through which the kinetics
of LAMP-1 trafficking could be determined.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
142
4.2 CD-MPR
The CD-MPR is an example of a protein that behaves differently to LAMP-1 in terms of the
kinetics with which it enters early endosomes, lysosomes or the endocytic pathway. It is
functionally distinct and has a different steady-state distribution from LAMP-1. The CD-MPR
mediates delivery of lysosomal enzymes from the TGN into the endocytic pathway. LAMP-1 is
predominantly localised to lysosomes whereas the CD-MPR is predominantly localised to the
TGN and the endosomes, in particular, the late endosome. Newly-synthesised 35S-methionine-
labelled CD-MPR was chased for various periods and trapped by HRPDAB cross-linking in
early endosomes, lysosomes or the endocytic pathway. Rabbit antiserum against bovine-liver
CD-MPR, known to cross-react with mouse CD-MPR, was used to immunoprecipitate the CD-
MPR from the soluble fraction of a cell lysate to quantitate the complimentary fraction of 35S-
CD-MPR that became trapped. Accordingly, the conditions for quantitative detection of the
CD-MPR had to be optimised.
4.2.1 Cross-reactivity of anti-bovine-CD-MPR serum with mouse CD-MPR
First I had to establish whether rabbit anti-bovine-CD-MPR serum was able to cross-react with
mouse CD-MPR in P388D1 cells. This was done via Western blotting (figure 4.2.1).
The CD-MPR has a molecular weight of about 46 kDa. The band in the 50 kDa position was
presumed to be the CD-MPR, confirming that the rabbit anti-bovine-CD-MPR serum was able
to cross-react with mouse CD-MPR.
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Figure 4.2.1 Cross-reactivity of rabbit anti-bovine-CD-MPR serum with
mouse CD-MPR. A post-nuclear supernatant (PNS) was prepared as in Methods
6.5.2 at 20·106 cells/ml. The PNS was lysed at 0.5% Triton X-100 and diluted as
indicated: 4X, 16X, 64X, 256X. Proteins were resolved on a non-reducing 10%
SDS-polyacrylamide gel and subjected to Western blotting, see Methods 6.7.2. The
blot was incubated with anti-bovine-liver-CD-MPR rabbit serum, diluted 100-fold.
The primary antibody was detected by HRP-linked donkey anti-rabbit whole
antibody (cat. no. NA934, Amersham) diluted 5000-fold. The blot was developed
with an ECL detection system. The arrow indicates the CD-MPR.
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4.2.2 Development of quantification methods for the 35S-CD-MPR
Quantification of soluble newly-synthesised 35S-CD-MPR from the cross-linking assay was to
be done by immunoprecipitation. This required an immunoprecipitation assay that was specific
and quantitative. Initially an unoptimised immunoprecipitation assay was set up, using the
LAMP-1 immunoprecipitation assays and methods from the literature as a guide. It was
generally performed as follows, with details and variations specified in the legends of figures
where necessary: P388D1 cells were metabolically labelled, washed 3 times with 10 ml
HeSBSA and lysed in lysis buffer. After preclearing by centrifugation at 8 000 g, the detergent-
soluble fraction of the lysate was incubated with anti-bovine-CD-MPR antiserum. The ag-ab
complexes were removed from solution by incubation with protein-A agarose beads for 2 h at
4C. The beads were washed 6 times with 1 ml washing buffer and then once with 1 ml dH2O.
The ag-ab complexes were eluted from the beads, analysed by 10% SDS-PAGE, followed by
autoradiography and densitometric analyses using InstantImager software. In an attempt to
develop the immunoprecipitation assay, a minimum metabolic labelling time required to give a
measurable signal was determined in figure 4.2.2. In light of the different elution profiles
obtained for LAMP-1 when either SDS-reducing sample buffer or Gly/HCl, pH 2.5 was used
to elute the ag-ab complexes, the effect of these two elution buffers on the elution of the CD-
MPR was compared in figure 4.2.2. Two bands (labelled I and II), one on either side of the 45
kDa band, were observed and assumed to be the CD-MPR. By using InstantImager software,
regions of interest in the gel lanes were scanned and quantified. A region where counts were
comparable to background (between the 24 and 20 kDa markers (box)) was designated as lane
background. Different levels of lane background were observed for the two elution buffers. In
the lanes where the metabolic labelling was 1 h, the levels of background were 18% (sample
buffer) and 12.5% (Gly/HCl) of the specific CD-MPR signal (box). The percentage of
background decreased with increasing times of metabolic labelling.
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Figure 4.2.2 Immunoprecipitation of CD-MPR after increasing times of
metabolic labelling. P388D1 cells were metabolically labelled with 35S-methionine
at 100 Ci/ml (specific-activity of 1000 Ci/mMole) for 1 h, 2 h, 4 h, 8 h and 20 h,
as indicated. The CD-MPR was immunoprecipitated from the soluble fraction of the
cell lysate using anti-CD-MPR serum and protein-A beads. Bead fractions were
split in half. Ag-ab complexes were either eluted with SDS-reducing sample buffer
or Gly/HCl, pH 2.5. Proteins were analysed by SDS-PAGE, followed by
autoradiography. Bands labelled I and II were presumed to be the CD-MPR.
Method: Cell samples from each labelling time were washed and then lysed at
~20·106 cells/ml imidazole lysis buffer (see Reagents 7.5). The lysate was
precleared twice by centrifugation at 8 000 g for 15 min. The precleared lysate
(3.26·106 cells 170 l) was incubated with 10 l anti-CD-MPR ab, overnight at
4ºC, followed by incubation with protein-A agarose beads (100 l) for 2 h at 4ºC.
Beads were washed 8 times with 1 ml imidazole washing buffer and once with 1 ml
dH2O. Bead fractions were split in half (50 l) during the 5th wash. Proteins were
eluted with 1X reducing SDS-sample buffer or 0.1 M Gly/HCl, pH 2.5: two rounds
(60l and then 40l) of 1X reducing SDS-sample buffer for 5 min at 95C, or two
rounds (50 l and then 24 l) of 0.1 M Gly/HCl, pH 2.5 for 5 min at room
temperature. The pH was subsequently neutralised with 2 M Tris, pH 8 (0.6l Tris
/ 10 l Gly/HCl). Samples were analysed by SDS-PAGE, followed by
autoradiography for 19 h. (Positions of molecular-weight markers were traced with
14C-labelled ink.)
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Since the reducing sample buffer gave a higher yield and the variation in lane background was
within experimental error, the reducing sample buffer was chosen as the provisional elution
buffer. 1 to 2 h of metabolic labelling yielded a sufficient signal for further experiments.
4.2.2.1 The specificity of the immunoprecipitation assay
The specificity of the immunoprecipitation of the CD-MPR was improved by the introduction
of two additional centrifugation steps and the selection of different lysis and elution conditions.
This resulted in the reduction of non-specific proteins.
To determine the specificity of the CD-MPR immunoprecipitation assay (figure 4.2.3), the
assay was performed in the presence of ab-serum (lanes 1 & 2), in the presence of control
rabbit serum (lane 3) and in the absence of serum (lane 4). Two bands, similar to those
assumed to be the CD-MPR in figure 4.2.2, were observed in lanes 1, 2 and 3 (box, arrows
labelled I and II). These bands will henceforth be referred to as band I and band II. The
observation of band II in lane 4 implied that at least a fraction of this band was due to non-
specific binding of labelled protein in the soluble fraction of the lysate to the beads. The
observation of both bands I and II in lane 3 implied that at least a fraction of these bands was
due to non-specific binding of labelled protein in the soluble fraction of the lysate to proteins in
rabbit serum. An additional centrifugation step (: 8 000 g for 10 min at 4C) prior to the
introduction of the beads (lane 1) resulted in a reduction, but not complete removal, of bands I
and II. The reduction of band II that corresponded to the non-specific band II observed in lane
4 was confirmed in figure 4.2.4. The introduction of a higher speed centrifugation step (100
000 g for 30 min) before the immunoprecipitation assay precleared the lysate more efficiently
in figure 4.2.5. The intensity of the non-specific bands I and II was reduced, when compared to
figure 4.2.3. A smear (brackets & dashed line in profile) became visible behind band II in the
ab lane and was absent from the control sera lanes.
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Figure 4.2.3 Specificity of the CD-MPR immunoprecipitation assay. The
soluble fraction of metabolically labelled cell lysate was incubated with anti-CD-
MPR serum (lanes 1 and 2), control rabbit serum (lane 3) and without serum (lane
4). To remove non-specific aggregates, the mixture for lane 1 was subjected to
centrifugation before the introduction of the beads. Ag-ab complexes were collected
by protein-A beads, eluted with SDS-reducing sample buffer and subjected to SDS-
PAGE and InstantImager analyses. The lane profile for lane 2 was obtained through
InstantImager scanning software and aligned to the lane by eye. At least a fraction
of bands labelled I and II, previously presumed to be the CD-MPR, is non-specific.
Method: Cells were metabolically labelled for 1 h. The labelled protein was then
chased for 1 h. Cell lysate was prepared as in figure 4.2.2, except that cells were
lysed at a 2.5-fold higher concentration (50·106 cells/ml). For lanes 1 and 2, 10l of
anti-CD-MPR serum was incubated for 1 h at 4C with 40 l (2·106 cells) of
detergent-soluble cell lysate made up to a final volume of 180 l with imidazole
immunoprecipitation buffer (see Reagents 7.5). For lane 3, control rabbit serum was
used and for lane 4, no serum was used. For lane 1, an additional centrifugation step
(: 8 000 g for 10 min at 4C) was performed prior to the introduction of the beads.
Ag-ab complexes were removed from solution with 50 l protein-A beads which
were then washed 5 times with 1 ml imidazole washing buffer (see Reagents 7.5)
and once with 1 ml dH2O. Proteins were eluted from the beads with SDS-reducing
sample buffer and processed as in figure 4.2.2.
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Figure 4.2.4 Removal of non-specific band II by centrifugation. The
immunoprecipitation was simulated in the absence of serum (lane 2). For lane 1, an
additional centrifugation step (: 8 000 g for 10 min at 4ºC) was performed prior to
the introduction of the beads. A comparison with lane 2 and lane 4 in figure 4.2.3
suggested that the fraction of band II that was due to non-specific binding of
proteins in the soluble fraction of the lysate to the beads could be removed by
centrifugation.
Figure 4.2.5 Immunoprecipitation of CD-MPR after a high-speed preclearing
centrifugation step. Cell lysate was prepared as in figure 4.2.3, except now the
cell lysate was precleared by centrifugation as follows, once at 8 000 g for 15 min
and once at 100 000 g for 30 min at 4C. The immunoprecipitation was performed
with ab serum (lane 1), two different control sera (A and B, lane 2 and 3) and no
sera (lane 4). Samples were processed and analysed as in figure 4.2.3. A smear
(brackets and dashed line in profile) became visible behind band II in lane 1 and
was absent from the control sera lanes. Band II was also more intense in lane 1. This
smear and at least a fraction of band II appeared to be the CD-MPR. (NA: not
applicable)
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The CD-MPR is glycosylated and thus a broad band was not unexpected. The smear and at
least part of band II thus appeared specific. To further improve the specificity of the
immunoprecipitation assay a different set of lysis conditions was tested (figure 4.2.6). Cells
were lysed in a Tris lysis buffer (CD-MPR lysis buffer, see Reagents 7.5) with additional
protease inhibitors and gentle mixing overnight at 4C. While PMSF is just a ser and cys
protease inhibitor and leupeptin is a trypsin inhibitor, the Complete Protease Inhibitor Cocktail
Tablet contains inhibitors of a broad range of ser-, cys- and metalloproteases, as well as
calpains. The smear (bracket) surrounding band II (lane 3) was more intense relative to the
non-specific bands I and II, when compared to the previous lysis conditions (figure 4.2.5).
Extending the ag-ab incubation period had no effect on the relative intensities of the specific
band (smear) and the non-specific bands I and II, lane 3 (1 h ag-ab incubation) versus lane 4
(16 h ag-ab incubation). The 16 h incubation was chosen because it was more convenient.
Centrifugation after 16 h ag-ab incubation seemed to remove some background, though not
significantly (lane 4 versus lane 5).
In an attempt to further optimise the elimination of the non-specific band II, the fact that it
may be a reduced product of a higher molecular-weight protein was considered. If so, it
could be shifted to a higher molecular-weight position by performing the elution under non-
reducing conditions. To examine the effect of non-reducing elution conditions on the
relative intensities of the specific and non-specific bands, the CD-MPR immunoprecipitate
was eluted from the beads and analysed with non-reducing sample buffer (figure 4.2.7).
The contaminating bands disappeared for the control serum lane 2 (arrow). In addition to the
broad band in the 45 kDa range (box), another broad band in the ~90 kDa range (box)
appeared. This was indicative of the CD-MPR dimer and, was not unexpected since
interchain disulphide bonds can be formed during the solubilisation process (Li et al., 1990).
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Figure 4.2.6 Immunoprecipitation of CD-MPR after different lysis conditions.
Cells were metabolically labelled for 2 h and the labelled protein was chased for 1
h. For lysis, cells were incubated at 50·106 cells/ml in a Tris lysis buffer (CD-MPR
lysis buffer, see Reagents 7.5) with gentle mixing overnight at 4C, followed by
centrifugation once at 8 000g for 15 min, to remove the major fraction of the
insoluble material, and once at 100 000 g for 30 min, as in figure 4.2.5. The
immunoprecipitation assay was performed in the absence of serum (lane 1),
presence of contol serum (lane 2) or in the presence of ab-serum (lanes 3, 4 and 5).
For lanes 1, 2 and 3 the incubation was 1 h and for lanes 4 and 5, 16 h. For lane 5 an
additional centrifugation (: 8 000 g for 10 min at 4ºC) step was introduced prior to
the addition of the beads. The ag-ab complexes were processed and analysed as in
figure 4.2.3, except that 5l (instead of 10l) ab-serum or control serum was used
and beads were washed with a Tris washing buffer (CD-MPR washing buffer, see
Reagents 7.5) instead of imidazole washing buffer. The smear behind band II
(brackets and dashed line in profile) was more intense. The non-specific band I was
reduced to negligible levels.
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Figure 4.2.7 CD-MPR immunoprecipitate analysis under non-reducing
conditions. Cells were metabolically labelled for 2 h, followed by a chase for 2 h.
Cell lysate was prepared and the immunoprecipitation performed as in figure 4.2.6.
The cell lysate was incubated with ab for 16 h and the ag-ab incubation mixture was
precleared by centrifugation (8 000 g for 10 min). Non-reducing conditions were
used for both elution and subsequent SDS-PAGE. The lane profile was obtained
through InstantImager scanning software. The boxes indicate the possible two forms
of the CD-MPR. The arrow shows the absence of non-specific bands.
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The two bands (boxes) obtained under non-reducing conditions were fairly specific. However,
such conditions were not ideal. Future experiments would be based on very low counts for
which gel bands would have to be cut out and solubilised for counting. Cutting out two bands
would require more hands-on manipulation and would thus increase experimental error. The
possible dimer would therefore have to be reduced. When the CD-MPR immunoprecipitate
was reduced by the addition of -mercapto-ethanol after its elution from the beads with non-
reducing sample buffer (figure 4.2.8), the 90 kDa band was partially reduced to a 45 kDa band.
This confirmed that at least some of the 90 kDa band consisted of a non-reduced dimer of the
CD-MPR. The fact that not all protein at the 90 kDa position were reduced, implied either
incomplete reduction or the presence of non-specific protein. The contaminating bands
(arrows) in the 45 kDa range of the control-serum lane reappeared under reducing conditions.
The results therefore suggested that elution with sample buffer (reducing or non-reducing) was
not suitable. In an attempt to avoid the elution of these contaminating proteins, the
immunoprecipitation products were eluted with a milder non-reducing buffer (0.1 M Gly/HCl,
pH 2.5). Samples were then separated on SDS-PAGE under non-reducing or reducing
conditions (figures 4.2.9 & 4.2.10). Complete reduction of the protein in the 90 kDa range was
observed. Results confirmed the band below the 97 kDa position was a dimer of the 45 kDa
band. The contaminating bands in the 45 kDa range (control-serum lane 2) were negligible.
Background in this region remained constant under non-reducing and reducing conditions.
When the two non-reducing elution buffers were compared under reducing SDS-PAGE
conditions, the contaminating bands in the control-serum lanes contributed 41% to the specific
signal in the ab-serum lane when sample buffer was used (figure 4.2.8) and 20 25% when
Gly/HCl, pH 2.5 was used (figure 4.2.9 and figure 4.2.10). Gly/HCl was thus a more specific
elution buffer and was chosen for subsequent experiments. It must be noted, however, that the
effective yield of the specific signal was 25% less when Gly/HCl was used.
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Figure 4.2.8 CD-MPR immunocomplex analysis under non-reducing or
reducing conditions. Cell lysate was prepared and immunoprecipitation performed
as in figure 4.2.6 in the absence of serum (lane 1) or in the presence of control
serum (lane 2) or ab serum (lane 3). CD-MPR immunocomplexes were eluted from
the beads with non-reducing sample buffer and resolved using SDS-PAGE under
non-reducing or reducing conditions. The gel was exposed to the InstantImager and
subjected to densitometric analyses.
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Figure 4.2.9 CD-MPR elution with a gentler non-reducing buffer. Cell lysate
was prepared and immunoprecipitation performed as in figure 4.2.6. The ag-ab
complexes were eluted with a gentler non-reducing buffer (0.1 M Gly/HCl, pH 2.5).
The eluted products were resolved using SDS-PAGE under non-reducing or
reducing conditions. The gel was exposed to the InstantImager and subjected to
densitometric analyses.
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Figure 4.2.10 A repeat of figure 4.2.9. The band pattern in figure 4.2.9 was
reproduced.
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4.2.2.2 Quantitative immunoprecipitation of the CD-MPR
The immunoprecipitation conditions derived above and summarised in Methods were used to
determine the range of protein concentration that would generate a linear dose-response of the
immunoprecipitated CD-MPR. Fixed amounts of protein-A beads (50 µl) and anti-CD-MPR
serum (5 µl) were used to precipitate CD-MPRs from increasingly higher concentrations of this
antigen. Two different methods were compared for the quantification of the CD-MPR, namely
InstantImager software analyses and scintillation counting. Immunoprecipitation products were
divided into two sets, each of which was resolved on separate gels. One gel was dried and
exposed to the InstantImager (figure 4.2.11). The specific signal of the CD-MPR was
quantitated using InstantImager software. A region above the 20 kDa marker (box) was chosen
as lane background on the basis that radioactivity in this region was consistently lower than the
rest of the lane. Lane background was subtracted from the corresponding signal in the 45 kDa
range (box) to obtain the specific signal due to the CD-MPR. After lane background was
removed from corresponding regions A and B in control-sera lanes 1 and 8, regions A and B
still contributed about 17% of the comparable specific CD-MPR signal in lanes 2 and 7,
respectively. This was probably due to non-specific labelled proteins that were bound by non-
specific proteins in the polyclonal anti-serum. Gel pieces corresponding to the CD-MPR signal
and suitable lane background (boxes) were excised and processed for scintillation counting.
Data obtained from scintillation counting were analysed similar to those obtained using the
InstantImager. The two detection methods were reproducible as can be seen from the linear
relationship between the data obtained from the respective methods (figure 4.2.12). The
scintillation counter yielded 180-fold higher counts per min than the InstantImager as was
determined from the slope of the graph. The excision of CD-MPR gel bands and scintillation
counting was chosen as the method for 35S-CD-MPR quantification because of its 180-fold
higher detection sensitivity that would result in better experimental resolution.
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Figure 4.2.11 Quantification of immunoprecipitated 35S-CD-MPR. P388D1 cells
were metabolically labelled with 35S-methionine for 2h and lysed to prepare 35S-
CD-MPR. Increasing amounts of the detergent-soluble fraction of the cell lysate
were added to the immunoprecipitation assay in order to apply an increasing
concentration of 35S-CD-MPR (indicated as the antigen concentration, where 1 unit
of antigen is that amount of 35S-CD-MPR obtained from 106 cells). 35S-CD-MPR
was immunoprecipitated with a constant amount of ab serum (5 l) and protein-A
beads (50 µl). In lanes 1 and 8 control rabbit anti-serum was used. The ag-ab
complexes were processed as in figures 4.2.9 B and 4.2.10 B. The eluted products
were divided into two sets, each of which was resolved on separate gels. One gel
was dried and exposed to the InstantImager, as in this figure. The CD-MPR signal
for the corresponding antigen concentrations was determined from the dried gel
using InstantImager software. The other gel was processed wet. The InstantImager
generated image was used to determine the position of the CD-MPR relative to
molecular-weight markers. These parameters were used to excise the CD-MPR
band from the dried and silver-stained wet gels for solubilisation and scintillation
counting. The results were analysed graphically as illustrated in figures 4.2.12 and
4.2.13.
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Figure 4.2.12 Comparison of two methods for the quantification of
immunoprecipitated CD-MPR, InstantImager scanning software versus
scintillation counting. The 35S-CD-MPR signal was determined from the dried gel
that was exposed to the InstantImager (figure 4.2.11) using the InstantImager
software. It was then processed for scintillation counting. The data obtained from
the scintillation counter were plotted against the data obtained from the Imager.
Results reflected a lin ar relationship with a slope of 182.15.9.
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The second gel was processed and analysed in the wet state, in exactly the same way as the
dried gel was for scintillation counting. The results obtained for the two independent gels and
the two different detection methods were normalised against their respective maximum signal
to allow direct comparison on the same graph (figure 4.2.13). Results obtained from the two
different quantitation methods (squares) were more reproducible than results from two
different gels (circles and open squares). A curve representing Michaelis-Menton kinetics was
fitted to the data and generated a Km of 6.04 units/ml. The response could be considered
approximately linear up to an antigen concentration of about 6 units/ml. This concentration of
antigen is equivalent to the concentration of CD-MPR in the detergent-soluble fraction of a cell
lysate prepared at a concentration of 6·106 cells/ml. Pulse-chase experiments were designed
such that the theoretical maximal concentration of the cells in the final sample is about 10·106
cells/ml. When cell loss due to washes in between experimental steps was factored in, the
working cell lysate concentration range was most likely in the range of 6·106 cells/ml, within
the linear dose-response range.
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Figure 4.2.13 Optimisation of the cell-concentration range to be used for the
quantitative immunoprecipitation of 35S-CD-MPR. For direct comparison, the
35S-CD-MPR signal for the corresponding antigen concentrations determined using
InstantImager software (closed squares) or scintillation counting (open symbols -
from two independent gels), as explained in figure 4.2.11, were normalised by
expressing the individual values as a percentage of the maximum signal of
immunoprecipitated 35S-CD-MPR. The curve shows Michaelis-Menton kinetics
with a Km = 6.04 units/ml.
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4.2.3 Biosynthetic pathway for the CD-MPR
Having established the conditions for the quantitative immunoprecipitation of the CD-MPR,
the following experiments were performed to observe the pathway of newly-synthesised CD-
MPR for the delivery of lysosomal enzymes into lysosomes. Conditions for quantitative
localisation along the endocytic pathway, as were set up using NAGA and LAMP-1 (4.1.3.2),
were applied to the kinetic experiments for the CD-MPR. To observe the kinetics of entry of
newly-synthesised CD-MPR into the endocytic pathway, early endosomes or lysosomes,
newly-synthesised CD-MPR was labelled with 35S-methionine and chased through the
endoplasmic reticulum, Golgi, TGN and into the endocytic pathway. The newly-synthesised
35S-CD-MPR was trapped as it entered early endosomes, lysosomes or the endocytic pathway
by HRPDAB cross-linking (see Introduction 3.3 and Results 4.1.3.2). In control samples, the
CD-MPR was not cross-linked. Samples were processed for the quantification of soluble 35S-
CD-MPR by using the optimised conditions as obtained in 4.2.2. The fraction of cross-linked
35S-CD-MPR was then determined by comparing the soluble 35S-CD-MPR of the cross-linked
samples with that of the controls. The fraction of cross-linked 35S-CD-MPR was plotted against
time, where time zero was when the 35S-methionine was added to the incubation medium.
4.2.3.1 The biosynthetic processing of newly-synthesised 35S-CD-MPR
To determine the kinetics of processing of newly-synthesised 35S-CD-MPR, the data of total
newly-synthesised immunoprecipitable 35S-CD-MPR (dpm) formed with time in the non-cross-
linked fractions of all the kinetic experiments were combined into one graph, as in figure
4.2.14. CD-MPR expression levels and/or 35S-methionine incorporation into mature protein
were much lower than for LAMP-1. Even though the CD-MPR was metabolically labelled at
five-fold higher concentrations of 35S-methionine, it generally yielded lower counts (dpms).
These data could be analysed in one of two ways.
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Figure 4.2.14 Biosynthetic processing of 35S-CD-MPR. P388D1 cells were
starved in methionine-free medium for 30 min at 37C. At time zero, 35S-
methionine was added at 5·10-7 M (specific-activity = 1175 Ci/mmole) and cells
were labelled for 5 min. 35S-CD-MPR was then chased by replacing the 35S-
methionine-containing medium with unlabelled methionine-containing medium.
Cells were washed and lysed. 35S-CD-MPR was immunoprecipitated from the
detergent-soluble fraction of the lysate, processed via SDS-PAGE and quantitated
by scintillation counting (see Methods). Different coloured symbols refer to
independent experiments. Since all experiments did not extend across the entire
time-course, individual experiments were normalised to a best-fit steady state that
started at approximately 60 min and averaged around 500 dpm. An exponential
curve, with (1) or without (2) background, was manually fitted to the points. The
data were compatible with a half-time of 8 (curve 2) or 18 (curve 1) min for the
processing into immunoprecipitable CD-MPR.
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When an exponential curve (figure 4.2.14, curve 1), allowing for background as a degree of
freedom, was plotted through the data, as for LAMP-1, the 5 min pulse of 35S-CD-MPR was
processed within 60-80 min into mature immunoprecipitable 35S-CD-MPR with a half-time of
18 min. With this type of analysis, a substantial background (arrow) is indicated by the curve.
The background was that which remained after lane background was subtracted. It could
probably be due to non-specific labelled proteins that bound to non-specific proteins in the
polyclonal antiserum. Although the non-specific bands observed in figure 4.2.6 were
predominantly removed after a change in the elution conditions and were only faintly visible in
figure 4.2.11 (regions A and B, 17% of the 35S-CD-MPR after a 2 h labelling period),
depending on the labelling kinetics and the turnover time of the non-specific proteins compared
to that of the CD-MPR, these non-specific proteins could potentially have been present at
levels that influenced the CD-MPR count after a 5 min labelling period.
However, it is also possible that the substantial amount of signal detectable within 5 min could
be specific. Figure 4.1.28 shows that a 5 min methionine pulse was incorporated into TCA-
precipitable protein within 5 min. If the epitopes for the polyclonal anti-CD-MPR became
available within this initial 5 min period, a specific signal could be expected at these early time
points. In this scenario, a linear increase would start from zero (cf. figure 4.1.28) to be
followed, after the end of the 5 min pulse, by a first-order process to steady state. If this was
the case, subsequent processing occurred with a half-time of 8 min (figure 4.2.14, curve 2).
This option (curve 2) was used to analyse my results.
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4.2.3.2 Entry of 35S-CD-MPR into the endocytic pathway
The endocytic pathway includes early endosomes, late endosomes and lysosomes. Based on
previous studies, a steady-state presence of the CD-MPR has been observed in both early and
late endosomes, predominantly the late endosomes, and has generally not been detected in
lysosomes (see Introduction 3.2.2). Here, the kinetics of entry of newly-synthesised 35S-CD-
MPR into the endocytic pathway was observed by cross-linking 35S-CD-MPR as it entered the
endocytic pathway, see figure 4.2.15. This provides the time-course for how newly-synthesised
35S-CD-MPR entered the endocytic pathway as a whole.
The data are compatible with a rapid (relative to 35S-LAMP-1) entry of 35S-CD-MPR into the
endocytic pathway. Within the resolution allowed for by the scatter of the data, no early rise of
cross-linked 35S-CD-MPR could be observed. Maximum cross-linking had already been
reached at 10 min (5 min after completion of the 5 min pulse). On average, the fraction of 35S-
CD-MPR that could be cross-linked in the endocytic pathway at steady state was about 42%. A
comparative set of data was obtained with a different experimental approach. The CD-MPR
was first labelled with 35S-methionine and then chased to steady state. HRP was then
internalised for the indicated times (figure 4.2.16) to indicate its progressive colocalisation with
CD-MPRs at steady state. The highest fraction of CD-MPR that could be cross-linked once
HRP had filled the entire endocytic pathway after about 60 min was about 30%. Within the
experimental variation, this confirmed the previous value for the fraction of CD-MPR in the
entire endocytic pathway at steady state. (It has been reported that 20% of intracellular CD-
MPRs reside in the endocytic pathway of fibroblasts (Stein et al., 1987a)).
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Figure 4.2.15 Delivery of newly-synthesised 35S-CD-MPR to the endocytic
pathway. The endocytic pathway of P388D1 cells was filled with HRP (70 min). In
the continued presence of HRP, cells were starved in methionine-free medium (30
min), metabolically labelled with 35S-methionine for 5 min and further incubated in
the presence of unlabelled methionine for the indicated times, when samples were
taken and cooled on ice. One half of each sample was treated for HRPDAB cross-
linking. The other half served as a measure for total CD-MPR. In both cases,
soluble (non-cross-linked) CD-MPR was quantified by scintillation counting of the
appropriate band after SDS-PAGE of immunoprecipitated soluble CD-MPR (see
Methods). Delivery of 35S-CD-MPR into the endocytic pathway was expressed as
the amount of cross-linked 35S-CD-MPR, as a fraction of the total 35S-CD-MPR, in
each sample. The curve through the data points was fitted manually and suggested
that the fraction of 35S-CD-MPR cross-linked at steady state was about 42%.
Different coloured symbols refer to independent experiments.
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Figure 4.2.16 Colocalisation of endocytosed HRP with CD-MPR at steady
state. P388D1 cells were starved in methionine-free medium for 30 min and
metabolically labelled with 35S-methionine for 1 h. The 35S-methionine-labelled
proteins were equilibrated to steady-state levels by incubation of the cells in
medium with unlabelled methionine at 37ºC for 1 h. HRP (3 mg/ml) was
endocytosed for the indicated times, when samples were taken and cooled on ice.
Samples were processed as in figure 4.2.15. The curve through the data points was
fitted manually. Maximal colocalisation of HRP with CD-MPR was ~30% after
about 60 min of HRP internalisation.
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4.2.3.3 Entry of 35S-CD-MPR into lysosomes
CD-MPRs have generally not been detected in lysosomes. It has thus been assumed that they
do not enter lysosomes. However, rapid entry into and exit from lysosomes, such that they are
present at undetectable levels at steady state, cannot be excluded. The kinetics of any possible
entry of newly-synthesised 35S-CD-MPR into lysosomes was followed by cross-linking protein
in lysosomes and measuring any loss of 35S-CD-MPR from the soluble lysate by
immunoprecipitation (figure 4.2.17). Variation between duplicate immunoprecipitations from
the same sample ranged from10% during initial time points to3% at later time points. The
pattern of the data points is compatible with an initial increase in the fraction of 35S-CD-MPR
in lysosomes, followed by a decrease toward a very low steady-state level of about 5%. Results
thus suggest a transient presence of the CD-MPR in lysosomes. When the entry of 35S-CD-
MPR into lysosomes was compared with its entry into the endocytic pathway (figure 4.2.19), it
was observed that during the initial period of the time-course the two curves could be
considered as being co-incident. This would suggest that the bulk of the 35S-CD-MPR entered
the endocytic pathway directly via lysosomes. Presumably, once the lysosomal enzymes have
dissociated, the CD-MPRs would leave the lysosomes and enter the late endosomes from
where they are recycled to the TGN. In view of the observed fast kinetics of the CD-MPR and
the extent of experimental variation as a result of low CD-MPR expression levels, I have not
been able to clearly resolve the passage of the CD-MPR through lysosomes.
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Figure 4.2.17 Delivery of newly-synthesised 35S-CD-MPR into lysosomes. An
HRP-uptake pulse (30 min) was chased into lysosomes for 40 min in P388D1 cells.
The cells were then starved in methionine-free medium for 30 min (HRP was
chased for a total period of 70 min, equivalent to a delivery time of 100 min.),
labelled with 35S-methionine for 5 min, followed by further incubation in the
presence of unlabelled methionine for the indicated times when samples were taken
and cooled on ice. Samples were processed for measuring non-cross-linked 35S-CD-
MPR as in figure 4.2.15. Delivery of 35S-CD-MPR into lysosomes was expressed as
the amount of cross-linked 35S-CD-MPR, as a fraction of the total 35S-CD-MPR, in
each sample. The curve through the data points was fitted manually and suggested
that the fraction of 35S-CD-MPR cross-linked at steady state was about 5%. Error
bars indicate variation (SEM) between duplicate immunoprecipitations from the
same sample. Different coloured symbols refer to independent experiments.
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4.2.3.4 Entry of 35S-CD-MPR into early endosomes
The kinetics of entry of 35S-CD-MPR into early endosomes were observed by cross-linking
protein in early endosomes and measuring any loss of 35S-CD-MPR from the soluble lysate by
immunoprecipitation, see figure 4.2.18. The data reflect systematic variation and scatter around
a straight line. The points were thus averaged to calculate the average level of the 35S-CD-MPR
in early endosomes at steady state. The average level of 7% suggests a low degree of entry of
the 35S-CD-MPR into early endosomes, probably due to residual recycling from late endomes.
4.2.3.5 Entry of 35S-CD-MPR into late endosomes and conclusion
Taken together, the data for the CD-MPR suggest that newly-synthesised CD-MPRs entered
the endocytic pathway directly via lysosomes where they remained transiently. Presumably the
receptors left the lysosomes as soon as the hydrolytic enzymes had dissociated. This would
explain their low steady-state levels in lysosomes, as is suggested by the data and confirmed by
other studies. The receptors would then probably return to the TGN via late endosomes, re-bind
enzymes and then cycle between the TGN and late endosomes, as reported in the literature.
Because HRP could not be loaded exclusively into late endosomes, it was not possible to
measure specific cross-linking of 35S-CD-MPR in this compartment. Entry of 35S-CD-MPR
into late endosomes could be calculated as the difference between the amount of 35S-CD-MPR
in the total endocytic pathway and the combined amounts in early endosomes and lysosomes.
However, the entry of 35S-CD-MPR into early endosomes could not be kinetically resolved due
to low CD-MPR expression levels. The steady-state level of the 35S-CD-MPR in early
endosomes was calculated from the average of the data points. The entry of the 35S-CD-MPR
into late endosomes was thus calculated as the difference between the amount of 35S-CD-MPR
in the total endocytic pathway and lysosomes, while the calculation of its steady-state level in
late endosomes took the early endosomes into account.
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Figure 4.2.18 Delivery of newly-synthesised 35S-CD-MPR to early endosomes.
P388D1 cells were starved in methionine-free medium (30 min), labelled with 35S-
methionine (5 min) and further incubated in the presence of unlabelled methionine
for the indicated times when samples were taken and cooled on ice. HRP was
internalised during the last 5 min of each time point. Samples were processed for
measuring non-cross-linked 35S-CD-MPR as in figure 4.2.15. Delivery of 35S-CD-
MPR into early endosomes was expressed as the amount of cross-linked 35S-CD-
MPR, as a fraction of the total 35S-CD-MPR, in each sample. The average of the
data points were calculated to be about 7% and taken to be the steady-state level in
early endosomes. Different symbols refer to independent experiments.
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Figure 4.2.19 Comparison of the entry of 35S-CD-MPR into individual
compartments. The data obtained for the experiments where 35S-CD-MPR was
cross-linked in the endocytic pathway (EP), lysosomes (LYS) and early endosomes
(early EN) were used to calculate the curve for 35S-CD-MPR entry into late
endosomes (late EN). The 35S-CD-MPR’sentry was determined by subtracting the
lysosomal curve from the endocytic pathway curve while its steady-state level was
calculated by taking into consideration the steady-state of the 35S-CD-MPR in early
endosomes as well. At steady state, the 35S-CD-MPR level was at about 31% in late
endosomes.
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When the data in figures 4.2.15, 4.2.17 and 4.2.18 were combined in this way, the kinetics of
delivery to late endosomes could be constructed as in figure 4.2.19. From the curves, it was
observed that at steady state about 42% 35S-CD-MPR occurs in the endocytic pathway, 5% in
lysosomes, 30% in late endosomes and 7% in early endosomes. At steady state, the CD-MPR is
present in early endosomes and lysosomes at an insignificant level. In view of the extent of
experimental variation and statistical inaccuracies of the results due to low CD-MPR
expression levels, no definite conclusions can be made about the CD-MPR pathway.
4.2.3.6 Technical limitations of the experimental system
In addition to the technical limitations discussed for LAMP-1 in section 4.1.4.6, kinetic results
for the CD-MPR were also restricted by various aspects that were intrinsic to the CD-MPR.
The CD-MPR had lower expression levels and possibly higher background (discussed in
4.2.3.1) relative to the specific signal. The fraction of the CD-MPR in the endocytic pathway
was lower than for LAMP-1, further reducing the scope for resolution of the kinetics. The CD-
MPR had a much smaller lumenal domain than LAMP-1 (cf. figures 3.2.1 and 3.1.1). Since the
physical process of cross-linking involved trapping of the lumenal portion of a protein, a
protein with a very small lumenal domain as the CD-MPR could easily escape the cross-linking
process or leak from the cross-linked meshwork. This could contribute to variation in the cross-
linking efficiency.
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5 DISCUSSION AND CONCLUSION
The aim of this project was to characterise the pathway of newly-synthesised LAMP-1 for
delivery into lysosomes.
Most previous studies toward answering this question have considered the steady-state
distribution of LAMP-1. The absence of LAMP-1 from a particular compartment has been
interpreted to imply that it did not move through the compartment at all. However, it is
possible that LAMP-1 moved rapidly in and out of this compartment, so that LAMP-1 did not
accumulate to levels that were detectable by the techniques employed. The presence of LAMP-
1 in a compartment other than lysosomes has sometimes been interpreted to imply that this
compartment is a station en route to lysosomes. The fraction of total cellular LAMP-1 in this
compartment has been taken to be a measure of the importance of this route. However, the
presence of LAMP-1 in a particular compartment could also be a result of recycling from other
compartments. The fraction of total cellular LAMP-1 in a particular compartment at steady
state is in no way a measure of the fraction of newly-synthesised LAMP-1 that actually moves
in and out of the compartment. Hence, steady-state distribution levels provide insufficient
information for outlining the pathway followed by LAMP-1 en route to lysosomes.
In studies where a kinetic approach has been used, the newly-synthesised LAMP-1 was
labelled with radio-active material (eg. 35S-methionine) for relatively long pulse periods, thus
yielding poor kinetic resolution. In some cases, the half-times (T½ [time]) of the appearance of
newly-synthesised labelled material in specific compartments were correlated to the rate at
which the newly-synthesised material was delivered to these compartments. However, the half-
time of accumulation in a specific compartment depends on the flux (fm/T½ [molecules per
time]) of the specific protein into the compartment in relation to its pool-size (m [molecules])
in the compartment at steady state. Hence, the half-time alone cannot serve as a direct measure
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of the rate at which the protein travels to the compartment. In studies where the shapes of the
time-courses for newly-synthesised LAMP entry into compartments have been compared and
interpreted as determining the pathways followed by LAMP proteins, no controls were in place
to clearly define the source of these incoming proteins. For example, a simultaneous increase
of LAMPs in two different compartments does not necessarily imply that the source is the
biosynthetic pathway. An increase of LAMP in a particular compartment is the net result of
LAMP moving in and out of this compartment. The LAMP that is leaving could thus enter
another compartment. As a result, it is not correct to assume that the protein moving into a
compartment is coming from the biosynthetic pathway. Differences between curves were
sometimes based on one or two experimental points, hence making definitive interpretations
difficult.
Only one study (Cook et al., 2004) has thus far managed to show transient presence of labelled
newly-synthesised LAMP-1 in early endosomes. While these observations have identified early
endosomes as a compartment that lies en route to lysosomes, the authors have relied on in vitro
studies to suggest that delivery via early endosomes is the major pathway.
In the present study, I observed the movement of newly-synthesised LAMP-1 into either early
endosomes or lysosomes relative to the movement into both compartments. By comparing the
shapes of the resulting time-courses, I am able to conclusively say that the bulk of newly-
synthesised LAMP-1 that entered the endocytic pathway was delivered to lysosomes via early
endosomes, and that this was the major pathway.
At steady state LAMP-1 is predominantly localised to late endosomes and lysosomes, more so
lysosomes. It has been reported that 2% of LAMP-1 occurs on the cell surface of chicken
fibroblasts (Lippencott-Schwartz and Fambrough, 1986) and HL60 cells (Carlsson and Fukuda,
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1992). Results obtained here suggest that at steady state about 67% LAMP-1 occurs in the
endocytic pathway (figure 4.1.30), 38% in lysosomes (figure 4.1.31), 6% in early endosomes
(figure 4.1.32) and 23% in late endosomes (figure 4.1.33). At steady state, the maximal
fraction of LAMP-1 that could be cross-linked in the endocytic pathway was 76% (figure
4.1.26). Within experimental error, this compares well with the 67% observed for the kinetic
experiments (figure 4.1.31). The remaining 24 33% seems too large an amount to be
accounted for by compartments outside of the endocytic pathway. A substantial fraction could
therefore be due to incomplete cross-linking.
From the individual curves of the kinetic experiments of LAMP-1, significant experimental
variation in the fraction of cross-linking was observed during the first 10 min when LAMP-1
was cross-linked in the endocytic pathway (figure 4.1.30), 30 min when LAMP-1 was cross-
linked in lysosomes (figure 4.1.31) and 15 min, as well as during the 40-50 min interval, when
LAMP-1 was cross-linked in early endosomes (figure 4.1.32). Increased experimental variation
in the fraction of cross-linking correlated with conditions when less than 50% of newly-
synthesised-labelled LAMP-1 was processed to immunoprecipitable LAMP-1 (during the first
15 min, figure 4.1.29) and/or when the fraction of cross-linked LAMP-1 was low. Factors that
may potentially have contributed to experimental variations were discussed in Results 4.1.4.6.
The experimental variations do not negatively affect the interpretation of the results however,
since conclusions about the movement of LAMP-1 are not dependent on any particular time
point(s). They are based on the general trend and shape of the experimental kinetic curves in
comparison to predicted kinetic curves (see figures 3.4.1 and 3.4.2). There is a clear difference
in the pattern of the two sets of curves predicted for the two alternative scenarios. For the
scenario where LAMP-1 is delivered to lysosomes via early endosomes (figure 3.4.1): During
the initial time-points curve (3), which depicts LAMP-1 cross-linked in early endosomes, is co-
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incident with curve (1), which depicts LAMP-1 cross-linked in the endocytic pathway. This
implies that initially the bulk of newly-synthesised LAMP-1 in the endocytic pathway is
present in early endosomes. Curve (3) rises as the net flow of newly-synthesised LAMP-1 into
early endosomes increases. The slope of the curve decreases as the net flow into early
endosomes reaches a maximum and then becomes negative as the net flow of newly-
synthesised LAMP-1 is movement out of early endosomes. Curve (3) is thus indicative of a
transient presence of newly-synthesised LAMP-1 in early endosomes. During the early time-
points when the bulk of newly-synthesised LAMP-1 occurs in early endosomes, it could be
present in lysosomes at insignificant levels, hence the observed delay in curve (2). When this
set of curves is compared with that which depicts LAMP-1 entry into lysosomes directly
(figure 3.4.2), the curve that is co-incident with the endocytic pathway curve (1) during the
initial time points varies and there is a marked difference in the amplitude of curve (3). The
experimentally obtained curves, super-imposed on the same graph (figure 4.1.33), best fit the
pattern of the set of predicted curves that depicts LAMP-1 delivery via early endosomes (figure
3.4.1). It was observed that the bulk of newly-synthesised-labelled LAMP-1 entered the
endocytic pathway via early endosomes with subsequent delivery to lysosomes. I can conclude
that the pathway via early endosomes is the only major pathway during the initial stages of
entry into the endocytic pathway.
The study was extended to the CD-MPR to serve as a control of a protein that behaves
differently to LAMP-1. LAMP-1 is predominantly localised to late endosomes and lysosomes
whereas the CD-MPR delivers resident lysosomal hydrolytic enzymes to lysosomes and is
predominantly localised to the TGN and endosomes, more specifically late endosomes. It has
been reported that 20% of the intracellular CD-MPRs reside in the endocytic pathway of
fibroblasts (Stein et al., 1987a). Results obtained here show that at steady state about 42% of
the CD-MPR occurs in the endocytic pathway (figure 4.2.15), 5% in lysosomes (figure 4.1.17),
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7% in early endosomes (figure 4.2.18) and 30% in late endosomes (figure 4.2.19). Using a
different approach, the maximal fraction of CD-MPR that could be cross-linked in the
endocytic pathway was 30% (figure 4.2.16). Within experimental error, this compares well
with the 42% observed for the kinetic experiments (figure 4.2.15). A large amount of the
remaining 58  70% is localised to compartments outside of the endocytic pathway,
presumably the TGN. A substantial fraction could probably also be due to incomplete cross-
linking.
The CD-MPR suffice as a control for the experimental approach. The kinetic results for the
CD-MPR are different from that of LAMP-1. The data suggest that CD-MPRs are delivered
into the endocytic pathway via lysosomes, remain in lysosomes transiently and at steady state
are present in early endosomes and lysosomes at insignificant levels. This would support the
observations in the literature that CD-MPRs have generally not been detected in lysosomes.
Presumably the CD-MPR would leave the lysosomes as soon as the lysosomal enzymes have
dissociated and enter late endosomes from where they would be recycled to the TGN.
However, the entry of CD-MPR-enzyme complexes into lysosomes would be contrary to the
observations from studies that involved the inhibition of intra-organellar ATP-dependent
acidification in CHO mutants (Merion et al., 1983; Robbins et al., 1983; Robbins et al., 1984).
These have suggested that enzymes dissociate from MPRs in an acidic pre-lysosomal
organelle. In view of the extent of experimental variation and statistical inaccuracies due to low
CD-MPR expression levels, results are not conclusive. Factors that may potentially have
contributed to experimental variation were discussed in Results 4.1.4.6 and 4.2.3.6.
Based on my results and previous studies, I propose that LAMP-1 is sorted at the TGN into
vesicles that deliver their contents to lysosomes along the indirect pathway, intracellularly via
early endosomes or along the secretory route, plasma membrane and endocytosis. While my
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results show delivery via early endosomes (figure 5.1), it does not preclude the possibility that
LAMP-1 is transported to early endosomes along the secretory route, plasma membrane and
endocytosis. Results for AP-1 are very contradictory and might imply that AP-1 only plays a
minor or a secondary role in LAMP-1 trafficking. LAMP-1 sorting is not affected in 1A-
deficient mouse fibroblasts (Meyer et al., 2000). However, depletion of AP-1 by ribonucleic-
acid (RNA) interference did increase cell-surface expression (less than two fold), although the
effects were much lower than for other adaptors (Le Borgne et al., 1998). Immunofluorescence
in mammalian cells has localised AP-3 to perinuclear buds or vesicles of the TGN as well as
those in the cell periphery (Dell'Angelica et al., 1997; Dell'Angelica et al., 1998; Simpson et
al., 1996; Simpson et al., 1997). AP-3 may thus function at both the TGN and early
endosomes. Using immuno-electron microscopy, LAMPs have been colocalised with AP-3 to a
novel tubular sorting endosome where AP-3 has been implicated in sorting LAMPs from
recycling membrane proteins destined for the plasma membrane or the TGN (Peden et al.,
2004). AP-2 depletion results in a five to ten-fold increase in cell-surface expression of
LAMPs, much more than did the depletion of other adaptor proteins (Janvier and Bonifacino,
2005). If LAMP-1 is delivered intracellularly via early endosomes, LAMP-1 could be sorted
into AP-3containing vesicles at the TGN, transported to early endosomes where it would
possibly be prevented from recycling to the plasma membrane by AP-3 and then delivered to
lysosomes along the endocytic pathway. Due to rapid and extensive membrane traffic between
the plasma membrane and early endosomes, LAMPs which escape the AP-3 sorting machinery
in early endosomes would appear on the plasma membrane from where they would be sorted
by AP-2 and re-internalised. If LAMP-1 was transported to early endosomes via the secretory
pathway and cell surface, AP-2mediated sorting at the cell surface would be encountered first.
Sorting machineries are saturable and specific for molecular determinants located in the
cytoplasmic tail of lysosomal membrane proteins, as has been shown by experiments in which
lysosomal membrane proteins were overexpressed or the tyr motif of the cytoplasmic tail was
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mutated (Harter and Mellman, 1992; Honing and Hunziker, 1995; Honing et al., 1996; Marks
et al., 1996). If the sorting process in the plasma-membrane/early endosomal compartment is
efficient, LAMP-1 is delivered to lysosomes without being detected on the cell surface, since
the movement through the plasma-membrane/early endosomal compartment is transient and
rapid. When there is an excess of LAMP-1 and the sorting machinery is saturated or the
signalling motifs in the cytoplasmic tail are altered and the sorting machinery are inefficient,
movement of LAMP-1 through the plasma-membrane/early endosomal compartment would
become slower, the steady-state concentration of LAMP-1 on the plasma membrane would
increase and thus LAMP-1 would be detected on the cell surface. This would explain why
lysosomal membrane proteins with variable tyr motifs in their cytoplasmic tails have different
cell-surface steady-state distributions. The variation in the tyr-based sorting signal causes the
different lysosomal membrane proteins to bind to the sorting machinery in the plasma-
membrane/early endosomal compartment with different affinities. High-affinity binding would
result in efficient sorting, rapid flow through the cell surface and no detection on the plasma
membrane. Low-affinity binding would result in inefficient sorting, slower movement through
the cell surface and a higher cell-surface steady-state distribution. Delivery of newly-
synthesised LAMP-1 to lysosomes via the plasma-membrane/early endosomal compartment is
thus compatible with the apparent contradictory observations in the literature, that is, the
presence or the absence of LAMP-1 on the cell surface at steady state.
Delivery of newly-synthesised lysosomal material via early endosomes could also explain why
small quantities of lysosomal material were observed in early endosome-like mycobacterial
phagosomes (Clemens and Horwitz, 1995; Thilo and de Chastellier, 1995). In light of the
findings that mycobacteria are able to survive in the lysosomal environment (Gomes et al.,
1999) and that an adaptive immune response against mycobacteria is not determined by the
degree of lysosomal delivery (Majlessi et al., 2007), the reason that mycobacteria generally
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remain in immature phagosomes is probably not to avoid lysosomes per se. It could be because
the early endosome is a strategic site where they would have continued access to newly-
synthesised cellular material, sustenance for their intracellular survival.
In addition to functioning in lysosomes, lysosomal membrane proteins may also function at the
cell surface and in early endosomes. In human peripheral blood mononuclear cells LAMP-1
and LAMP-2 are activation-dependent cell-surface glycoproteins that mediate cell adhesion to
the vascular endothelium (Kannan et al., 1996). LAMP-2 and LAMP-3 might be indicators of
platelet activation (Kannan et al., 1995). Recently it has been shown that LAMPs are required
for the maturation of phagosomes, specifically the transition from the early to the late stage
(Huynh et al., 2007). LAMP-1and LAMP-2deficient phagosomes from FcIIA-transfected
MEFs (isolated from double-knockout mice) were positive for early endosomal markers Rab5
and phosphatidylinostol 3-phosphate, failed to accumulate the late endosomal marker Rab7 and
did not fuse with lysosomes. This introduces the possibility that newly-synthesised LAMPs
could be delivered to early endosomes for the purpose of facilitating their maturation.
Lysosomal membrane proteins may thus be transported along the indirect pathway to reach the
different destinations where they are required to function. In addition to targeting the
lysosomal membrane proteins to the correct destinations, the variable targeting signals could
also ensure that these proteins are present at the required concentrations. Proteins which only
function in lysosomes may then follow the direct pathway that could involve the ubiquitin-
ligase Nedd4 and ubiquitinated GGA3, as for LAPTM5 (Pak et al., 2006).
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OUTLOOK
Future studies could use our approach to explore whether other lysosomal proteins are also
delivered to lysosomes via early endosomes. Maybe only certain lysosomal proteins with a
common purpose are delivered via early endosomes. This purpose might be to promote the
maturation of the early endosome, as has been inferred to by Huynh et al. (2007). By
identifying these proteins we could home in on what they have in common and subsequently
also the possible mechanism that they employ in the maturation process.
Figure 5.1 Model proposed for LAMP-1 delivery to lysosomes. Newly-
synthesised LAMP-1 from the biosynthetic pathway is delivered to lysosomes via
early endosomes.
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6 METHODS
6.1 MATERIALS
The rat hybridoma cell line which secretes the monoclonal antibody against mouse LAMP-1
(ID4B) was purchased from the Developmental Studies Hybridoma Bank, Department of
Biology, University of Iowa. (The immunogen was NIH/3T3 mouse embryo fibroblast tissue
culture cell membranes). The mouse macrophage cell line, P388D1, was obtained from the
Institute of Genetics, University of Cologne, Cologne, Germany. Dulbecco’s Minimum
Essential Medium, DMEM, used to culture the hybridomas, RPMI-1640 (developed by Moore
et al. in 1966 at the Roswell Park Memorial Institute), used to culture the macrophages, and
the bovine foetal-calf serum were purchased from Highveld Biological, South Africa.
Methionine-free minimum essential medium (MEM) or methionine-free RPMI 1460 and trans-
label 35S-L-Methionine (Specific-Activity = 1175 µCi/mmole) (cat. no. 51006) were purchased
from MP (formerly ICN) Biomedicals, Solon, Ohio, USA. NCTC-135 medium (developed by
the Tissue Culture Section, Laboratory of Biology, National Cancer Institute (NCI), Bethesda,
MD; cat. no. N-3262) and opi media supplement (oxaloacetate, pyruvate, and bovine insulin;
cat. no. O-5003) were obtained from Sigma-Aldrich, St. Louis, MO, USA. Precision Plus
protein standards (cat. no. 161-0374) were purchased from Biorad, Hercules, California.
Complete Protease Inhibitor Cocktail Tablets were bought from Roche Pharmaceuticals, F.
Hoffmann-La Roche Ltd., Basel, Switzerland. The Enhanced Chemiluminescence Detection
(ECL) kit (cat. no. RPN2132) from Amersham Biosciences, Piscataway, USA or the KPL
LumiGLO (cat. no. 54-61-02) from KPL, Inc., Gaithersburg, Maryland USA was used for
Western blotting detection. Control antibody against the low-density lipoprotein (LDL)
receptor was a gift from the LDL group, Department of Medical Biochemistry, UCT, Cape
Town, South Africa. Rabbit anti-bovine liver CD-MPR antibody was a gift from Nancy Dahms
at the Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin,
USA. Sheep anti-rat-Fc immunoglobulin (AAR02) was purchased from Serotec, Dusseldorf,
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Germany. Rabbit polyclonal anti-mouse EEA1 antibody (cat. no. ab14453-50) was purchased
from Abcam, Cambridge, UK. Rabbit polyclonal anti-human Rab 5b IgG (cat. no. SC-598,
cross-reacts with mouse Rab 5b) was obtained from Santa Cruz Biotechnology, Santa Cruz,
USA. HRP-linked goat anti-rat whole antibody (cat. no. NA935), HRP-linked donkey anti-
rabbit whole antibody (cat. no. NA934) and peroxidase-linked polyclonal anti-rabbit secondary
antibody (cat. no. NIF824) were products from GE Healthcare, Buckinghamshire, UK.
Horseradish-peroxidase was supplied by Seravac Biotech (Pty) Ltd., Epping, Cape Town,
South Africa. 3’3 Diaminobenzidine was a product from Sigma. ImmunoPure Immobilized
Protein-G (cat. no. 20398/9) and Protein-A (cat. no. 20333) beads were purchased from Pierce,
Rockford, USA. Ultrafree-15 centrifugal filter devices were products from Millipore, Millipore
Corporation, USA. High-speed spins at 40 − 100 000g were performed using polyallomer
centrifuge tubes, (5 X 20 mm and 14 X 95 mm) purchased from Beckman Coulter, Inc.,
Fullerton, CA, USA.
6.2 SPECIALISED EQUIPMENT AND SOFTWARE
Cells were counted using a Z1 Coulter Particle Counter, Beckman Coulter. A transfer
apparatus that was custom made by Mr Hall at the Department of Medical Biochemistry, UCT
and BioRad’s miniproteinII and III were used for Western blotting. Developed Western blot
films were scanned with BioRad’s Gel Doc 1000 system. Radio-actively labelled protein bands
on dried gels were visualised by radio-active scanning and digitally analysed using an Instant
Imager electronic autoradiographer from Packard InstantImager Co., Meriden, CT, USA.
Radioactivity in solubilised gel pieces was quantified using a scintillation counter (Packard
Liquid Scintillation Analyzer).
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6.3 CELL CULTURE
The hybridoma cell line, ID4B, and the macrophage cell line, P388D1, were cultured as
monolayers on 175 cm2 tissue culture flasks. These were maintained in 30 ml medium in an
incubator (Queue) with a 37°C, 5% CO2 environment.
6.3.1 Culturing of the hybridoma cell line, ID4B, and harvesting ab-TCM
This cell line was cultured in DMEM, supplemented with 10% (v/v) NCTC-135, 20% (v/v)
heat-inactivated (56C, 0.5 h) foetal-bovine serum and opi (1vial/l medium). The anti-LAMP-1
rat antibodies secreted into the medium (ID4B-TCM) were harvested and the medium was
replenished every 36 h. The harvested ab-TCM was centrifuged at 200 g for 4 min. The
pelleted cells were returned to the cell culture. The medium was centrifuged again at 1250 g for
10 min to remove any remaining cells. The supernatant was retained and stored as the first
batch of ab-TCM. This process was repeated until the cells were approximately 70% confluent.
The ab-TCM from the 70% confluent cells was harvested as the second batch of ab-TCM until
the morphology of ~30% of cells was indicative of dying cells. The ab-TCM was then
collected only once all cells were dead. This was then pooled and stored with the second batch
of ab-TCM, which were kept separate. Initially, when the cells are few, the amount of antibody
secreted into the medium is low and thus the antibody concentration of the first batch of ab-
TCM is low. When the cells are confluent, a large amount of antibody is secreted into the
medium as a result of the greater number of cells. When the cells die, they break-up and release
a greater amount of antibody relative to the living cells. The antibody concentration of the
second batch is thus higher.
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6.3.2 Culturing and harvesting of the mouse macrophage cell line, P388D1
This cell line was cultured in RPMI 1640 medium (Koren et al., 1975) containing 10% heat-
inactivated (56C, 0.5 h) foetal-bovine serum, 100 U/ml penicillin, 100 g/ml streptomycin.
The medium was replenished every 48 h. Two or three days before cells were to be used for an
experiment, the medium was replenished every 24 h. Cells in suspension were harvested from
6 flasks into a 500 ml sterile bottle and transferred to 50 ml tubes or directly into sterile 50 ml
tubes. These were then centrifuged (200 g, 3 min) at 4C. Cell pellets were pooled with 8 ml
HeSBSA (10 mM Hepes, 140 mM NaCl, 1 mg/ml BSA, pH 7.4) or the appropriate medium,
depending on the purpose for which the cells were to be used. Cells were washed with 10 ml of
the appropriate buffer/medium and counted. (A wash step entailed the following: The cells
were suspended in 10 ml of the appropriate buffer/medium and then pelleted at 200 g, 4 min at
4ºC.)
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6.4 PREPARATION OF ANTIBODY
6.4.1 Storage of ab-TCM
Storage of ab-TCM: The harvested ab-TCM was centrifuged at 1250 g for 10 min to remove
suspended cells. Tris(hydroxymethyl)amino methane (Tris), 1 M at pH 8.0 and NaN3 were then
added to the supernatant (ab-TCM) at a final concentration of 5% (v/v) and 0.02% (w/v),
respectively. The medium was stored at -20°C or -70°C for long-term storage. When ab-TCM
was thawed for use, it was centrifuged again at 1250 g for 15 min to remove any precipitable
protein (Harlow and Lane, 1988).
6.4.2 Purification of antibody using protein-G affinity chromatography
ID4B antibody was purified using a column packed with protein-G (Akerstrom and Bjorck,
1986; Akerstrom et al., 1987) beads as per manufacturer’s instructions (Pierce). ID4B-TCM
was mixed with binding buffer (0.1 M Na-acetate, pH 4) at a ratio of 1:1. The mixture was run
through a 2 ml protein-G column at a flow rate of 1 ml/min. The column was washed with
binding buffer. The bound protein (antibody) was eluted with 100 mM Glyc/HCl, pH 2.65. The
acidity of the eluted antibody solution was neutralised by the addition of 50l of 1 M Tris per
1 ml fraction. This solution was dialysed against phosphate-buffered saline (PBS), 8 mM
Na2HPO4, 2 mM NaH2PO4, 47 mM NaCl, pH7.4.
6.4.3 Concentration of antibody
The second batch of harvested ab-TCM (refer to 6.3.1 and 6.4.1) was concentrated by
filtration through an Ultrafree-15 centrifugal filter device. 15 ml ab-TCM was poured into
Ultrafree-15 centrifugal filter device and the cap was closed tightly. This was then placed into a
standard, disposable 50 ml centrifuge tube. The assembled device was centrifuged at 1250 g for
1 h. The concentrated ab-TCM was retrieved from the concentrate “pocket” located below the 
membrane surface. The filtrate was discarded and the process was repeated. It took ~15 h to
concentrate 1395 ml to 62 ml, ie. to produce 22,5 X concentrated ab-TCM.
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6.5 PREPARATION OF LYSOSOMAL MEMBRANE
This method was adapted from Haylett and Thilo (1986).
6.5.1 35S-Labelled lysosomal membrane
Harvested P388D1 cells were washed twice with methionine-free medium and resuspended in
this medium at 10·106 cells/ml. 35S-Methionine (specific-activity = 1175 Ci/mmol) and
methionine were added such that the final methionine concentration was 2·106 M and specific
activity was 20 Ci/mmol. Cells were labelled for 2 h at 37ºC, 5 % CO2 in a conical flask on a
shaker or with occasional mixing (every 15 min). Cells were washed once with 50 ml,
transferred to a new tube and washed five times with 10 ml HeSBSA. The process was then the
same as for the unlabelled lysosomal membrane (below).
6.5.2 Unlabelled lysosomal membrane
Harvested P388D1 cells were pooled into 10 ml HeSBSA in a 10 ml tube. Cells were washed
once with 10 ml HeSBSA and once with 10 ml homogenisation buffer (HB: 23 ml dH2O +73
ml HB27 (see Reagents 7.5)). Cells were resuspended in HB that contained 1mM PMSF, 0.1
mM leupeptin at 20− 40·106 cells/ml. Cells were cracked in a cell cracker with 12 passes. The
cracked cells were transferred to a 10 ml tube and centrifuged at 1000 g for 15 min. If the
separation between the pellet and supernatant was not clear, the pellet was resuspended in 2 ml
HB, PMSF, leupeptin. The resuspended pellet and supernatant were centrifuged again at 1000
g for 15 min. The post-nuclear supernatants (PNS) were pooled. The PNS (1.7 ml) was
carefully layered on top of 10 ml 27% Percoll in HB (27 ml Percoll + 73 ml HB27), resting on
a 0.5 ml sucrose cushion at the bottom of a polyallomer tube. These tubes and their content
were then subjected to centrifugation in an ultra-centrifuge at 50 000 g for 1.5 h at 4ºC in a
SW40Ti swing-out rotor. Two bands were visible on the resultant gradient. Lysosomes were
present in the lower band and early endosomes in the upper band (previously established in our
laboratory using lysosomal and early endosomal markers). Fractions (0.5 ml) were collected
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from the bottom of the gradient using a fraction collector. The fractions that corresponded to
the lysosomal band were pooled and stored at -20ºC or -70ºC if stored for long periods. To
remove the Percoll, the lysosomal membrane was resuspended in HB, 1 mM PMSF, 0.1 mM
leupeptin (final volume = 11.5 ml), transferred to polyallomer tubes and centrifuged at 100 000
g, for 1 h at 4ºC in an SW40Ti swing-out rotor. The supernatant was removed with a Pasteur
pipette and discarded. A little supernatant was left to collect the lysosomal membrane which
slid off the Percoll easily. To remove lumenal lysosomal protein, the lysosomal membrane was
resuspended in 5 ml HB, 1 mM PMSF, 0.1 mM leupeptin and sonicated for ~2 min at 30
seconds bursts. (NB. The lysosomal membrane was returned to ice at every interval.) The
polyallomer tubes were filled to the top and centrifuged again at 100 000 g for 1 h at 4ºC in a
SW40Ti swing-out rotor. The lysosomal membrane was collected as described above. To
remove the remaining Percoll, the lysosomal membranes were centrifuged once or twice for 20
min at 100 000 g (30 psi) in an airfuge at 4ºC. The lysosomal membranes were solubilised in
lysis buffer (10 mM Tris (pH 7.5), 5 mM EDTA, 150 mM NaCl, 0.05% NP-40, 1 mM PMSF,
0.1 mM leupeptin) (D'Souza and August, 1986) and stored at 4ºC if used the next day or at -
20ºC until use.
6.5.3 Preparation of cross-linked early endosomes and lysosomes
P388D1 cells were harvested and washed twice with 10 ml RPMI/Hepes/BSA (1 mg/ml). Cells
were split in half and both sets were resuspended at 5·106 cells/ml RPMI/Hepes/BSA. Mannan
(1 mg/ml) was added to both cell suspensions. Cells were warmed for 10 min at 37C and then
HRP (1 mg/ml) was added. One batch of cells was allowed to internalise HRP for 5 min to
prepare early endosomes and the other batch for 30 min to prepare lysosomes. HRP
internalisation was stopped by adding 50 ml cold HeSBSA and placing the flasks containing
the suspended cells in a mixture of ice and water (ice-water). Cells were pelleted (200 g for 4
min). The cells that contained the HRP-filled early endosomes were washed twice with 10 ml
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
189
cold HeSBSA and kept aside on ice for further processing. The cells that contained the 30 min
HRP pulse were washed thrice with cold 10 ml RPMI/Hepes/BSA and resuspended at 5·106
cells/ml RPMI/Hepes/BSA. HRP was chased into lysosomes by incubating the cells for 70 min
at 37C after which the flask that contained the suspended cells was placed in ice-water. The
cells were washed twice with 10 ml cold HeSBSA. Both sets of cells were then processed for
HRPDAB cross-linking (refer to section 6.11.4). The cells were washed once with 10 ml HB
and resuspended at 40·106 cells/ml cold HB that contained Complete Protease Inhibitors
(diluted 25-fold, see Reagents 7.5). Each set of cells were cracked separately in a cell cracker
with 12 passes. The homogenates were centrifuged at 800 g for 5 min and 2 3 ml of each
supernatant were layered on top of 9 ml 27% Percoll in HB, resting on a 0.5 ml sucrose
cushion at the bottom of a polyallomer tube. If necessary, more HB was added to fill the tube
to the top. These tubes and their contents were then subjected to centrifugation in an ultra-
centrifuge at 35 000 g for 1.5 h at 4ºC in a SW40Ti swing-out rotor. The brown band at the top
that corresponded to the early endosomes was collected from the gradient that contained the
material of the cells in which the early endosomes were cross-linked. The brown band at the
bottom that corresponded to the lysosomes was collected from the gradient that contained the
material of the cells in which the lysosomes were cross-linked. The fractions were stored at 4ºC
and were washed the next day in a final volume of about 12.5 ml HB to remove the Percoll
(100 000 g for 2 h at 4ºC). The cross-linked material was collected and concentrated by
centrifugation (8 000 g for 30 min at 4ºC). Membranes were solubilised in 10 mM Tris/HCL
pH 7.4, 0.9% NaCl (TBS), 1% Triton-X 100, 25-fold diluted Complete Protease Inhibitors
Cocktail (see Reagents 7.5). Detergent-resistant material was pelleted at 8 000 g for 30 min and
the supernatant collected. The protein concentration was determined using the bicinchoninic
acid (BCA) assay, see section 6.9.2.
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6.6 SDS-PAGE
This method was adapted from (Laemmli, 1970). Proteins were separated on mini-gels using
gel electrophoresis. The dimensions of the lower gels were ~ 800 mm long, 140 mm wide and
1.5 mm thick. The required concentrations of polyacrylamide solutions were prepared from a
30% Acrylamide, 0.8% bisacrylamide stock solution. For the lower gel solutions, the stock
acrylamide was diluted with a lower gel buffer, 1.5 M Tris, 0.4% SDS, pH 8.8, such that the
solution was in 0.375 M Tris, 0.1% SDS, pH 8.8. Ammonium persulphate (AMPS) and
N,N,N’,N’-tetramethylethylendiamine (TEMED) were added to final concentrations of 0.02%
and 0.039% TEMED, respectively. For the upper gel solution, the stock acrylamide was diluted
to 4.2% with an upper gel buffer, 0.5 M Tris, 0.4% SDS, pH 6.3 such that the solution was in
0.125 M Tris, 0.1 SDS, pH 6.3. AMPS and TEMED were added to final concentrations of
0.085% and 0.426%, respectively. Gels were run in a discontinuous buffering system using
running buffer, 0.025 M Tris, 0.192 M Glycine, 0.1% SDS, pH 8.3, at 25 mA until the samples
had gone into the stacker and then at 30 mA for ~3 h.
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6.7 WESTERN BLOT
Proteins were resolved using SDS-PAGE andAmersham’s Rainbow molecular-weight markers
or BioRad’s Precision Plus protein standards. The proteins were transferred from SDS-
polyacrylamide gels to nitrocellulose membranes (Burnette, 1981) using transfer buffer, 20
mM Tris, 150 mM Glyc, 20% methanol at 4ºC.
6.7.1 Western blot no.1
A transfer apparatus that was custom made for 800 mm X 140 mm gels by Mr Hall for the
LDL laboratory at the Department of Medical Biochemistry was used. The transfer was
performed at 100 mA for 16 to 20 h.
Treatment of the blot after transfer
Immediately following transfer, the nitrocellulose (NC) membrane was incubated in 200 ml
blocker (10 mM Tris/HCl pH 7.4, 0.9% NaCl, 5% BSA) at 4ºC for 30 min on a rocking
platform. NaCl prevents non-specific ionic bonds and BSA prevents non-specific hydrophobic
bonds. The NC membrane was cut into strips (one lane per strip). A strip was then incubated
with anti-LAMP-1 primary antibody (ID4B-TCM, 20-50 µg/ml), diluted 5- or 25-fold with the
blocker, for 90 min at room temperature (RT) on a rocking platform. The NC membrane was
then washed once in 200 ml solution 1 (10 mM Tris/HCl pH 7.4, 0.9% NaCl) for 10 min, twice
in 200 ml solution 1, 0.05% NP40, for 20 min and then once in 200 ml solution 1 for 10 min.
The detergent removes probe bound to the NC non-specifically, through hydrophobic bonds.
This process was then repeated with the secondary antibody (sheep anti-mouse serum diluted
500-fold) and the tertiary antibody (rabbit anti-sheep/goat horseradish-peroxidase-linked
antibody diluted 2000-fold). To minimise the volumes of antibodies used, cling-wrap (Glad-
wrap) was sealed around the NC membrane to serve as containers. The minimum volume
required was 100 µl/cm2.) The NC was briefly blotted with paper towels or dried between 2
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pieces of 3M Whatman papers (~1 h at RT or 15 min at 37ºC). It was then wrapped in cling-
wrap and developed with the enhanced chemiluminescence detection system.
6.7.2 Western blot no.2
BioRad’s Miniprotein II or III cell system was used to resolve the proteins by SDS-PAGE (200
V for 45 min) and to transfer the proteins to a NC membrane (100 V for 1 h) at 4ºC.
Treatment of the blot after transfer
Immediately following transfer, the NC membrane was blocked in 5% fat-free milk powder,
TBS-T (10 mM Tris/HCL pH 7.4, 0.9% NaCl, 0.1% Tween 20) overnight at 4ºC and washed
with TBS-T as follows: two quick washes, one 15 min wash and two 5 min washes. The blot
was then incubated in primary antibody in TBS-T, 0.5% fat-free milk powder for 1 h at room
temperature and the washing process was repeated. The primary antibody was detected with
peroxidase-linked secondary antibody in TBS-T, 0.5% fat-free milk powder and the washing
process was repeated. The blot was developed with the enhanced chemiluminescence detection
system (ECL) or KPL luminoglo.
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6.8 LINKAGE OF ANTI-RAT-Fc ANTIBODY TO CN-BrACTIVATED
SEPHAROSE 4B
(This method was adapted from the Pharmacia protocol on Affinity Chromatography by the
LDL group, department of Medical Biochemistry, UCT.)
To 8 mg of ligand (AAR-02), 0.5 volumes of 0.6 M NaHCO3 (pH 8.6), 1.5 M NaCl was added.
The mixture was made up to a volume such that the final coupling buffer concentrations were
0.2 M NaHCO3 (pH 8.6), 0.5 M NaCl. This constituted the coupling solution. Freeze-dried,
cyanogen bromide(CNBr)-activated Sepharose 4B beads (0.57 g) were suspended in 5 ml 1
mM HCl at 4ºC. The beads were washed on a sintered glass filter (porosity G3) with
approximately 120 ml 1 mM HCl (4ºC) and dried until cracks appeared in the gel cake. The gel
was immediately transferred to coupling solution which contained the ligand at a gel:buffer
ratio of 1:2. (NB. The 12 ml Greiner blue-capped tube is suitable for this). The suspension was
rotated for 2 h at room temperature or overnight at 4ºC. The residual active groups on the gel
were blocked by incubating the gel in a solution of 0.2 M Glyc, pH 8 for 2 h at room
temperature or 16 h at 4ºC. The excess absorbed protein was washed away with alternative
high and low pH solutions; coupling buffer (0.2 M NaHCO3, pH 8.3; 0.5 M NaCl) followed by
acetate buffer (0.1 M Na-acetate pH 4, 0.5 M NaCl). This was repeated 4 or 5 times. The
coupled gel was stored at 4 to 8ºC.
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6.9 PROTEIN DETERMINATION
6.9.1 Lowry protein assay
This method was reviewed as a standard protocol for the quantitation of proteins in (Peterson,
1979). Protein standards in the concentration range of 0.04− 0.30 mg/ml were prepared from 1
mg/ml BSA in a final volume of 250 µl. An equal volume (250 µl) of 1 M NaOH was added to
the BSA standards. The unknown sample was prepared such that it contained 20 − 40 µg 
protein in 500 µl 0.5 M NaOH. NaOH (0.5 M, 500 µl) was used as a blank. A mixture (2.5 ml)
consisting of (0.01%) CuSO4 / (0.02%) NaK Tartrate / (1.96%) Na2CO3 was added to all tubes.
The solutions were thoroughly mixed and incubated at room temperature for 10 min. Folin
reagent (Folin− Ciocalteu’s phenol reagent, Merck Art 9001, diluted 1 + 1.5 ml H2O, 250 µl)
was added to each tube and the solutions were immediately mixed. The solutions were
incubated at room temperature for 30 min. Absorbances of all standards and samples were read
at 660 nm.
6.9.2 BCA protein assay
(This method was done in a microplate as per the Pierce protocol.)
Protein standards in the concentration range of 5 − 250 µg/ml were prepared from BSA (2
mg/ml). Sample buffer and dH2O were used as blanks. The standards or samples (25 µl) were
pipetted into microplate wells. The BCA working reagent was prepared such that it contained
reagent A and reagent B in a ratio of 50:1. The working reagent (200 µl) was then added to the
wells. The microplate was gently agitated such that the samples were thoroughly mixed. The
plate was covered and incubated at 37ºC for 30 min. After the incubation period the plate was
cooled to room temperature and absorbances were read at 562 nm.
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6.9.3 TCA precipitation
Radio-actively−labelled samples (5 µl) were aliqouted in 1 ml eppendorf tubes and diluted
with 100 µl HeSBSA (1 mg/ml). TCA (1ml, 10%) was added to each sample. The suspension
was thoroughly mixed and duplicate aliquots (100 µl) were taken for scintillation counting.
The samples were placed on ice for 30 min and then centrifuged at 8 000 g for 30 min.
Aliquots (100 µl) were again taken for scintillation counting. The radio-activelylabelled
precipitated protein was then determined as a fraction of the total radioactivity or an amount in
dpm.
6.9.4 NAGA assay
The Oxford glucose method was used. NAGA is only active at the low pH of 5. The assay was
thus performed in a Na2HPO4 (anhydrous) /citric acidH2O buffer, pH 5 that was prepared by
diluting 20 ml of 100 mM Na2HPO4 (anhydrous) with ~10 ml of 100 mM citric acid.H2O. The
unknown samples (5 or 10 µl) were aliqouted into eppendorfs and placed on ice. The substrate
solution (200 µl, 3 mM p-nitrophenyl acetyl glucosaminade in Na2HPO4/citric acid buffer) was
added to the samples, mixed and placed on ice. (The activity of NAGA is very low on ice.) The
samples were then incubat d at 37ºC for 20 min after which the reaction was slowed down by
placing the samples in ice-water. The reaction was stopped by the addition of 700 µl 0.05 M
NaOH to each sample. Lysis buffer and dH2O were used as controls. NAGA releases acetyl
glucosaminade from the substrate. p-Nitrophenol, a coloured product of which the absorbance
can be read at 405 nm, is generated in the process.
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6.10 METABOLIC LABELLING OF CELLS
6.10.1 Continuous labelling
Cells were washed once with MEM and incubated at 37C for 2 h in MEM containing 35S-
methionine at 1.16·10-7 M (specific-activity = 1175 Ci/mmole) and 5% CO2 at 10·106 cells/ml.
The labelling process was stopped by placing the cells on ice. Cells were lysed as described in
section 6.12.1.
6.10.2 Pulse-chase experiments
Cells were washed twice with 4 ºC methionine-free RPMI 1640 and starved in this medium at
10·106 cells/ml for 30 min at 37ºC, 5% CO2. 35S-Methionine was then added to the warm
medium at 10-6 to 10-7 M (specific-activity = 1175 Ci/mmole) and the cells were metabolically
labelled at 37C, 5% CO2 for 5 min. The labelling was stopped by placing the flask containing
the suspension of cells in ice-water. Cells were pelleted by centrifugation at 200 g for 4 min at
4C and washed thrice with 10 ml cold RPMI/Hepes/BSA (1 mg/ml). A volume of
RPMI/Hepe/BSA(1 mg/ml) that would result in a 5·106 cells/ml suspension of cells was
warmed to 37C. The pelleted cells were resuspended in 1 ml cold RPMI/Hepes/BSA (1
mg/ml) and transferred to the warmed medium. This was time zero. The cells were then
incubated for the specified chase periods. The chase was stopped by collecting samples of 1 ml
(5·106 cells) and transferring them to 10 volumes of cold HeS-BSA. During the labelling
process HRP was either localised to the endocytic pathway, lysosomes or early endosomes.
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6.11 LOCALISATION OF HRP IN ENDOSOMES TO TRAP PROTEINS
During endocytosis of HRP, the medium contained 1 mg/ml HRP and 1 mg/ml mannan, unless
otherwise stated. Mannan was always added at least 5 min prior to the addition of HRP.
6.11.1 The endocytic pathway
HRP was endocytosed for 70 min before the starvation of the cells, during the 30 min
starvation and throughout the experiment.
6.11.2 The early endosomes
HRP was endocytosed during the last 5 min of the chase periods.
6.11.3 The lysosomes
HRP was endocytosed for 30 min and then chased for 40 min prior to the starvation period.
The rest of the experiment was performed in the absence of HRP.
6.11.4 HRPDAB cross-linking
To cross-link the proteins in the HRP-containing endosomes/lysosomes the metabolically
labelled and HRP-containing cells were subjected to HRPDAB cross-linking. The cells
(~5·106 cells) were washed twice with cold HeS-BSA (10 ml) and once with 10 ml Hepes-
Saline (HeS, 10 mM Hepes, 140 mM NaCl, pH 7.4) during which the cells were transferred to
a clean tube. Cells were resuspended in 2 ml HeS and split into two 1 ml aliquots. One aliquot
(~2·106 cells) was treated with diaminobenzidine (DAB) and hydrogen peroxide (H202) as
follows: DAB was prepared fresh at 3 mg/ml in HeS. The DAB suspension was mixed in a
sonicator bath for 5 min and filtered through a 0.4m Millipore filter. The filtered DAB was
added at 180 l/ml of cell suspension. The cells were gently mixed and incubated in the dark
on ice for 30 min, with occasional mixing. The cells were then warmed to room temperature in
a 37C waterbath. H202 (0.3%) was added to the cells at 20l/ml of cell suspension, such that
the final concentration of H202 was 0.03%. Cells were incubated in the dark for 20 min at
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room temperature with occasional mixing. The cross-linking process was stopped by adding 4
volumes of cold HeS-BSA. The other aliquot was treated exactly the same, but DAB and H202
were not added. This served as the control. The cells were washed three times with 10 ml cold
Hepes-Saline BSA (HeS-BSA). Cells were lysed as described in section 6.12.2.
6.12 LYSIS
6.12.1 General lysate preparation of metabolically labelled cells for
immunoprecipitation of LAMP-1
The cells were washed three times with 10 ml cold Hepes-Saline BSA (HeS-BSA). On the
third wash the cells were transferred to a clean tube. The labelled cells were then incubated on
ice for 30 min in LAMP-1 lysis buffer at a final cellular concentration of ~40·106 cells/ml, with
occasional mixing on a vortex. The lysate was freeze-thawed three times, using liquid N2 for
snap freezing and a 37C water-bath for rapid thawing. Detergent-resistant material was
removed by centrifugation in a microfuge twice at 8 000 g for 15 min at 4ºC. The detergent-
soluble material was retained for immunoprecipitation. If kept for long periods, lysates were
stored at -70C.
6.12.2 Lysate preparation for cross-linking experiments
Cells in the samples collected during pulse-chase experiments were centrifuged at 200 g for 3
min, resuspended in ~1 ml HeSBSA and transferred to an eppendorf tube (1.5 ml). Cells
(2.5·106) were then pelleted at 200 g for 3 min and resuspended in 200 l LAMP/CD-MPR
lysis buffer (see Reagents 7.5). The lysate was incubated overnight on a shaker or a roller at
4ºC. (Freeze-thawing was not appropriate for cross-linked material. It led to inconsistent
results.) Detergent-resistant material was removed by centrifugation, twice at 8 000 g for 30
min at 4ºC for LAMP-1; or once at 8 000 g for 30 min and once at 100 000 g for 30 min at 4ºC
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for the CD-MPR. The detergent-soluble material was retained for immunoprecipitation as
described in 6.13.
6.13 IMMUNOPRECIPITATION
Antibody (10 µl of 10-fold concentrated ID4B-TCM or 5 µl rabbit anti-bovine-CD-MPR
serum) was added to 160-180 µl of the detergent-soluble fraction of the lysate, prepared in
6.12. The antibody-lysate mixture was incubated on a vortex shaker, overnight at 4°C. The
following day it was centrifuged at 8 000 g for 15 min at 4°C to remove any precipitable
material. The supernatant was then incubated with 50 µl beads (protein-G for rat antibodies and
protein-A for rabbit antibodies) for 2 h at 4°C on a vortex shaker. The immuno-complexed
beads were washed thrice with cold LAMP lysis buffer/CD-MPR washing buffer (see Reagents
7.5), transferred to a clean tube during the 4th wash, washed again twice with cold LAMP lysis
buffer/CD-MPR washing buffer and once with dH2O. Immunocomplexes were eluted as in
6.14.
6.14 ELUTION OF IMMUNOCOMPLEXES FROM BEADS
The antigen-antibody complexes were eluted with 0.1 M Gly/HCl, pH 2.6 at room temperature.
Beads were incubated with 55 µl of buffer for 5 min, on a vortex shaker. The beads were
pelleted and 40 µl of the eluent was collected. The elution was repeated with 20 µl elution
buffer, 20 µl eluent was collected and pooled with the first eluent. The pH of the eluent was
increased to 7.0 with 3.6 µl of 2 M Tris at pH 8.0.
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6.15 SDS-PAGE AND PRODUCT ANALYSES OF SAMPLES FROM CROSS-
LINKING EXPERIMENTS
Three-foldconcentrated, reducing-SDS-sample buffer (31.8 µl) was added to the total eluent
of 60 µl. Samples were incubated at 95°C for 5 min. High molecular-weight markers or
precision-plus dual-colour molecular-weight markers (2.5 µl) were added per sample to aid in
the cutting-out of the LAMP-1/CD-MPR bands. The eluents were then resolved by SDS-PAGE
on mini-gels (7% for LAMP-1 and 10% for CD-MPR). Samples were run through a 5% stacker
at 25 mA. Thereafter the current was maintained at 30 mA until the appropriate separation was
attained. For the LAMP-1, the front was run off the gel for 40 min. For the CD-MPR, the front
was run to a position 1 cm from the edge of the gel. The gel was silver-stained and the LAMP-
1/CD-MPR bands were excised from the gel using the molecular-weight markers as reference
points. The gel pieces (1.5 mm thick, ~1 cm wide, ~1 − 2 cm long) were solubilised in 2 ml
30% H2O2 at 60°C overnight. The solubilised gel pieces were then counted in a Packard Liquid
Scintillation Analyzer.
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6.16 GEL-STAINING
6.16.1 Coomassie Staining
The staining solution (46% methanol, 8% glacial acetic acid, 0.1% Coomassie brilliant blue R)
was freshly made before use. A fraction of the methanol was added to the dye to solubilise the
dye. The suspension was stirred and the solubilised dye carefully decanted. The process was
repeated until only white sediment remained and was discarded. The rest of the methanol, the
glacial acetic acid and dH2O were then added. The gel was incubated in staining solution for 15
min. The gel was rinsed once quickly (30 sec) in dH2O to remove the excess dye. The gel was
incubated in ~150 ml destain solution (20% methanol, 8% glacial acetic acid) for 30 min to 1 h
after which the destain solution was replaced with fresh destain solution. Sponges (~2 cm3)
were immersed in the destain solution (~400 ml) and suspended above the gel to facilitate the
destain process. Gel was left to destain overnight.
6.16.2 Silver Staining
This method was adapted from (Meril et al., 1984). Protein bands on the gels were fixed
overnight in 12% TCA, 2% Cu(II)Cl2 and 50% methanol. Gels were then sequentially soaked
in the following solutions while continually being agitated: 10% ethanol, 5% acetic acid
(solution 1) for 30-40 min; 0.01% KMnO4 for 10 min; solution 1 for 20 min; 10% ethanol for
40 min; de-ionised water for 30 min; 0.1% AgNO3 for 20 min; de-ionised water for 1 min; 10%
K2CO3 for 1.5 min; 2% K2CO3, 0.01% formaldehyde until the protein bands became visible,
usually for ~3-4 min; de-ionised water for 30 seconds, 3% acetic acid overnight. The following
day protein bands were cut from the wet gels using molecular-weight markers as a reference.
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7 ADDENDUM
7.1 ABBREVIATIONS
 AAR-02 : rabbit anti-rat IgG antibody
 ab : antibody
 ABL93 : rat anti-mouse LAMP-2 antibody
 ab-TCM : antibody-containing tissue-culture medium
 ag-ab : antigen complexed to antibody
 AP : adaptor protein
 cat. no. : catalogue number
 CD8 : a cell-surface protein
 CD-MPR : cation-dependent mannose 6-phospate receptor
 cf. : compare
 chs: chapters
 CI-MPR : cation-independent mannose 6-phosphate receptor
 CN-Br : cyanogen-bromide
 CO2 : carbon dioxide
 COS-1 : transformed African Green Monkey Kidney Fibroblasts
 CURL : compartment of uncoupling of receptor and ligand
 DAB : diaminobenzidine
 dH2O : distilled water
 EDTA : ethylenediaminotetra-acetic disodium salt
 EN : endosomes
 EP : endocytic pathway
 Endo H : endoglycosidase H
 FITC-D : Fluorescein isothiocyanate-dextran
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 GST : Glutathione-S-transferase
 g : gravitational acceleration
 HCl : hydrochloric acid
 H2O2 : hydrogen peroxide
 HeLa : An immortalised cel line derived from Henrieta Lacks’ cervical cancer cels.
 HeS : hepes-saline
 HeS-BSA : hepes-salinebovine serum albumin
 HMW : high molecular-weight markers
 HRP : horse-radish peroxidase
 ID4B : rat-anti-mouse LAMP-1 antibody
 LAMP : lysosomal-associated membrane protein
 LAP : lysosomal acid phosphatase
 LAPTM5 : lysosomal-associated multispanning membrane protein 5
 LEP 100 : chicken LAMP-1
 LIMP : lysosomal integral membrane protein
 LDL : low density lipoprotein
 LYS : lysosomes
 MEM : methionine-free minimum essential medium
 MEF : mouse embryonic fibroblasts
 MW : molecular-weight
 NAGA : N-acetyl glucosaminidase
 NRK : normal rat kidney cells
 N2 : nitrogen
 Na-acetate : sodium acetate
 NaCl : sodium chloride
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 NP40 : non-ionic detergent P40
 P : page
 P388D1 : mouse macrophage cell line
 PMSF : para-methyl sulphonyl fluoride
 protein-G−ID4B : rat-anti-mouse LAMP-1 antibody complexed to protein-G beads
 RNA : ribonucleic acid
 SDS : sodium dodecyl sulphate
 SDS-PAGE : sodium dodecyl sulphate - polyacrylamide gel electrophoresis
 TCA : trichloro-acetic acid
 TCM : tissue-culture medium
 Tris : Tris(hydroxymethyl) amino methane
 β-counter : beta-counter or scintillation counter
 µ1B : subunit of the AP-1 complex in polarised epithelial and glandular cells
 µ3B : subunit of the AP-3 complex in neuronal cells

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7.2 SINGLE AMINO-ACID CODE
A Ala alanine M Met methionine
C Cys cysteine N Asn asparagine
D Asp aspartic acid P Pro proline
E Glu glutamic acid Q Gln glutamine
F Phe phenylalanine R Arg arginine
G Gly glycine S Ser serine
H His histidine T Thr threonine
K Lys lysine V Val valine
I Ile isoleucine W Trp tryptophan
L Leu leucine Y Tyr tyrosine
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7.3 UNITS
1. Ci : Curies
2. Ci/mmol : Curie per mmole
3. h : hour/s
4. kDa : kilo-Dalton
5. lr : litre
6. M : molar (moles per litre)
7. mA : milliamps
8. min : minute/s
9. mM : milli-molar (millimoles per litre)
10. U/ml : Units per ml
11. v/v : volume by volume
12. w/v : weight by volume
13. °C : degree Celsius
14. µCi/ml : micro-Curie per millilitre
15. µg/ml : microgram per millilitre
16. µl : microlitre
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7.4 EQUATIONS
1. The amount of sample eluted from beads with every elution round (figure 4.1.12).
En = fL(1-f)(n-1),
where En is the amount of LAMP eluted at round n
L is total bead load
f is the fraction of LAMP-1 eluted with each elution round
2. The total amount of protein synthesised in terms of the total amount of methionine
(mmoles) incorporated into protein as determined in figure 4.1.20.
M = p / (fS),
where M is the total amount of methionine incorporated into protein (mmoles)
p is the total amount of protein precipitated in terms of 35S-methonine counts (dpm)
f is the dpm to Ci conversion factor : 2200109 dpm/Ci
S is the specific-activity of methionine in the medium (Ci/mmol)
3. The fraction of 35S-LAMP-1 or 35S-CD-MPR cross-linked.
Y = (1-(S-X)/(T-X))*100,
where Y is the fraction of cross-linked LAMP-1/CD-MPR (%)
X is lane background (dpm)
S is soluble LAMP-1 (dpm) from the cross-linked sample
T is soluble LAMP-1 (dpm) from the non-cross-linked sample (total LAMP-1)
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7.5 REAGENTS
1) HeSBSA (Hepes-saline with bovine serum albumin) : 10 mM Hepes, 140 mM NaCl, 1
mg/ml BSA, pH 7.4.
2) HeS (Hepes-saline) : 10 mM Hepes, 140 mM NaCl, pH 7.4.
3) Binding buffer : 0.1 M Na-acetate, pH 4
4) Complete Protease Inhibitor Cocktail Tablets (commercially-purchased tablets that
contain a cocktail of a broad range of ser-, cys- and metalloproteases, as well as
calpains)
Stock: One tablet was dissolved in 1 ml of dH2O.
Working solution: stock was diluted 25-fold with the buffer that was used for lysis.
5) LAMP-1 lysis buffer : 10 mM Tris (pH 7.5), 5 mM EDTA, 150 mM NaCl, 0.05% NP-
40, inhibitors (1 mM PMSF, 1 M leupeptin or 25-fold diluted Complete Protease
Inhibitors Cocktail).
6) Elution buffer : 0.1 M Gly/HCl, pH 2.6
7) Imidazole buffer : 50 mM imidazole, 150 mM NaCl, 2 mM EDTA, 1 mg/ml BSA, 5
mM Na--glycerophosphate, pH 7
8) Imidazole lysis buffer : imidazole buffer, 1% Triton, 0.1% Na-deoxycholate, 1 mM
PMSF, 1M pepstatin.
9) Imidazole immunoprecipitation/washing buffer : imidazole buffer, 0.05% Triton
10) CD-MPR buffer (Tris buffer) : 25 mM Tris, 5 mM EDTA, 150 mM NaCl, pH 7.5
11) CD-MPR lysis buffer (Tris lysis buffer) : Tris buffer, 1% Triton, 0.1% Na-
Deoxycholate, 1 mM PMSF, 25-fold diluted Complete Protease Inhibitors Cocktail.
12) CD-MPR immunoprecipitation/washing buffer (Tris washing buffer) : Tris buffer,
0.05% Triton.
13) Lower gel buffer : 1.5 M Tris, 0.4% SDS, pH 8.8
14) Upper gel buffer : 0.5 M Tris, 0.4% SDS, pH 6.3
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15) Running buffer : 0.025 M Tris, 0.192 M Glycine, 0.1% SDS, pH 8.3
16) Non-reducing SDS-sample buffer (concentrated 4-fold) : 40% (v/v) glycerol, 9.2%
(w/v) SDS, 0.001% (w/v) Bromophenol blue, 33.2% (v/v) upper gel buffer
17) Reducing SDS-sample buffer (concentrated 4-fold) : Non-reducing SDS-sample buffer
(concentrated 4-fold), 20% (v/v)-mercaptoethanol
18) Coomassie stain : 46% methanol, 8% glacial acetic acid, 0.1%Coomassie Brilliant
BlueR
19) Destain : 20% methanol, 8% glacial acetic acid
20) Gel drying solution : 3% glacial acetic acid, 2% glycerol (glycerol was not included
when gel was cut-up for solubilisation)
21) Transfer buffer : 20 mM Tris, 150 mM Glycine, 20% methanol
22) Phosphate buffered saline (PBS) : 8 mM Na2HPO4, 2 mM NaH2PO4, 47 mM NaCl,
pH7.4
23) Tris buffered saline (TBS) : 10 mM Tris/HCL pH 7.4, 0.9% NaCl
24) Tris buffered saline-Tween 20 (TBS-T) : 10 mM Tris/HCL pH 7.4, 0.9% NaCl, 0.1%
Tween 20
25) HB27 : 342 mM Sucrose, 2.74 mM EDTA, 13.7 mM Hepes
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
210
7.6 LIST OF FIGURES
Figure 2.1 Intracellular trafficking pathways. .................................................................................................... 5
Figure 2.2 Pathways to be considered for the lysosomal delivery of LAMP-1. ............................................... 11
Figure 2.3 Pathways to be considered for the delivery of the CD-MPR into the endocytic pathway............... 12
Figure 3.1.1 The structure of LAMP-1 and LAMP-2.......................................................................................... 16
Figure 3.1.2 The structure of LIMP-I (LAMP-3). ............................................................................................... 17
Figure 3.1.3 The structure of limp-II. .................................................................................................................. 18
Figure 3.1.4 The structure of LAP....................................................................................................................... 19
Figure 3.1.5 The structure of endolyn.. ............................................................................................................... 20
Figure 3.2.1 A schematic diagram of the CI-MPR and the CD-MPR ................................................................. 53
Figure 3.3.1 HRPDAB cross-linking................................................................................................................. 78
Figure 3.3.2 HRP Internalisation.. ....................................................................................................................... 79
Figure 3.3.3 Sample processing and analyses ..................................................................................................... 80
Figure 3.4.1 Scenario 1 with LAMP-1 entering via early endosomes. ................................................................ 82
Figure 3.4.2 Scenario 2 with LAMP-1 entering via lysosomes. .......................................................................... 83
Figure 4.1.1 Purification of ID4B from TCM ..................................................................................................... 86
Figure 4.1.2 Binding of antibody from foetal-calf serum to protein-G beads. .................................................... 87
Figure 4.1.3 Western blot of LAMP-1 from lysosomal membrane fractions. ..................................................... 88
Figure 4.1.4 Immunoprecipitation of LAMP-1 from 35S-labelled lysosomal membrane. ................................... 89
Figure 4.1.5 Western blot of LAMP-1 from detergent-soluble cell extract......................................................... 91
Figure 4.1.6 Immunoprecipitation of LAMP-1 from 35S-labelled, detergent-soluble cell extract. ...................... 92
Figure 4.1.7 Comparison of the binding efficiencies of protein-G beads versus Dynabeads. ............................. 95
Figure 4.1.8 Comparison of the binding efficiencies of protein-G beads and AAR-02 beads. ........................... 96
Figure 4.1.9 Comparison of LAMP-2 immunoprecipitation by Dynabeads versus protein-G beads. ................. 97
Figure 4.1.10 Comparison of LAMP-2 immunoprecipitation by protein-G beads versus AAR-02 beads. ........... 98
Figure 4.1.11 Comparison of the efficiencies of two elution buffers. ................................................................. 101
Figure 4.1.12 Determination of the number of elution rounds required to remove the maximum amount
of LAMP-1−ID4B complexes from the beads..............................................................................102
Figure 4.1.13 Quantitation of immunoprecipitated 35S-LAMP-1 using Instant Imager scanning software
versus liquid scintillation counting................................................................................................105
Figure 4.1.14 The elimination of a non-specific signal by centrifugation after the antigen-antibody
incubation step in the immunoprecipitation assay.........................................................................108
Figure 4.1.15 The binding capacity of protein-G beads. ..................................................................................... 109
Figure 4.1.16 Optimisation of the cell-concentration range to be used for the quantitative
immunoprecipitation of 35S-LAMP-1............................................................................................111
Figure 4.1.17 Optimisation of the antibody volume required for the quantitative immunoprecipitation of
LAMP-1.. ......................................................................................................................................112
Figure 4.1.18 The effect of high LAMP-1 concentrations in the immunoprecipitation assay on detecting
differences of LAMP-1 abundance. ............................................................................................114
Figure 4.1.19 Reproducibility of immunoprecipitation of 35S-LAMP-1. ............................................................ 116
Figure 4.1.20 Determination of the methionine concentration in the medium required for optimal rates
of protein synthesis and efficient incorporation of 35S-methionine. ..............................................118
Figure 4.1.21 Characterisation of early endosomes by EEA1 and Rab 5b. ......................................................... 121
Figure 4.1.22 The effect of concentration in a 5 min pulse of HRP uptake on the cross-linking of NAGA. .......123
Figure 4.1.23 The effect of concentration in a 30 min pulse of HRP uptake on the cross-linking of
lysosomal FITC-D and NAGA......................................................................................................124
Figure 4.1.24 Time required for HRP to fill the endocytic pathway, and thus also for HRP delivery to
lysosomes, to effect maximal cross-linking of NAGA..................................................................125
Figure 4.1.25 The effect of HRP concentration in a 30 min pulse on the cross-linking of LAMP-1 in
lysosomes.. ....................................................................................................................................126
Figure 4.1.26 Maximal cross-linking of LAMP-1 in the endocytic pathway. ..................................................... 128
Figure 4.1.27 A diagrammatic representation of the pulse-chase experiments. .................................................. 129
Figure 4.1.28 Determination of the kinetics with which total protein is processed. ............................................ 132
Figure 4.1.29 Biosynthetic processing of immunoprecipitable 35S-LAMP-1...................................................... 133
Figure 4.1.30 Delivery of newly-synthesised 35S-LAMP-1 into the endocytic pathway..................................... 134
Figure 4.1.31 Delivery of newly-synthesised 35S-LAMP-1 to lysosomes. .......................................................... 136
Figure 4.2.1 Cross-reactivity of rabbit, anti-bovine-CD-MPR serum with mouse CD-MPR............................ 143
Figure 4.2.2 Immunoprecipitation of CD-MPR after increasing times of metabolic labelling.......................... 145
Figure 4.2.3 Specificity of the CD-MPR immunoprecipitation assay. .............................................................. 147
Figure 4.2.4 Removal of non-specific band II by centrifugation....................................................................... 148
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
211
Figure 4.2.5 Immunoprecipitation of CD-MPR after a high-speed preclearing centrifugation step.................. 148
Figure 4.2.6 Immunoprecipitation of CD-MPR after different lysis conditions................................................ 150
Figure 4.2.7 CD-MPR immunoprecipitate analysis under non-reducing conditions. ........................................ 151
Figure 4.2.8 CD-MPR immunocomplex analysis under non-reducing or reducing conditions......................... 153
Figure 4.2.9 CD-MPR elution with a gentler non-reducing buffer.................................................................... 154
Figure 4.2.10 A repeat of figure 4.2.9 ................................................................................................................. 155
Figure 4.2.11 Quantification of immunoprecipitated 35S-CD-MPR. ................................................................... 157
Figure 4.2.12 Comparison of two methods for the quantification of immunoprecipitated CD-MPR,
InstantImager scanning software versus scintillation counting. ....................................................158
Figure 4.2.13 Optimisation of the cell-concentration range to be used for the quantitative
immunoprecipitation of 35S-CD-MPR...........................................................................................160
Figure 4.2.14 Biosynthetic processing of 35S-CD-MPR...................................................................................... 162
Figure 4.2.15 Delivery of newly-synthesised 35S-CD-MPR to the endocytic pathway. ...................................... 165
Figure 4.2.16 Colocalisation of endocytosed HRP with CD-MPR at steady state. ............................................. 166
Figure 4.2.17 Delivery of newly-synthesised 35S-CD-MPR into lysosomes. ...................................................... 168
Figure 4.2.18 Delivery of newly-synthesised 35S-CD-MPR to early endosomes.. .............................................. 170
Figure 4.2.19 Comparison of the entry of 35S-CD-MPR into individual compartments...................................... 171
Figure 5.1 Model proposed for LAMP-1 delivery to lysosomes. ................................................................... 181
7.7 LIST OF TABLES
Table 3.1.1 Nomenclature and properties of the major lysosomal membrane glycoproteins. ............................... 14
Table 4.1.1 The effect of buffer conditions on the efficiency of ID4B binding to protein-G beads, in two
different binding buffers. ....................................................................................................................99
Table 4.1.2 The effect of time and temperature on the efficiency of ID4B binding to protein-G beads. .............. 99
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
212
7.8 REFERENCES
Ahle, S., Mann, A., Eichelsbacher, U. and Ungewickell, E. (1988). Structural relationships
between clathrin assembly proteins from the Golgi and the plasma membrane. EMBO J. 7,
919-929.
Akasaki, K., Fukuzawa, M., Kinoshita, H., Furuno, K. and Tsuji, H. (1993). Cycling of
two endogenous lysosomal membrane proteins, lamp-2 and acid phosphatase between the cell
surface and lysosomes in cultured rat hepatocytes. J. Biochem. 114, 598-604.
Akasaki, K., Michihara, A., Fujiwara, Y., Mibuka, K. and Tsuji, H. (1996). Biosynthetic
transport of a major lysosome-associated membrane glycoprotein 2, LAMP-2: A significant
fraction of newly synthesized LAMP-2 is delivered to lysosomes by way of early endosomes.
J. Biochem. 120, 1088-1094.
Akasaki, K., Michihara, A., Fukuzawa, M., Kinoshita, H. and Tsuji, H. (1994). Cycling of
an 85 kDa lysosomal membrane glycoprotein between the cell surface and lysosomes in
cultured rat hepatocytes. J. Biochem. 116, 670-676.
Akasaki, K., Michihara, A., Mibuka, K., Fujiwara, Y. and Tsuji, H. (1995). Biosynthetic
transport of a major lysosomal membrane glycoprotein, lamp-1: Convergence of biosynthetic
and endocytic pathways occurs at three distinctive points. Exp. Cell Res. 220, 464-473.
Akerstrom, B. and Bjorck, L. (1986). A physicochemical study of protein G, a molecule with
unique immunoglobulin G-binding properties. J. Biol. Chem. 261, 10240-10247.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
213
Akerstrom, B., Nielsen, E. and Bjorck, L. (1987). Definition of IgG- and albumin binding
regions of streptococcal protein G. J. Biol. Chem. 262, 13388-13391.
Barriocanal, J. G., Bonifacino, J. S., Yuan, L. and Sandoval, I. V. (1986). Biosynthesis,
glycosylation, movement through the Golgi system, and transport to lysosomes by an N-linked
carbohydrate-independent mechanism of three lysosomal integral membrane proteins. J. Biol.
Chem. 261, 16755-16763.
Beguinot, L., Lyall, R. M., Willingham, M. C. and Pastan, I. (1984). Down-regulation of
the epidermal growth factor receptor in KB cells is due to receptor internalization and
subsequent degradation in lysosomes. Proc. Natl. Acad. Sci. USA 81, 2384-2388.
Bittencourt, Marcello de Carvalho, Herren, S., Graber, P., Vilbois, F., Pasquali, C.,
Berney, C., Plitz, T., Nicoletti, F. and Kosco-Vilbois, M. H. (2005). Extracellular lysosome-
associated membrane protein-1 (LAMP-1) mediates autoimmune disease progression in the
NOD model of type 1 diabetes. Eur. J. of Immunol. 35, 1501-1509.
Black, M. W. and Pelham, H. R. B. (2000). A selective transport route from the Golgi to late
endosomes that requires the yeast GGA proteins. J. Cell Biol. 151, 587-600.
Bleekemolen, J. E., Stein, M., Slot, J. W. and Geuze, H. J. (1988). The two mannose 6-
phosphate receptors have almost identical subcellular distributions in U937 monocytes. Eur. J.
Cell Biol. 47, 366-372.
Bonifacino, J. S. (2004). Role of the mammalian retromer in sorting of the cation-independent
mannose-6-phosphate receptor. J. Cell Biol. 165, 123-133.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
214
Bonifacino, J. S. and Dell'Angelica, E. C. (1999). Molecular bases for the recognition of
tyrosine-based sorting signals. J. Cell Biol. 145, 923-926.
Braun, M., Waheed, A. and von Figura, K. (1989). Lysosomal acid phosphatase is
transported to lysosomes via the cell surface. EMBO J. 8, 3633-3640.
Bright, N. A., Gratian, M. J. and Luzio, J. P. (2005). Endocytic delivery to lysosomes
mediated by concurrent fusion and kissing events in living cells. Current Biol. 15, 360-365.
Brown, M. S. and Goldstein, J. L. (1976). Receptor-mediated control of cholesterol
metabolism. Science 191, 150-154.
Brown, W. J., Constantinescu, E. and Farquhar, M. G. (1984). Redistribution of mannose-
6-phosphate receptors induced by tunicamycin and chloroquine. J. Cell Biol. 99, 320-326.
Brown, W. J., Goodhouse, J. and Farquhar, M. G. (1986). Mannose-6-phosphate receptors
for lysosomal enzymes cycle between the Golgi complex and endosomes. J. Cell Biol. 103,
1235-1247.
Brown, W. J. and Farquhar, M. G. (1984a). Accumulation of coated vesicles bearing
mannose 6-phosphate receptors for lysosomal enzymes in the Golgi region of I-cell fibroblasts.
Proc. Natl. Acad. Sci. USA 81, 5135-5139.
Brown, W. J. and Farquhar, M. G. (1984b). The mannose-6-phosphate receptor for
lysosomal enzymes is concentrated in cis-Golgi cisternae. Cell 36, 295-307.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
215
Burnette, W. N. (1981). "Western blotting": Electrophoretic transfer of proteins from SDS-
PAGE to unmodified nitrocellulose and radiographic detection with antibody and
radioiodinated protein A. Anal. Biochem. 112, 195-203.
Canfield, W. M., Johnson, K. F., Ye, R. D., Gregory, W. and Kornfeld, S. (1991).
Localization of the signal for rapid internalization of the bovine cation-independent mannose 6-
phosphate/insulin-like growth factor-II receptor to amino acids 24-29 of the cytoplasmic tail. J.
Biol. Chem. 266, 5682-5688.
Carlsson, S. R., Lycksell, P. O. and Fukuda, M. (1993). Assignment of O-glycan attachment
sites to the hinge-like regions of human lysosomal membrane glycoproteins lamp-1 and lamp-
2. Arch. Biochem. Biophys. 304, 65-73.
Carlsson, S. R., Roth, J., Piller, F. and Fukuda, M. (1988). Isolation and characterization of
human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2. Major sialoglycoproteins
carrying polylactosaminoglycan. J. Biol. Chem. 263, 18911-18919.
Carlsson, S. R. and Fukuda, M. (1990). The polylactosaminoglycans of human lysosomal
membrane glycoproteins lamp-1 and lamp-2. Localization on the peptide backbones. J. Biol.
Chem. 265, 20488-20495.
Carlsson, S. R. and Fukuda, M. (1992). The lysosomal membrane glycoprotein lamp-1 is
transported to lysosomes by two alternative pathways. Arch. Biochem. Biophys. 296, 630-639.
Chang, T., Reid, P. C., Sugi, S., Ohgami, N., Cruz, J. C. and Chang, Catherine C. Y.
(2005). Niemann-pick type C disease and intracellular cholesterol trafficking. J. Biol. Chem.
280, 20917-20920.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
216
Chao, H. H., Waheed, A., Pohlmann, R., Hille, A. and von Figura, K. (1990). Mannose 6-
phosphate receptor dependent secretion of lysosomal enzymes. EMBO J. 9, 3507-3513.
Chavez, C. A., Bohnsack, R. N., Kudo, M., Gotschall, R. R., Canfield, W. M. and Dahms,
N. M. (2007). Domain 5 of the cation-independent mannose 6-phosphate receptor
preferentially binds phophodiesters (mannose 6-phophate N-acetylglucosamine ester).
Biochemistry-US. 46, 12604-12617.
Chavrier, P., Parton, R. G., Hauri, H. P., Simons, K. and Zerial M. (1990). Localisation of
low molecular weight GTP binding proteins to exocytic and endocytic compartments. Cell 62,
317-329.
Chen, J. W., Goldstein, J. L. and Brown, M. S. (1990). NPXY, a sequence often found in
cytoplasmic tails, is required for coated pit-mediated internalization of the low density
lipoprotein receptor. J. Biol. Chem. 265, 3116-3123.
Chen, J. W., Pan, W., D'Souza, M. P. and August, J. T. (1985). Lysosome-associated
membrane proteins: Characterisation of LAMP-1 of macrophage P388 and mouse embryo 3T3
cultured cells. Arch. Biochem. Biophys. 239, 574-586.
Clague, M. J., Urbe, S., Aniento, F. and Gruenberg, J. (1994). Vacuolar ATPase activity is
required for endosomal carrier vesicle formation. J. Biol. Chem. 269, 21-24.
Clemens, D. L. and Horwitz, M. A. (1995). Characterisation of the mycobacterium
tuberculosis phagosome and evidence that phagosomal maturation is inhibited. J. Exp. Med.
181, 257-270.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
217
Cohn, Z. A. and Ehrenreich, B. A. (1969). The uptake, storage, and intracellular hydrolysis
of carbohydrates by macrophages. J. Exp. Med. 129, 201-225.
Cook, N. R., Row, P. E. and Davidson, H. W. (2004). Lysosome-associated membrane
protein 1 (Lamp1) traffics directly from the TGN to early endosomes. Traffic 5, 685-699.
Courtoy, P. J. (1993). Analytical subcellular fractionation of endosomal compartments in rat
hepatocytes. Subcell. Biochem. 19, 29-68.
Courtoy, P. J., Quintart J. and Baudhuin, P. (1984). Shift of equilibrium density induced by
3,3'-diaminobenzidine cytochemistry: A new procedure for the analysis and purification of
peroxidase-containing organelles. J. Cell Biol. 98, 870-876.
Croze, E., Ivanov, I. E., Kreibich, G., Adenisk, M., Sabatini, D. D. and Rosenfeld, M. G.
(1989). Endolyn-78, a membrane glycoprotein present in morphologically diverse components
of the endosomal and lysosomal compartments: Implications for lysosome biogenesis. J. Cell
Biol. 108, 1597-1613.
Crump, C. M., Xia g, Y., Thomas, L., Gu, F., Austin, C., Tooze, S. A. and Thomas, G.
(2001). PACS-1 binding to adaptors is required for acidic cluster motif-mediated protein
traffic. EMBO J. 20, 2191-2201.
Cuervo, A. M. and Dice, J. F. (1996). A receptor for the selective uptake and degradation of
proteins by lysosomes. Science 273, 501-503.
Dahms, N. M. and Kornfeld, S. (1987). 46 kDa Mannose 6-phosphate receptor: Cloning,
expression, and homology to the 215 kDa mannose 6-phosphate receptor. Cell 50, 181-192.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
218
Dahms, N. M. and Kornfeld, S. (1989). The cation-dependent mannose 6-phosphate receptor
(structural requirements for mannose 6-phosphate binding and oligomerization). J. Biol. Chem.
264, 11458-11467.
Dahms, N. M., Lobel, P. and Kornfeld, S. (1989). Mannose 6-phosphate receptors and
lysosomal enzyme targeting. J. Biol. Chem. 264, 12115-12118.
Davidson, H. W. (1995). Wortmanin causes mistargeting of procathepsin D. evidence for the
involvement of a phosphatidylinositol 3-kinase in vesicular transport to lysosomes. J. Cell Biol.
130, 797-805.
Dell'Angelica, E. C., Klumperman, J., Stoorvogel, W. and Bonifacino, J. S. (1998).
Association of the AP-3 adaptor complex with clathrin. Science 280, 431.
Dell'Angelica, E. C., Mullins, C., Caplan, S. and Bonifacino, J. S. (2000). Lysosome-related
organelles. FASEB J. 14, 1265-1278.
Dell'Angelica, E. C., Ooi, C. E. and Bonifacino, J. S. (1997). 3A-adaptin, a subunit of the
adaptor-like complex AP-3. J. Biol. Chem. 272, 15078-15084.
Dell'Angelica, E. C., Puertollano, R., Mullins, C., Aguilar, R. C., Vargas, J. D., Hartnell,
L. M. and Bonifacino, J. S. (2000). GGAs: A family of ADP ribosylation factor-binding
proteins related to adaptors and associated with the Golgi complex. J. Cell Biol. 149, 81-94.
Dell'Angelica, E. C., Shotelersuk, V., Aguilar, R. C., Gahl, W. A. and Bonifacino, J. S.
(1999). Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to
mutations in the3A subunit of the AP-3 adaptor. Mol. Cell 3, 11-21.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
219
Denzer, K., Weber, B., Hille-Rehfeld, A., von Figura, K. and Pohlmann, R. (1997).
Identification of three internalization sequences in the cytoplasmic tail of the 46 kDa mannose
6-phosphate receptor. Biochem. J. 326 ( Pt 2), 497-505.
Diment, S., Sandoval, I. V. and von Figura, K. (1998). A di-leucine-based motif in the
cytoplasmic tail of LIMP-II and tyrosine mediate selective binding of AP-3. EMBO J. 17,
1304-1314.
Dintzis, S. M. and Pfeffer, S. R. (1990). The mannose 6-phosphate receptor cytoplasmic
domain is not sufficient to alter the cellular distribution of a chimeric EGF receptor. EMBO J.
9, 77-84.
Dintzis, S. M., Velculescu, V. E. and Pfeffer, S. R. (1994). Receptor extracellular domains
may contain trafficking information. J. Biol. Chem. 269, 12159-12166.
Doray, B., Ghosh, P., Griffith, J., Geuze, H. J. and Kornfeld, S. (2002a). Cooperation of
GGAs and AP-1 in packaging MPRs at the trans-Golgi network. Science 297, 1700-1703.
Doray, B., Bruns, K., Ghosh, P. and Kornfeld, S. (2002b). Interaction of the cation-
dependent mannose 6-phosphate receptor with GGA proteins. J. Biol. Chem. 277, 18477-
18482.
D'Souza, P. M. and August, J. T. (1986). A kinetic analysis of biosynthesis and localisation
of a lysosome-associated membrane glycoprotein. Arch. Biochem. Biophys. 249, 522-532.
Duncan, J. R. and Kornfeld, S. (1988). Intracellular movement of two mannose 6-phosphate
receptors: Return to the Golgi apparatus. J. Cell Biol. 106, 617-628.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
220
De Duve, C. (1983). Lysosomes revisited. Eur. J. Biochem. 137, 391-397.
Ehrenreich, B. A. and Cohn, Z. A. (1969). The fate of peptides pinocytosed by macrophages
in vitro. J. Exp. Med. 129, 227-245.
Eskelinen, E., Cuervo, A. M., Taylor, Matthew R. G., Nishino, I., Blum, J. S., Dice, J. F.,
Sandoval, I. V., Lippincott-Schwartz, J., August, J. T. and Saftig, P. (2005). Unifying
nomenclature for the isoforms of the lysosomal membrane protein LAMP-2. Traffic 6, 1058-
1061.
Eskelinen, E., Schmidt, C. K., Neu, S., Willenborg, M., Fuertes, G., Salvador, N., Tanaka,
Y., Lullmann-Rauch, R., Hartmann, D., Heeren, J. et al. (2004). Disturbed cholesterol
traffic but normal proteolytic function in LAMP-1/LAMP-2 double-deficient fibroblasts. Mol.
Biol. Cell 15, 3132-3145.
Eskelinen, E., Tanaka, Y. and Saftig, P. (2003). At the acidic edge: Emerging functions for
lysosomal membrane proteins. Trends Cell Biol. 13, 137-145.
Fambrough, D. M. (1995). The family of LAMP-2 proteins arises by alternative splicing from
a single gene: Characterisation of avian LAMP-2 gene and identification of mammalian
homologues of LAMP-2b and LAMP-2c. DNA Cell Biol. 14, 863-867.
Fukuda, M., Viitala, J., Matteson, J. and Carlsson, S. R. (1988). Cloning of cDNAs
encoding human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2. Comparison of
their deduced amino acid sequences. J. Biol. Chem. 263, 18920-18928.
Fukuda, M. (1990). Lysosomal membrane glycoproteins. J. Biol. Chem. 265, 7548-7551.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
221
Fukuda, M. (1991). Lysosomal membrane glycoproteins. J. Biol. Chem. 266, 21327-21330.
Furuno, K., Ishikawa, T., Akasaki, K., Yano, S., Tanaka, Y., Yamaguchi, Y., Tsuji, H.,
Himeno, M. and Kato, K. (1989a). Morphological localisation of a major lysosomal
membrane glycoprotein in the endocytic membrane system. J. Biochem. 106, 708-716.
Furuno, K., Yano, S., Akasaki, K., Tanaka, Y., Yamaguchi, Y., Tsuji, H., Himeno, M. and
Kato, K. (1989b). Biochemical analysis of the movement of a major lysosomal membrane
glycoprotein in the endocytic membrane system. J. Biochem. 106, 717-722.
Furuta, K., Ikeda, M., Nakayama, Y., Nakamura, K., Tanaka, M., Hamasaki, N.,
Himeno, M., Hamilton, S. R. and August, J. T. (2001). Expression of lysosome-associated
membrane proteins in human colorectal neoplasms and inflammatory diseases. Am. J. Pathol.
159, 449-455.
Gabel, C. A., Goldberg, D. E. and Kornfeld, S. (1983). Identification and characterization of
cells deficient in the mannose 6-phosphate receptor: Evidence for an alternate pathway for
lysosomal enzyme targeting. Proc. Natl. Acad. Sci. USA 80, 775-779.
Gamp, A., Tanaka, Y., Lullmann-Rauch, R., Wittke, D., D'Hooge, R., De Deyn, Peter P.,
Moser, T., Maier, H., Hartmann, D., Reiss, K. et al. (2003). LIMP-2/LGP85 deficiency
causes ureteric pelvic junction obstruction, deafness and peripheral neuropathy in mice. Human
Molecular Genetics 12, 631-646.
Geuze, H. J., Slot, J. W., Strous, Ger J. A. M., Hasilik, A. and von Figura, K. (1984).
Ultrastructural localisation of the mannose 6-phosphate receptor in rat liver. J. Cell Biol. 98,
2047-2054.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
222
Geuze, H. J., Slot, J. W., Strous, Ger J. A. M., Hasilik, A. and von Figura, K. (1985).
Possible pathway for lysosomal enzyme delivery. J. Cell Biol. 101, 2253-2262.
Geuze, H. J., Slot, J. W., Strous, Ger J. A. M., Lodish, H. F. and Schwartz, A. L. (1983).
Intracellular site of asialoglycoprotein receptor-ligand uncoupling: Double-label
immunoelectron microscopy during receptor-mediated endocytosis. Cell 32, 277-287.
Geuze, H. J., Stoorvogel, W., Strous, Ger J. A. M., Slot, J. W. and Bleekemolen, J. E.
(1988). Sorting of mannose 6-phosphate receptors and lysosomal membrane proteins in
endocytic vesicles. J. Cell Biol. 107, 2491-2501.
Glickman, J. N., Conibear, E. and Pearse, B. M. (1989). Specificity of binding of clathrin
adaptors to signals on the mannose-6-phosphate/insulin-like growth factor II receptor. EMBO
J. 8, 1041-1047.
Gomes, M. S., Paul, S., Moreira, A. L., Appelberg, R., Rabinovitch, M. and Kaplan, G.
(1999). Survival of mycobacterium avium and mycobacterium tuberculosis in acidified
vacuoles of murine macrophages. Infect. Immun. 67, 3199-3206.
Gonzalez-Noriega, A., Grubb, J. H., Talkad, V. and Sly, W. S. (1980). Chloroquine inhibits
lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor
recycling. J. Cell Biol. 85, 839-852.
Gough, N. R. and Fambrough, D. M. (1997). Different steady state subcellular distributions
of the three splice variants of lysosome-associated membrane protein LAMP-2 are determined
largely by the COOH-terminal amino acid residue. J. Cell Biol. 137, 1161-1169.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
223
Gough, N. R., Zweifel, M. E., Martinez-Augustin, O., Aguilar, R. C., Bonifacino, J. S. and
Fambrough, D. M. (1999). Utilization of the indirect lysosome targeting pathway by
lysosome-associated membrane proteins (LAMPs) is influenced largely by the C-terminal
residue of their GYXXtargeting signals. J. Cell Sci. 112, 4257-4269.
Granger, B. L., Green, S. A., Gabel, C. A., Howe, C. L. and Helenius, A. (1990).
Characterisation and cloning of lgp110, a lysosomal membrane glycoprotein from mouse and
rat cells. J. Biol. Chem.
Green, S. A., Zimmer, K., Griffiths, G. and Mellman, I. (1987). Kinetics of intracellular
transport and sorting of lysosomal membrane and plasma membrane proteins. J. Cell Biol. 105,
1227-1240.
Griffiths, G., Hoflack, B. and Simons, K. (1988). The mannose 6-phosphate receptor and the
biogenesis of lysosomes. Cell 52, 329-341.
Griffiths, G. and Simons, K. (1986). The trans-Golgi network: Sorting at the exit site of the
Golgi complex. Science 234, 438-443.
Guarnieri, F. G., Arterburn, L. M., Penno, M. B. and Cha, Y. (1993). The motif tyr-X-X-
hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated
membrane protein1. J. Biol. Chem. 268, 1941-1946.
Hall, C. W., Liebaers, I., DiNatale, P., and Neufeld, E. F. (1978). Enzymatic diagnosis of
the genetic mucopolysaccharide storage disorders. Methods Enzymol. 50, 439-456.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
224
Hancock, M. K., Haskins, D. J., Sun, G. and Dahms, N. M. (2002a). Identification of
residues essential for carbohydrate recognition by the insulin-like growth factor II/Mannose 6-
phosphate receptor. J. Biol. Chem. 277, 11255-11264.
Hancock, M. K., Yammani, R. D. and Dahms, N. M. (2002b). Localization of the
carbohydrate recognition sites of the insulin-like growth factor II / mannose 6-phosphate
receptor to domains 3 and 9 of the extracytoplasmic region. J. Biol. Chem. 277, 47205-47212.
Harding, C. V. and Geuze, H. J. (1993). Immunogenic peptides bind to class II MHC
molecules in an early lysosomal compartment. J. Immunol. 151, 3988-3998.
Harlow, E. and Lane, D. (1988). Antibodies: A laboratory manual. Chs. 6, 7, 8 & 11. New
York: Cold Spring Harbor Laboratory.
Harter, C. and Mellman, I. (1992). Transport of the lysosomal membrane glycoprotein
lgp120 to lysosome does not require appearance on the plasma membrane. J. Cell Biol. 117,
311-325.
Hasilik, A. and Neufeld, E. F. (1980a). Biosynthesis of lysosomal enzymes in fibroblasts.
Phosphorylation of mannose residues. J. Biol. Chem. 255, 4946-4950.
Hasilik, A. and Neufeld, E. F. (1980b). Biosynthesis of lysosomal enzymes in fibroblasts.
Synthesis as precursors of higher molecular weight. J. Biol. Chem. 255, 4937-4945.
Hatem, C. L., Gough, N. R. and Fambrough, D. M. (1995). Multiple mRNAs encode the
avian lysosomal membrane protein LAMP-2, resulting in alternative transmembrane and
cytoplasmic domains. J. Cell Sci. 108, 2093-2100.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
225
Haylett, T. and Thilo, L. (1986). Limited and selective transfer of plasma-membrane
glycoproteins to membrane of secondary lysosomes. J. Cell Biol. 103, 1249-1256.
Hemer, F., Korner, C. and Braulke, T. (1993). Phosphorylation of the human 46-kDa
mannose 6-phosphate receptor in the cytoplasmic domain at serine 56. J. Biol. Chem. 268,
17108-17113.
Hickman, S., Shapiro, L. J. and Neufeld, E. F. (1974). A recognition marker required for
uptake of a lysosomal enzyme by cultured fibroblasts. Biochem. Biophys. Res. Commun. 57,
55-61.
Hieber, V., Distler, J., Myerowitz, R., Schmickel, R. D. and Jourdian, G. W. (1976). The
role of glycosidically bound mannose in the assimilation of -galactosidase by generalized
gangliosidosis fibroblasts. Biochem. Biophys. Res. Commun. 73, 710-717.
Hille-Rehfeld, A. (1995). Mannose 6-phosphate receptors in sorting and transport of lysosomal
enzymes. Biochim. Biophys. Acta 1241, 177-194.
Hirsch, D. S., Stanley, K. T., Chen, L., Jacques, K. M., Puertollano, R. and Randazzo, P.
A. (2003). Arf regulates interaction of GGA with mannose-6-phosphate receptor. Traffic 4, 26-
35.
Hoflack, B. (1998). Mutant rab 7 causes the accumulation of cathepsin D and CI mannose 6-
phosphate receptor in an early endocytic compartment. J. Cell Biol. 140, 1075-1089.
Hoflack, B. and Kornfeld, S. (1985a). Lysosomal enzyme binding to mouse P388D1
macrophage membranes lacking the 215 kDa mannose-6-phosphate receptor: Evidence for the
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
226
existence of a second mannose-6-phosphate receptor. Proc. Natl. Acad. Sci. USA 82, 4428-
4432.
Hoflack, B. and Kornfeld, S. (1985b). Purification and characterisation of a cation-dependent
mannose 6-phosphate receptor from murine P388D1 macrophages and bovine liver. J. Biol.
Chem. 260, 12008-12014.
Honing, S., Griffith, J. M., Geuze, H. J. and Hunziker, W. (1996). The tyrosine-based
lysosomal targeting signal in lamp-1 mediates sorting into Golgi-derived clathrin-coated
vesicles. EMBO J. 15, 5230-5239.
Honing, S. and Hunziker, W. (1995). Cytoplasmic determinants involved in direct lysosomal
sorting, endocytosis and basolateral targeting of rat lgp120 (lamp-1) in MDCK cells. J. Cell
Biol. 128, 321-332.
Honing, S., Sandoval, I. V. and von Figura, K. (1998). A di-leucine-based motif in the
cytoplasmic tail of LIMP-II and tyrosinase mediates selective binding of AP-3. EMBO J. 17,
1304-1314.
Honing, S., Sosa, M., Hille-Rehfeld, A. and von Figura, K. (1997). The 46-kDa mannose 6-
phosphate receptor contains multiple binding sites for clathrin adaptors. J. Biol. Chem. 272,
19884-19890.
Howe, C. L., Granger, B. L., Green, S. A., Gabel, C. A., Helenius, A. and Mellman, I.
(1988). Derived protein sequence, oligosaccharides, and membrane insertion of the 120 kDa
lysosomal membrane glycoprotein (lgp120): Identification of a highly conserved family of
lysosomal membrane glycoproteins. Proc. Natl. Acad. Sci. USA 85, 7577-7581.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
227
Hunziker, W. and Geuze, H. J. (1996). Intracellular trafficking of lysosomal membrane
proteins. Bioessays 18, 379-389.
Huynh, K. K., Eskelinen, E., Scott, C. C., Malevanets, A., Saftig, P. and Grinstein, S.
(2007). LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J. 26,
316-324.
Ihrke, G., Bruns, J. R., Luzio, J. P. and Weisz, O. A. (2001). Competing sorting signals
guide endolyn along a novel route to lysosomes in MDCK cells. EMBO J. 20, 6256-6264.
Ihrke, G., Gray, S. R. and Luzio, J. P. (2000). Endolyn is a mucin-like type 1 membrane
protein targeted to lysosomes by its cytoplasmic tail. Biochem J. 345, 287-296.
Ihrke, G., Kyttala, A., Russell, Mathew, R. G., Rous, B. A. and Luzio, J. P. (2004).
Differential use of two AP-3-mediated pathways by lysosomal membrane proteins. Traffic 5,
946-962.
Jadot, M., Canfield, W. M., Gregory, W. and Kornfeld, S. (1992). Characterization of the
signal for rapid inter alization of the bovine mannose 6-phosphate/insulin-like growth factor-II
receptor. J. Biol. Chem. 267, 11069-11077.
Janvier, K. and Bonifacino, J. S. (2005). Role of the endocytic machinery in the sorting of
lysosome-associated membrane proteins. Mol. Biol. Cell 16, 4231-4242.
Jimbow, K., Hara, H., Vinayagamoorthy, T., Luo, D., Dakour, J. Yamada, K., Dixon, W.
and Chen, H. (1994). Molecular control of melanogenesis in malignant melanoma: Functional
assessment of tyrosinase and lamp gene families by UV exposure and gene co-transfection, and
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
228
cloning of a cDNA encoding calnexin, a possible melanogenesis "chaperone". J. Dermatol. 21,
894-906.
Jing, S. Q., Spencer, T., Miller, K., Hopkins, C. and Trowbridge, I. S. (1990). Role of the
human transferrin receptor cytoplasmic domain in endocytosis: Localization of a specific
signal sequence for internalization. J. Cell Biol. 110, 283-294.
Johnson, K. F., Chan, W. and Kornfeld, S. (1990). Cation-dependent mannose 6-phosphate
receptor contains two internalization signals in its cytoplasmic domain. Proc. Natl. Acad. Sci.
USA 87, 10010-10014.
Johnson, K. F. and Kornfeld, S. (1992a). The cytoplasmic tail of the mannose 6-
phosphate/insulin-like growth factor-II receptor has two signals for lysosomal enzyme sorting
in the Golgi. J. Cell Biol. 119, 249-257.
Johnson, K. F. and Kornfeld, S. (1992b). A his-leu-leu sequence near the carboxyl terminus
of the cytoplasmic domain of the cation-dependent mannose-6-phosphate receptor is necessary
for the lysosomal enzyme sorting function. J. Biol. Chem. 267, 17110-17115.
Jonas, A. J., Smith, M. L. and Schneider, J. A. (1982). ATP-dependent lysosomal cystine
efflux is defective in cystinosis. J. Biol. Chem. 257, 13185-13188.
Kanao, H., Enomoto, T., Kimura, T., Fujita, M., Nakashima, R., Ueda, Y., Ueno, Y.,
Miyatake, T., Yoshizaki, T., Buzard, G. S. et al. (2005). Overexpression of
LAMP3/TSC403/DC-LAMP promotes metastasis in uterine cervical cancer. Cancer Res. 65,
8640-8645.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
229
Kannan, K., Divers, S. G., Lurie, A. A., Chervanic, R., Fukuda, M. and Holcombe, R. F.
(1995). Cell surface expression of lysosome-associated membrane protein-2 (lamp2) and CD63
as markers of in vivo platelet activation in malignancy. Eur. J. Haematol. 55, 145-151.
Kannan, K., Stewart, R. M., Bounds, W., Carlsson, S. R., Fukuda, M., Betzing, K. W. and
Holcombe, R. F. (1996). Lysosome-associated membrane protein h-LAMP1 (CD107a) and h-
LAMP2 (CD107b) are activation-dependent cell surface glycoproteins in human peripheral
blood mononuclear cells which mediate cell adhesion to vascular endothelium. Cell. Immunol.
171, 10-19.
Karlsson, K. and Carlsson, S. R. (1998). Sorting of lysosomal membrane glycoproteins
LAMP-1 and LAMP-2 into vesicles distinct from mannose 6-phosphate Receptor/-adaptin
vesicles at the trans-Golgi network. J. Biol. Chem. 273, 18966-18973.
Kasper, D., Dittmer, F., von Figura, K. and Pohlmann, R. (1996). Neither type of mannose
6-phosphate receptor is sufficient for targeting of lysosomal enzymes along intracellular routes.
J. Cell Biol. 134, 615-623.
Kasuga, M., Kahn, R. C., Hedo, J. A., Van Obberghen, E. and Yamada, K. M. (1981).
Insulin-induced receptor loss in cultured human lymphocytes is due to accelerated receptor
degradation. Proc. Natl. Acad. Sci. USA 78, 6917-6921.
Klumperman, J., Hille, A., Veenendaal, T., Oorschot, V., Stoorvogel, W., von Figura, K.
and Geuze, H. J. (1993). Differences in the endosomal distributions of the two mannose 6-
phosphate receptors. J. Cell Biol. 121, 997-1010.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
230
Klumperman, J., Kuliawat, R., Griffith, J. M., Geuze, H. J. and Arvan, P. (1998).
Mannose 6-phosphate receptors are sorted from immature secretory granules via adaptor
protein AP-1, clathrin, and syntaxin 6-positive vesicles. J. Cell Biol. 141, 359-371.
Kobayashi, T., Beuchat, M., Lindsay, M., Frias, S., Palmiter, R. D., Sakuraba, H., Parton,
R. G. and Gruenberg, J. (1999). Late enosomal membranes rich in lysobisphosphatidic acid
regulate cholesterol transport. Nature Cell Biol. 1, 113-118.
Koren, H. S., Handwerger, B. S. and Wunderlich, J. R. (1975). Identification of
macrophage-like characteristics in a cultured murine tumor line. J. Immunol.
Kornfeld, S. (1987a). The interaction of phosphorylated oligosaccharides and lysosomal
enzymes with bovine liver cation-dependent mannose 6-phosphate receptor. J. Biol. Chem.
262, 123-129.
Kornfeld, S. (1987b). Studies of the biosynthesis of the cation dependent mannose 6-
phosphate receptor in murine cell lines. Arch. Biochem. Biophys. 257, 170-176.
Krise, J. P., Sincock, P. M., Orsel, J. G. and Pfeffer, S. R. (2000). Quantitative analysis of
TIP47-receptor cytoplasmic domain interactions: Implications for endosometotrans-Golgi
network trafficking. J. Biol. Chem. 275, 25188-25193.
Kundra, R. and Kornfeld, S. (1999). Asparagine-linked oligosaccharides protect lamp-1 and
lamp-2 from intracellular proteolysis. J. Biol. Chem. 274, 31309-31046.
Kunzli, B. M., Berberat, P. O., Zhu, Z. W., Martignoni, M., Kleeff, J., Tempia-Caliera, A.
A., Fukuda, M., Zimmermann, A., Friess, H. and Buchler, M. W. (2001). Influences of the
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
231
lysosomal associated membrane proteins (lamp-1, lamp-2) and mac-2 binding protein (mac-2-
BP) on the prognosis of pancreatic carcinoma. Am. Cancer Soc. 94, 228-239.
Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of
bacteriophage T4. Nature 227, 680-685.
Le Borgne, R., Alconada, A., Bauer, U. and Hoflack, B. (1998). The mammalian AP-3
adaptor-like complex mediates the intracellular transport of lysosomal glycoproteins. J. Biol.
Chem. 273, 29451-29461.
Le Borgne, R., Griffiths, G. and Hoflack, B. (1996). Mannose 6-phosphate receptors and
ADP-ribosylation factors cooperate for high affinity interaction of the AP-1 Golgi assembly
proteins with membranes. J. Biol. Chem. 271, 2162-2170.
Le Borgne, R. and Hoflack, B. (1997). Mannose 6-phosphate receptors regulate the formation
of clathrin-coated vesicles in the TGN. J. Cell Biol. 137, 335-345.
Le Borgne, R. and Hoflack, B. (1998). Protein transport from the secretory to the endocytic
pathway in mammalian cells. Biochim. Biophys. Acta 1404, 195-209.
Le Borgne, R., Schmidt, A., Mauxion, F., Griffiths, G. and Hoflack, B. (1993). Binding of
AP-1 Golgi adaptors to membranes requires phosphorylated cytoplasmic domains of the
mannose 6-phosphate/Insulin-like growth factor II receptor. J. Biol. Chem. 268, 22552-22556.
Lee, N., Wang, W. and Fukuda, M. (1990). Granulocytic differentiation of HL-60 cells is
associated with increase of poly-N-acetyllactosamine in asn-linked oligosaccharides attached
to human lysosomal membrane glycoproteins. J. Biol. Chem. 265, 20476-20487.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
232
Lehmann, L. E., Eberler, W., Krull, S., Prill, V., Schmidt, B., Sander, C., von Figura, K.
and Peters, C. (1992). The internalization signal in the cytoplasmic tail of lysosomal acid
phosphatase consists of the hexapeptide PGYRHV. EMBO J. 11, 4391-4399.
Lewis, V., Green, S. A., Marsh, M. and Vihko, P. (1985). Glycoproteins of the lysosomal
membrane. J. Cell Biol. 100, 1839-1847.
Li, M., Distler, J. J. and Jourdian, G. W. (1990). The aggregation and dissociation properties
of a low molecular weight mannose 6-phosphate receptor from bovine testis. Arch. Biochem.
Biophys. 283, 150-157.
Lippencott-Schwartz, J. and Fambrough, D. M. (1986). Lysosomal membrane dynamics:
Structure and interorganellar movement of a major lysosomal membrane glycoprotein. J. Cell
Biol. 102, 1593-1605.
Lippencott-Schwartz, J. and Fambrough, D. M. (1987). Cycling of the integral membrane
glycoprotein, LEP 100 between plasma membrane and lysosomes: Kinetic and morphological
analysis. Cell 49, 669-677.
Lobel, P., Fujimoto, K., Ye, R. D., Griffiths, G. and Kornfeld, S. (1989). Mutations in the
cytoplasmic domain of the 275 kd mannose 6-phosphate receptor differentially alter lysosomal
enzyme sorting and endocytosis. Cell 57, 787-796.
Lobel, P., Dahms, N. M. and Kornfeld, S. (1988). Cloning and sequence analysis of the
cation-independent mannose 6-phosphate receptor. The Journal of biological chemistry 263,
2563-2570.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
233
Lodish, H. F., Kong, N., Snider, M. and Strous, Ger J. A. M. (1983). Hepatoma secretory
proteins migrate from rough endoplasmic reticulum to Golgi at characteristic rates. Nature 304,
80-83.
Ludwig, T., Griffiths, G. and Hoflack, B. (1991). Distribution of newly synthesized
lysosomal enzymes in the endocytic pathway of normal rat kidney cells. J. Cell Biol. 115,
1561-1572.
Luzio, J. P., Pryor, P. R. and Bright, N. A. (2007). Lysosomes: Fusion and function. Nat.
Rev. Mol. Cell Biol. 8, 622-632.
Majeski, A. E. and Dice, J. F. (2004). Mechanisms of chaperone-mediated autophagy.
Internatl. J. Bioch. Cell Biol. 36, 2435-2444.
Majlessi, L., Combaluzier, B., Albrecht, I., Garcia, J. E., Nouze, C., Pieters, J. and
Leclerc, C. (2007). Inhibition of phagosome maturation by mycobacteria does not interfere
with presentation of mycobacterial antigens by MHC molecules. J. Immunol. 179, 1825-1833.
Mane, S. M., Marzella, L., Bainton, D. F., Holt, V. K., Ying, C., Hildreth, J. E. and
August, J. T. (1989). Purification and characterisation of human lysosomal membrane
glycoproteins. Arch. Biochem. Biophys. 268, 360-378.
Marks, M. S., Woodruff, L., Ohno, H. and Bonifacino, J. S. (1996). Protein targeting by
tyrosine- and di-leucine-based signals: Evidence for distinct saturable components. J. Cell Biol.
135, 341-354.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
234
Marsh, M., Schmid, S., Kern, H., Harms, E., Male, P., Mellman, I. and Helenius, A.
(1987). Rapid analytical and preparative isolation of functional endosomes by free flow
electrophoresis. J. Cell Biol. 104, 875-886.
Mathews, P. M., Martinie, J. B. and Fambrough, D. M. (1992). The pathway and targeting
signal for delivery of the integral membrane glycoprotein LEP100 to lysosomes. J. Cell Biol.
118, 1027-1040.
Mattei, M. G., Matterson, J., Chen, J. W., Williams, M. A. and Fukuda, M. (1990). Two
human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2, are encoded by genes
localized to chromosome 13q34 and chromosome Xq24-25, respectively. J. Biol. Chem. 265,
7548-7551.
Mauxion, F., Le Borgne, R., Munier-Lehmann, H. and Hoflack, B. (1996). A casein kinase
II phosphorylation site in the cytoplasmic domain of the cation-dependent mannose 6-
phosphate receptor determines the high affinity interaction of the AP-1 Golgi assembly
proteins with membranes. J. Biol. Chem. 271, 2171-2178.
McNeil, P. L. (2002). Repairing a torn cell surface: Make way, lysosomes to the rescue. J. Cell
Sci. 115, 873-879.
Medigeshi, G. R. and Schu, P. (2003). Characterization of the in vitro retrograde transport of
MPR46. J. Biol. Chem. 4, 802-811.
Mellman, I. S., Plutner, H., Steinman, R. M., Unkeless, J. C. and Cohn, Z. A. (1983).
Internalization and degradation of macrophage Fc receptors during receptor-mediated
phagocytosis. J. Cell Biol. 96, 887-895.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
235
Mellman, I. and Plutner, H. (1984). Internalization and degradation of macrophage Fc
receptors bound to polyvalent immune complexes. J. Cell Biol. 98, 1170-1177.
Meresse, S. and Hoflack, B. (1993). Phosphorylation of the cation-independent mannose 6-
phosphate receptor is closely associated with its exit from the trans-Golgi network. J. Cell Biol.
120, 67-75.
Meril, C. R., Goldman, D. and Van Keuren, Margaret L. (1984). Gel protein stains: Silver
stain. Methods Enzymol. 104, 441-447.
Merion, M., Schlesinger, P., Brooks, R. M., Moehring, J. M., Moehring, T. J. and Sly, W.
S. (1983). Defective acidification of endosomes in chinese hamster ovary cell mutants ''cross-
resistant'' to toxins and viruses. Proc. Natl. Acad. Sci. USA 80, 5315-5319.
Meyer, C., Zizioli, D., Lausmann, S., Eskelinen, E., Hamann, J., Saftig, P., von Figura, K.
and Schu, P. (2000). 1A-adaptin-deficient mice: Lethality, loss of AP-1 binding and
rerouting of mannose 6-phosphate receptors. EMBO J. 19, 2193-2203.
Mukherjee, S., Gnosh, R. N. and Maxfield, F. R. (1997). Endocytosis. Physiol. Rev. 77, 759-
803.
Mu, F-T., Callaghan, J. M., Steele-Mortimer, O., Stenmark, H., Parton, R. G., Campbell,
P. L., McCluskey, J., Yeo, J-P., Tock, E. P. C. and Toh, B-H. (1995). EEA1, an early
endosome-associated protein. EEA1 is a conserved alpha-helical peripheral membrane protein
flanked by cysteine "fingers" and contains a calmodulin-binding IQ motif. J. Biol. Chem. 270,
13503-13511.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
236
Mullins, C. (2005). Biogenesis of cellular organelles. Springer. p 33.
Mullins, C. and Bonifacino, J. S. (2001). The molecular machinery for lysosome biogenesis.
Bioessays 23, 333-343.
Nabi, I. R., Le Bivic, A., Fambrough, D. M. and Rodriguez-Boulan, E. (1991). An
endogenous MDCK lysosomal membrane glycoprotein is targeted basolaterally before delivery
to lysosomes. J. Cell Biol. 115, 1573-1584.
Nair, P., Rohrer, J. and Schaub, B. E. (2003). Characterisation of the endosomal sorting
signal of the cation-dependent mannose 6-phosphate receptor. J. Biol. Chem. 278, 24753-
24758.
Neiss, W. F. (1984). A coat of glycoconjugates on the inner surface of the lysosomal
membrane in the rat kidney. Histochem. Cell Biol. 80, 603-608.
Nicoziani, P., Vilhardt, F., Llorente, A., Hilout, L., Courtoy, J., Sandvig, K. and van
Deurs, B. (2000). Role for dynamin in late endosome dynamics and trafficking of the cation-
independent mannose 6-phosphate receptor. Mol. Biol. Cell 11, 481-495.
Nishino, I., Fu, J., Tanji, K., Yamada, T., Shimojo, S., Koori, T., Mora, M., Riggs, J. E.,
Oh, S. J., Koga, Y. et al. (2000). Primary LAMP-2 deficiency causes X-linked vacuolar
cardiomyopathy and myopathy (Danon disease). Nature 406, 906-909.
Obermuller, S., Kiecke, C., von Figura, K. and Honing, S. (2002). The tyrosine motifs of
lamp 1 and LAP determine their direct and indirect targeting to lysosomes. J. Cell Sci. 115,
185-194.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
237
Ogata, S. and Fukuda, M. (1994). Lysosomal targeting of LIMP II membrane glycoprotein
requires a novel leu-ile motif at a particular position in its cytoplasmic tail. J. Biol. Chem. 269,
5210-5217.
Ohkuma, S. and Poole, B. (1978). Fluorescence probe measurement of the intralysosomal pH
in living cells and the perturbation of pH by various agents. Proc. Natl. Acad. Sci. USA 75,
3327-3331.
Ohno, H., Fournier, M., Poy, G. and Bonifacino, J. S. (1996). Structural determinants of
interaction of tyrosine-based sorting signals with the adaptor medium chains. J. Biol. Chem.
271, 29009-29015.
Ohno, H., Stewart, J., Fournier, M., Bosshart, H., Rhee, I., Miyatake, S., Takashi, S.,
Gallusser, A., Kirchhausen, T. and Bonifacino, J. S. (1995). Interaction of tyrosine-based
sorting signals with clathrin-associated proteins. Science 269, 1872-1874.
Olson, L. J., Hancock, M. K., Dix, D., Kim, J. P. and Dahms, N. M. (1999). Mutational
analysis of the binding site residues of the bovine cation-dependent mannose 6-phosphate
receptor. J. Biol. Chem. 274, 36905-36911.
Olson, L. J., Zhang, J., Dahms, N. M. and Kim, J. P. (2002). Twists and turns of the cation-
dependent mannose 6-phosphate receptor (ligand-bound versus ligand-free receptor). J. Biol.
Chem. 277, 10156-10161.
Olson, L., Zhang, J., Lee, Y. C., Dahms, N. M. and Kim, J. P. (1999). Structural basis for
recognition of phosphorylated high mannose oligosaccharides by the cation-dependent
mannose 6-phosphate receptor. J. Biol. Chem. 274, 29889-29896.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
238
Ooi, C. E., Dell'Angelica, E. C. and Bonifacino, J. S. (1998). ADP-ribosylation factor 1
(ARF1) regulates recruitment of the AP-3 adaptor complex to membranes. J. Cell Biol. 142,
391-402.
Orsel, J. G., Sincock, P. M., Krise, J. P. and Pfeffer, S. R. (2000). Recognition of the 300-
kDa mannose 6-phosphate receptor cytoplasmic domain by 47-kDa tail-interacting protein.
Proc. Natl. Acad. Sci. USA 97, 9047-9051.
Oshima, A., Nolan, C. M., Kyle, J. W., Grubb, J. H. and Sly, W. S. (1988). The human
cation-independent mannose 6-phosphate receptor cloning and sequence of the full-length
cDNA and expression of functional receptor in COS cells. J. Biol. Chem. 263, 2553-2562.
Pain, R. H. (1963). The molecular weights of the peptide chains of gamma-globulin. Biochem.
J. 88, 234-239.
Pak, Y., Glowacka, W. K., Bruce, M. C., Pham, N. and Rotin, D. (2006). Transport of
LAPTM5 to lysosomes requires association with the ubiquitin ligase Nedd4, but not LAPTM5
ubiquitination. J. Cell Biol. 175, 631-645.
Pearse, B. M. (1988). Receptors compete for adaptors found in plasma membrane coated pits.
EMBO J. 7, 3331-3336.
Peden, A. A., Oorschot, V., Hesser, B. A., Austin, C. D. and Scheller, R. H. (2004).
Localization of the AP-3 adaptor complex defines a novel endosomal exit site for lysosomal
membrane proteins. J. Cell Biol. 164, 1065-1076.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
239
Peters, C., Braun, M., Weber, B., Wendland, M., Schmidt, B., Pohlmann, R., Waheed, A.
and von Figura, K. (1990). Targeting of a lysosomal membrane protein: A tyrosine-
containing endocytosis signal in the cytoplasmic tail of lysosomal acid phosphatase is
necessary and sufficient for targeting to lysosomes. EMBO J. 9, 3497-3506.
Peters, C. and von Figura, K. (1994). Minireview: Biogenesis of lysosomal membranes.
FEBS Letters 346, 108-114.
Peters, P. J., Borst, J., Oorschot, V., Fukuda, M., Krahenbuhl, O., Tschopp, J., Slot, J. W.
and Geuze, H. J. (1991). Cytotoxic T lymphocyte granules are secretory lysosomes,
containing both perforin and granzymes. J. Exp. Med. 173, 1099-1109.
Peterson, G. L. (1979). Review of the folin phenol protein quantitation method of lowry. Anal.
Biochem. 100, 201-220.
Pohlman, R., Waheed, A., Hasilik, A. and von Figura, K. (1982). Synthesis of
phosphorylated recognition marker in lysosomal enzymes is located in the cis part of Golgi
apparatus. J. Biol. Chem. 257, 5323-5325.
Pryor, P. R., Mullock, B. M., Bright, N. A., Gray, S. R. and Luzio, J. P. (2000). Lysosome
biogenesis requires rab 9 function and receptor recycling from endosome to the TGN. J. Cell
Biol. 149, 1053-1062.
Pryor, P. R., Mullock, B. M., Piper, R. C., Goldberg, D. E., Gabel, C. A. and Kornfeld, S.
(1983). Studies of the biosynthesis of the mannose 6-phosphate receptor in receptor-positive
and -deficient cell lines. J. Cell Biol. 97, 1700-1706.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
240
Puertollano, R., Aguilar, R. C., Gorshkova, I., Crouch, R. J. and Bonifacino, J. S. (2001).
Sorting of mannose 6-phosphate receptors mediated by GGAs. Science 292, 1712-1716.
Raposo, G., Tenza, D., Murphy, D. M., Berson, J. F. and Marks, M. S. (2001). Distinct
protein sorting and localization to premelanosomes, melanosomes, and lysosomes in pigmented
melanocytic cells. J. Cell Biol. 152, 809-823.
Reaves, B. J., Bright, N. A., Mullock, B. M. and Luzio, J. P. (1996). The effect of
wortmannin on the localisation of lysosomal type I integral membrane glycoproteins suggests a
role for phosphoinositide-3-kinase activity in regulating membrane traffic late in the endocytic
pathway. J. Cell Sci. 109, 749-762.
Reddy, S. T., Chai, W., Childs, R. A., Page, J. D., Feizi, T. and Dahms, N. M. (2004).
Identification of a low affinity mannose 6-phosphate-binding site in domain 5 of the cation-
independent mannose 6-phosphate receptor. J. Biol. Chem. 279, 38658-38667.
Reddy, S. T., Kumar, S. N., Haas, A. L. and Dahms, N. M. (2003). Biochemical and
functional properties of the full-length cation-dependent mannose-6-phosphate receptor
expressed in pichia pastoris. Biochem. Biophys. Res. Commun. 309, 643-651.
Renlund, M., Aula, P., Raivio, K. O., Autio, S., Sainio, K., Rapola, J. and Koskela, S.
(1983). Salla disease: A new lysosomal storage disorder with disturbed sialic acid metabolism.
Neurology 33, 57-66.
Rijnboutt, S. (1992). Identification of subcellular compartments involved in biosynthetic
processing of cathepsin D. J. Biol. Chem. 267, 15665-15672.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
241
Robbins, A. R., Oliver, C., Bateman, J. L., Krag, S. S., Galloway, C. J. and Mellman, I.
(1984). A single mutation in chinese hamster ovary cells impairs both Golgi and endosomal
functions. J. Cell Biol. 99, 1296-1308.
Robbins, A. R., Peng, S., S. and Marshall, J. L. (1983). Mutant chinese hamster ovary cells
pleiotropically defective in receptor-mediated endocytosis. J. Cell Biol. 96, 1064-1071.
Rohrer, J., Schweizer, A. and Johnson, K. F. (1995). A determinant in the cytoplasmic tail
of the cation-dependent mannose 6-phosphate receptor prevents trafficking to lysosomes. J.
Cell Biol. 130, 1297-1306.
Rohrer, J., Schweizer, A., Russell, D. and Kornfeld, S. (1996). The targeting of Lamp1 to
lysosomes is dependent on the spacing of its cytoplasmic tail tyrosine sorting motif relative to
the membrane. J. Cell Biol. 132, 565-576.
Rous, B. A., Reaves, B. J., Ihrke, G., Briggs, John A. G., Gray, S. R., Stephens, D. J.,
Banting, G. and Luzio, J. P. (2002). Role of adaptor complex AP-3 in targeting wild-type and
mutated CD63 to lysosomes. Mol. Biol. Cell 13, 1071-1082.
Runquist, E. A. and Havel, R. J. (1991). Acid hydrolases in early and late endosome fractions
from rat liver. J. Biol. Chem. 266, 22557-22563.
Sahagian, G. G., Distler, J. and Jourdian, G. W. (1981). Characterization of a membrane-
associated receptor from bovine liver that binds phosphomannosyl residues of bovine testicular
beta-galactosidase. Proc. Natl. Acad. Sci. 78, 4289-4293.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
242
Sahagian, G. G. and Neufeld, E. F. (1983). Biosynthesis and turnover of the mannose 6-
phosphate receptor in cultured chinese hamster ovary cells. J. Biol. Chem. 258, 7121-7128.
Saitoh, O., Wang, W., Lotan, R. and Fukuda, M. (1992). Differential glycosylation and cell
surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer
exhibiting distinct metastatic potentials. J. Biol. Chem. 267, 5700-5711.
Sandoval, I. V., Arredondo, J. J., Alcalde, J., Noriega, A. G., Vandekerckhove, J.,
Jimenez, M. A. and Rico, M. (1994). The residues leu(ile)475-ile(leu, val, ala)476, contained
in the extended carboxyl cytoplasmic tail, are critical for targeting of the resident lysosomal
membrane protein LIMP II to lysosomes. J. Biol. Chem. 269, 6622-6631.
Sarafian, V., Jadot, M., Foidart, J., Letesson, J. and Van Den Brule, Frederic. (1998).
Expression of lamp-1 and lamp-2 and their interactions with galectin-3 in human tumor cells.
Int. J. Cancer 75, 105-111.
Sawada, R., Jardine, K. A. and Fukuda, M. (1993). The genes of major lysosomal
membrane glycoproteins, lamp-1 and lamp-2. 5'-Flanking sequence of lamp-2 gene and
comparison of exon organization in two genes. J. Biol. Chem. 268, 9014-9022.
Schweizer, A., Kornfeld, S. and Rohrer, J. (1996). Cysteine34 of the cytoplasmic tail of the
cation-dependent mannose 6-phosphate receptor is reversibly palmitoylated and required for
normal trafficking and lysosomal enzyme sortting. J. Cell Biol. 132, 577-584.
Schweizer, A., Kornfeld, S. and Rohrer, J. (1997). Proper sorting of the cation-dependent
mannose 6-phosphate receptor in endosomes depends on a pair of aromatic amino acids in its
cytoplasmic tail. Proc. Natl. Acad. Sci. USA 94, 14471-14476.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
243
Silverstein, S. C. (1977). Endocytic uptake of particles by mononuclear phagocytes and the
penetration of obligate intracellular parasites. Am. J. Trop. Med. Hyg. 26, 161-169.
Simpson, F., Bright, N. A., West, M. A., Newman, L. S., Darnell, R. B. and Robinson, M.
S. (1996). A novel adaptor-related protein complex. J. Cell Biol. 133, 749-760.
Simpson, F., Peden, A. A., Christopoulou, L. and Robinson, M. S. (1997). Characterization
of the adaptor-related protein complex, AP-3. J. Cell Biol. 137, 835-845.
Sosa, M., Schmidt, B., von Figura, K. and Hille-Rehfeld, A. (1993). In vitro binding of
plasma membrane-coated vesicle adaptors to the cytoplasmic domain of lysosomal acid
phosphatase. J. Biol. Chem. 268, 12537-12543.
Starcevic, M., Nazarian, R. and Dell'Angelica, E. C. (2002). The molecular machinery for
the biogenesis of lysosome-related organelles: Lessons from Hermansky-Pudlak syndrome.
Cell Devel. Biol. 13, 271-278.
Stein, M., Braulke, T., Krentler, C., Hasilik, A. and von Figura, K. (1987a). 46 kDa
mannose 6-phosphate-specific receptor: Biosynthesis, processing, subcellular location and
topology. Biol. Chem. Hoppe-Seyler 368, 937-947.
Stein, M., Zijderhand-Bleekemolen, J. E., Geuze, H., Hasilik, A. and von Figura, K.
(1987b). Mr 46,000 mannose 6-phosphate specific receptor: Its role in targeting of lysosomal
enzymes. EMBO J. 6, 2677-2681.
Steinman, R. M., Mellman, I. S., Muller, W. A. and Cohn, Z. A. (1983). Endocytosis and
the recycling of plasma membrane. J. Cell Biol. 96, 1-27.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
244
Stenbeck, G. (2002). Formation and function of the ruffled border in osteoclasts. Seminars in
Cell & Developmental Biology 13, 285-292.
Stockli, J. and Rohrer, J. (2004). The palmitoyltransferase of the cation-dependent mannose
6-phosphate receptor cycles between the plasma membrane and endosomes. Mol. Biol. Cell 15,
2617-2626.
Stoorvogel, W. (1998). Analysis of the endocytic system by using horseradish peroxidase.
Trends Cell Biol. 8, 503-505.
Storch, S. and Braulke, T. (2001). Multiple C-terminal motifs of the 46-kDa mannose 6-
phosphate receptor tail contribute to efficient binding of medium chains of AP-2 and AP-3. J.
Biol. Chem. 276, 4298-4303.
Sun, G., Zhao, H., Kalyanaraman, B. and Dahms, N. M. (2005). Identification of residues
essential for carbohydrate recognition and cation dependence of the 46-kDa mannose 6-
phophate receptor. Glycobiology 15, 1136-1149.
Tagawa, K., Maruyama, K. and Ishiura, S. (1992). Amyloid beta/A4 precursor protein
(APP) processing in lysosomes. Ann. N. Y. Acad. Sci. 674, 129-137.
Tanaka, Y., Guhde, G., Suter, A., Eskelinen, E., Hartmann, D., Lullman-Rauch, R.,
Janssen, Paul M. L., Blanz, J., von Figura, K. and Saftig, P. (2000). Accumulation of
autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 406, 902-906.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
245
Tanaka, Y., Harada, R., Himeno, M. and Kato, K. (1990a). Biosythesis processing, and
intracellular transport of lysosomal acid phosphatase in rat hepatocytes. J. Biochem. (Tokyo)
108, 278-286.
Tanaka, Y., Yano, S., Okada, K., Ishikawa, T., Himeno, M. and Kato, K. (1990b).
Lysosomal acid phosphatase is transported via endosomes to lysosomes. Biochem. Biophys.
Res. Commun. 166, 1176-1182.
Thilo, L. and de Chastellier, C. (1995). Phagocytic processing of the macrophage
endoparasite, mycobacterium avium, in comparison to phagosomes which contain bacillus
subtilis or latex beads. Eur. J. Cell Biol. 68, 167-182.
Thilo, L., Stroud, E. and Haylett, T. (1995). Maturation of early endosomes and vesicular
traffic to lysosomes in relation to membrane cycling. J. Cell Sci. 108, 1791-1803.
Umeda, A., Fujita, H., Kuronita, T., Hirosako, K., Himeno, M. and Tanaka, Y. (2003).
Distribution and trafficking of MPR300 is normal in cells with cholesterol accumulated in late
endocytic compartments: Evidence for early endosome-to-TGN trafficking of MPR300. J.
Lipid Res. 44, 1821-1832.
Urbe, S., Tooze, S. A. and Barr, F. A. (1997). Formation of secretory vesicles in the
biosynthetic pathway. Biochim. Biophys. Acta 1358, 6-22.
Vaes, G. (1966). Subcellular localisation of glycosidases in lysosomes. Methods Enzymol. 8,
509-514.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
246
Vega, M. A., Rodriguez, F., Segui, B., Cales, C., Alcade, J. and Sandoval, I. V. (1991).
Targeting of lysosomal integral membrane protein LIMP II. J. Biol. Chem. 266, 16269-16272.
Vladutiu, G. D. and Rattazzi, M. C. (1978). Excretion-reuptake route of beta-hexosaminidase
in normal and I-cell disease cultured fibroblasts. J. Clin. Invest. 63, 595-601.
von Figura, K., Gieselmann, V. and Hasilik, A. (1984). Antibody to mannose 6-phosphate
specific receptor induces receptor deficiency in human fibroblasts. EMBO J. 3, 1281-1286.
von Figura, K. and Hille-Rehfeld, A. (1994). Proteolytic processing of cathepsin D in
prelysosomal organelles. J. Cell Biol. 64, 7-14.
von Figura, K. and Weber, E. (1978). An alternative hypothesis of cellular transport of
lysosomal enzymes in fibroblasts. Effect of inhibitors of lysosomal enzyme endocytosis on
intra- and extra-cellular lysosomal enzyme activities. Biochem. J. 176, 943-950.
Waguri, S., Dewitte, F., Le Borgne, R., Rouille, Y., Uchiyama, Y., Dubremetz, J. and
Hoflack, B. (2003). Visualization of TGN to endosome trafficking through fluorescently
labelled MPR and AP-1 in living cells. Mol. Biol. Cell 14, 142-155.
Waheed, A., Gottschalk, S., Hille-Rehfeld, A., Krentler, C., Pohlmann, R., Braulke, T.,
Hauser, H., Geuze, H. J. and von Figura, K. (1988). Human lysosomal acid phosphatase is
transported as a transmembrane protein to lysosomes in transfected baby hamster kidney cells.
EMBO J. 7, 2351-2358.
Wan, L., Molloy, S. S., Thomas, L., Liu, G., Xiang, Y., Rybak, S. L. and Thomas, G.
(1998). PACS-1 defines a novel gene family of cytosolic sorting proteins required for trans-
Golgi network localization. Cell 94, 205-216.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
247
Williams, M. A. and Fukuda, M. (1990). Accumulation of membrane glycoproteins in
lysosomes requires a tyrosine residue at a particular position in the cytoplasmic tail. J. Cell
Biol. 111, 955-966.
Williamson, A. R. and Askonas, B. A. (1968). Differential reduction of interchain disulphide
bonds of mouse immunoglobulin G. Biochem. J. 107, 823-838.
Willingham, M. C., Pastan, I. H. and Sahagian, G. G. (1983). Ultrastructural
immunocytochemical localization of the phosphomannosyl receptor in chinese hamster ovary
(CHO) cells. J. Histochem. Cytochem. 31, 1-11.
Yeo, K. T., Parent, J. B., Yeo, T. K. and Olden, K. (1985). Variability in transport rates of
secretory glycoproteins through the endoplasmic reticulum and Golgi in human hepatoma cells.
J. Biol. Chem. 260, 7896-7902.
Zhang, M., Dwyer, N. K., Love, D. C., Cooney, A., Comly, M., Neufeld, E., Pentchev, P.
G., Blanchette-Mackie, J. E. and Hanover, J. A. (2001). Cessation of rapid late endosomal
tubulovesicular trafficking in niemann-pick type C1 disease. Proc. Natl. Acad. Sci. USA 98,
4466-4471.
Zhang, Y. and Dahms, N. M. (1993). Site-directed removal of N-glycosylation sites in the
bovine cation-dependent M-P-R: Effects on ligand binding, intracellular targeting and
association with binding immunoglobulin protein (bip). J. Biochem. 295, 841-848.
Zhdankina, O., Strand, N. L., Redmond, J. M. and Boman, A. L. (2001). Yeast GGA
proteins interact with GTP-bound Arf and facilitate transport through the Golgi. Yeast 18, 1-18.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
248
Zhou, D., Li, P., Lin, Y., Lott, J., Hislop, A., Canaday, D., Brutkiewicz, R. and Blum, J.
(2005). Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens. Immunity 22,
571-581.
Zhu, Y., Doray, B., Poussu, A., Lehto, V. and Kornfeld, S. (2001). Binding of GGA2 to the
lysosomal enzyme sorting motif of the mannose 6-phosphate receptor. Science 292, 1716-1718.
Zhu, Y., Traub, L. M. and Kornfeld, S. (1998). ADP-ribosylation factor 1 transiently
activates high-affinity adaptor protein complex AP-1 binding sites on Golgi membranes. Mol.
Biol. Cell 9, 1323-1337.
Zhu, Y., Traub, L. M. and Kornfeld, S. (1999). High-affinity binding of the AP-1 adaptor
complex to trans-Golgi network membranes devoid of mannose 6-phosphate receptors. J. Biol.
Chem. 10, 537-549.
